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Radiotherapy-induced gastrointestinal toxicity (RIGT) involves damage to the gastrointestinal 
mucosa and is associated with symptoms including but not limited to, diarrhoea, pain, and 
rectal bleeding. Members of the matrix metalloproteinase (MMP) family have recently been 
identified as being upregulated in RIGT. Furthermore, the microvasculature has long been 
implicated in the development of toxicities following radiotherapy, however, the mechanisms 
behind this are yet to be explored. This thesis aimed to assess the microvascular response to 
irradiation, to further elucidate the role of MMPs in RIGT, and to assess the effect of MMP 
inhibition on microvascular endothelium following irradiation.  
This thesis consists of a general introduction, published literature review, three research 
chapters, one published and two submitted, and a general discussion. In chapter 1, the topic of 
this thesis is introduced, discussing the epidemiology and underlying pathobiology of RIGT. 
Chapter 2, a published critical review of the literature, consolidates literature on the role of 
MMPs, intestinal microvasculature, and vascular mediators in RIGT. This literature review 
surmised MMPs to be key regulators of endothelial mediators, and to play a key role in 
inducing damage to intestinal microvasculature following radiotherapy.  
The third chapter, published in Supportive Care in Cancer, utilized a Dark Agouti (DA) rat 
model of fractionated abdominal irradiation to assess changes to the intestinal 
microvasculature. A significant increase in apoptosis of microvascular cells 6 and 15 weeks 
from the first dose of irradiation was found, corresponding with histopathological damage and 
apoptosis in the jejunal and colonic crypts. This study suggested regional and timing-specific 




Chapter four assessed levels of MMPs in the jejunum and colon in the same DA rat model of 
RIGT. Whilst mRNA expression MMP-1, -2, and -14 significantly increased in the jejunum, 
only MMP-2 expression increased in the colon. MMP-2 immunostaining was also observed to 
be increased in both the jejunum and colon, a finding supported by western blotting, showing 
significantly increased MMP-2 protein levels in both the jejunum and colon at week 6. This 
supported a role for MMP-2 in the pathobiology of RIGT.  
Chapter five, the final research chapter, assessed vascular mediator expression in the DA rat 
model of RIGT, as well as the effects of irradiation and MMP inhibition on tumour-associated 
microvascular endothelial cells derived from DA rat mammary adenocarcinoma. This study 
confirmed an in vivo increase in the vascular mediators, VEGF, TGFβ, angiostatin, and 
endostatin. Cell culture results confirmed an increase in both MMP-2 and -9 following 
irradiation, significantly attenuated by MMP inhibition, however this attenuation did not alter 
the expression of vascular mediators or the toxicity profile of irradiation.  
In summary, this thesis contributed to the field of supportive care in cancer by elucidating a 
role for the intestinal microvasculature, MMPs, and vascular mediators, in RIGT. The 
findings of this thesis suggest these factors are likely part of a complex pathway involving 
many other mediators and intestinal components. Further research is now warranted to assess 
efficacy of treatments for RIGT targeting the intestinal microvasculature and MMPs. 
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Chapter 1 General introduction 
Radiotherapy is one of the most commonly prescribed therapies for cancer, with an optimal 
radiotherapy utilisation rate of 48% in Australia (Barton et al. 2014). In 2014 alone, over 
60,000 people receiving medicine-subsidised radiotherapy services in Australia (Barton et al. 
2014; Welfare 2017). Although developments have been made in increasing the safety profile 
of radiotherapeutic techniques, the prevalence of radiotherapy-induced toxicities remains high 
(Shadad et al. 2013a). Radiotherapy may induce many different toxicities, dependent on 
targeted area and treatment schedule. However one of the most common toxicities, 
particularly following abdominal and pelvic irradiation, is radiotherapy-induced 
gastrointestinal toxicity (RIGT) (Shadad et al. 2013a). RIGT is a broad term, encompassing 
clinical and histopathological manifestations of toxicity occurring throughout the 
gastrointestinal tract following irradiation. RIGT can present as both acute (occurring within 3 
months of treatment) or chronic (3 months – several years following treatment) (Theis et al. 
2010). This introductory chapter will further explore the epidemiology and pathobiology of 
RIGT, focussing on two key components, matrix metalloproteinases (MMPs) and the 
intestinal microvasculature.  
1.1 Clinical and histopathological manifestation of RIGT 
RIGT can manifest as both acute and chronic toxicity, with distinct side effects and 
histopathological features. Although the two forms of RIGT were once thought to be 
unrelated (Denham & Hauer-Jensen 2002), it is now understood they are continuations of the 
same pathology, with acute RIGT contributing to the development of chronic RIGT (Hauer-
Jensen, Denham & Andreyev 2014).  
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1.1.1 Acute RIGT 
Acute RIGT is a term encompassing acute radiation enteritis, radiation-induced enteropathy, 
and radiation-induced proctitis. It may occur during, or within days of, radiotherapy, with 
clinical symptoms including, but not limited to, diarrhoea, abdominal pain, and nausea and 
vomiting (Theis et al. 2010; Berbee & Hauer-Jensen 2012). Whilst acute RIGT may develop 
into chronic RIGT, these two conditions have distinct histopathological manifestations (Theis 
et al. 2010). This is likely due to differences in pathobiology, with acute RIGT driven by the 
direct effect of radiation, inducing reactive oxygen species (ROS), oxidative damage, 
activating transcription factors and pro-inflammatory mediators, and inducing an 
inflammatory response (Sonis, S. T. 2004; Liu et al. 2016).  
1.1.2 Chronic RIGT 
Chronic RIGT, also known as chronic radiation enteritis or chronic radiation enteropathy, 
typically occurs anywhere from 3 months to 6 years following radiotherapy, however cases 
have been reported up to 15 years following treatment (Theis et al. 2010). The clinical 
presentation of chronic RIGT includes a diverse set of symptoms such as diarrhoea, 
constipation, abdominal pain, rectal bleeding, and distention (Qin et al. 2013). Several 
complications are also associated with chronic RIGT, including faecal incontinence, bowel 
obstruction, fistula formation, transfusion-dependent bleeding, and secondary malignancy 
(Andreyev 2007; Qin et al. 2013). The pathobiology of acute and chronic RIGT will be 
explored in greater depth in both this introductory chapter and in the review of the literature in 
chapter 2. 




The general prevalence of both acute and chronic RIGT ranges from 33-72% depending on 
treatment modality, dose schedule, and target area (Roszak et al. 2012; Shadad et al. 2013b). 
However is difficult to accurately determine, largely due to discrepancies in the definition and 
grading of clinical RIGT (Roszak et al. 2012; Shadad et al. 2013a).  Despite this, several 
clinical studies have assessed the prevalence of radiation toxicity in specific cohorts. Roszak 
and colleagues (2012) assessed acute RIGT in 263 patients with cervical and endometrial 
cancer who had received definitive (radiation as sole local treatment) or adjuvant (treatment to 
lower risk of recurrence) radiotherapy. Acute RIGT occurred in 33.1% of patients, with 
definitive radiotherapy resulting in a 65.5% incidence of RIGT of any grade (grade 3-4 
=24.1%) (Roszak et al. 2012). Further, acute diarrhoea and abdominal pain have been shown 
in a systematic review to occur in anywhere from 20% to 70% of patients following 
abdominal or pelvic radiotherapy (Shadad et al. 2013a, 2013b).  
Rectal bleeding is one of the most common symptoms of chronic RIGT  (Andreyev 2007; 
Kim, Huh & Park 2013). A recent study by Kim and colleagues (2013) assessed 32 patients 
who had received definitive or postoperative radiotherapy for uterine cervical cancer and were 
subsequently diagnosed with rectal mucosal damage. The median interval was 19.5 months (2 
- 114 month range) from last radiotherapy treatment and rectal bleeding was the most frequent 
symptom, occurring in 72.4% of patients (Kim, Huh & Park 2013). The most common 
endoscopic findings were congested mucosa (62.5%), telangiectasia (56.3%), and ulceration 
(15.6%) (Kim, Huh & Park 2013). In another study assessing 100 patients who had received 
radiotherapy for pelvic malignancies 5 years prior, 20% of patients presented with chronic 
RIGT (grade 1-2 – 75%, grade 3-4 – 25%) (Hernandez-Moreno et al. 2015). In addition to 
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this, 28.3% of patients had a change in daily number of stools, 35% had changes to the 
consistency of stools, and 12.1% had blood or mucus in stools (Hernandez-Moreno et al. 
2015). Thus, the prevalence of chronic RIGT continues to be high, and places a significant 
burden on patients, often long after the cessation of treatment.  
1.3 Pathobiology 
1.3.1 5-phase model 
The pathobiology of RIGT is complex and not yet fully understood. Much of the current 
understanding of the development of RIGT can be summarized by the 5-phase model 
developed by Sonis in 2004. In the first phase, initiation, radiation directly damages DNA, as 
well as generates reactive oxygen species (ROS) (Sonis, S. T. 2004; Liu et al. 2016). The 
second phase, message generation, involves the up-regulation of transcription factors, 
particularly NFκB (Sonis, S. T. 2004). This then results in the activation of pro-inflammatory 
cytokines such as TNF-α, IL-1β, and IL-6, and many other downstream mediators, including 
MAPK, and cyclooxygenase-2 (COX-2) (Sonis, S. T. 2004; Yeoh et al. 2007; Al-Dasooqi et 
al. 2013; Liu et al. 2016). Following this, the signalling and amplification stage occurs, in 
which these cytokines and mediators cause tissue damage, as well creating a positive 
feedback loop to further upregulate transcription factors and cytokines (Sonis, S. T. 2004; Al-
Dasooqi et al. 2013). The fourth phase, ulceration, encompasses the accumulation of this 
tissue damage, resulting in ulceration, bacterial penetration, and immune cell infiltration. The 
final phase is healing, in which resolution of ulcers, remodelling of the extracellular matrix 
(ECM), and epithelial proliferation and differentiation occurs (Sonis, S. T. 2009). Despite 
this, the intestinal tissue often never returns to its ‘normal’ state, and fibrotic thickening and 
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long term changes in mediator expression can lead to chronic RIGT (Hauer-Jensen, Denham 
& Andreyev 2014).  
1.3.2 Recent updates in the pathobiology of RIGT 
The study of the pathobiology of RIGT continues to be a focus in research surrounding cancer 
therapy-induced toxicities, due to the limited number of currently available treatments (Lalla 
et al. 2014). Matrix metalloproteinases (MMPs) have now been implicated in the 
pathobiology of RIGT (Strup-Perrot et al. 2006; Angenete et al. 2009). Strup-Perrot and 
colleagues (2006) found a significant increase in mRNA expression of MMP -2, -3, -9, and -
14, and protein levels of MMP-2 and -14, associated with increased diarrhoea and 
histopathological damage, in the colon of rats irradiated with a single abdominal dose of 10 
Gy. Further, Mangoni and colleagues (2015) reported MMP-2 and -13 to be significantly 
increased in both the jejunum and colon following 12 Gy total body irradiation in mice 
(Mangoni et al. 2015). In the same study, inhibition of MMPs, reduced radiotherapy-induced 
jejunal and colonic damage (Mangoni et al. 2015). One of the proposed mechanisms by which 
MMPs contribute to the development of RIGT is through the degradation of the extracellular 
matrix (ECM), leading to microvascular tube formation and the release of vascular mediators.  
The intestinal endothelium is also intricately involved in the development of RIGT, with 
several pre-clinical studies, utilising rat and human endothelial cell culture models, 
implicating vascular mediators in its pathobiology (Wang, J et al. 2002; Oh et al. 2014). 
Several of these mediators, including vascular endothelial growth factor (VEGF), and the 
anti-angiogenic mediators, angiostatin and endostatin, are potentially involved in pathological 
angiogenesis, telangiectasia, and rectal bleeding in chronic RIGT (Park et al. 2012; Laterza et 
al. 2013; Stansborough et al. 2016). Transforming growth factor β (TGFβ), a multifunctional 
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growth factor involved in fibrosis, has also been suggested to play a key role in the 
development of intestinal fibrosis and vascular sclerosis characteristic of chronic RIGT 
(Wang, J, Zheng & Hauer-Jensen 2001; Boerma et al. 2013). Further, TGFβ has been shown 
to be increased in both pre-clinical and clinical studies, supporting its role in the development 
of chronic RIGT (Wang, J, Zheng & Hauer-Jensen 2001; Milliat et al. 2006; Kruse et al. 
2009; Al-Dasooqi et al. 2013). It is clear from these studies the pathobiology of RIGT is truly 
complex, involving relationships between transcription factors and many downstream 
mediators, thus further studies are required to identify targets for potential novel treatments of 
both acute and chronic RIGT. 
1.4 Treatment of RIGT 
The recommendation of preventative and therapeutic measures for both acute and chronic 
RIGT remain limited (Lalla et al. 2014). Preventative agents recommended, or suggested, by 
the Multinational Association for Supportive Care in Cancer (MASCC) in the most recent 
mucositis guidelines include intravenous amifostine for radiation proctitis, and systemic 
sulfasalazine for pelvic radiation-induced enteropathy (Lalla et al. 2014). These agents 
scavenge free radicals, preventing oxidative damage, and inhibit pro-inflammatory mediators, 
respectively (Uzal et al. 2012; Fuccio, Frazzoni & Guido 2015). Currently, the only suggested 
treatments for RIGT include hyperbaric oxygen for radiation-induced proctitis, and sucrulfate 
enemas for chronic radiation-induced proctitis in patients with rectal bleeding (Laterza et al. 
2013; Lalla et al. 2014; Bansal et al. 2016). These treatments act by promoting 
neovascularisation and decreasing tissue hypoxia, and forming a protective barrier over 
damaged mucosa and stimulating epithelial healing, respectively (Laterza et al. 2013; Lalla et 
al. 2014; Bansal et al. 2016). Whilst these agents may reduce the severity, or promote healing, 
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of RIGT in some patients, a lack of understanding of the pathobiology of RIGT hinders the 
development of more targeted treatments. Better understanding the role of factors contributing 
to RIGT pathobiology, such as those explored in this thesis, MMPs and the intestinal 
microvasculature, can contribute to the development of targeted and efficacious preventative 
and therapeutic agents.   
1.5 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a group of enzymes, consisting of 24 different 
members in humans, which primarily are responsible for the remodelling of the ECM 
(Biancheri et al. 2013). However, the roles of MMPs in normal and pathological states are 
diverse. They can upregulate many mediators, including many of the pro-inflammatory 
cytokines known to be involving in RIGT pathobiology, and activating vascular mediators 
such as VEGF, angiostatin, and endostatin, via the sequestering of ECM components, 
expanded upon in Chapter 2 (Bergers et al. 2000; Strup-Perrot et al. 2006; Mittal et al. 2016). 
MMPs are predominantly regulated at the transcription level and are released as inactive 
zymogens by various cell types, including epithelial cells, endothelial cells, macrophages, 
neutrophils, and T cells (Biancheri et al. 2013). They can then be activated via cleavage of the 
pro-domain (Yan & Boyd 2007). Several MMPs have been implicated in the development of 
RIGT, however the MMP -1, -2, -9, -12, and -14 will be explored in more depth, both in this 
introductory chapter, and throughout the thesis, due to their possible roles and relationships 
with other mediators and the intestinal microvasculature in the development of acute and 
chronic RIGT (Strup-Perrot et al. 2006; Angenete et al. 2009; Al-Dasooqi et al. 2010).  




MMP-1 is classified as a collagenase due to its ability to degrade collagen and gelatin. 
However, it is also capable of activating pro-MMP-9 (Mittal et al. 2016). Transcription of 
MMP-1 can be increased in response to pro-inflammatory cytokines, epidermal growth factor, 
as well as following activation of p38 mitogen-activated protein kinases (MAPK) (Salmela et 
al. 2004; Mittal et al. 2016). Both of these mediators have previously been shown to be 
increased in pre-clinical studies of RIGT and are thought to be involved in regulating 
apoptosis (Sonis, S. T. 2002; Salmela et al. 2004; Mittal et al. 2016).  
1.5.2 MMP-2 
MMP-2, also known as gelatinase A, is capable of degrading several ECM components, 
including collagen IV and VXII, gelatin, elastin, plasminogen, and decorin, to activate 
downstream products such as VEGF, TGFβ, and form angiostatin, endostatin, and tumstatin 
(Sternlicht & Werb 2001; Manicone & McGuire 2008). MMP-2 is uniquely regulated by 
MMP-14 (MT1-MMP), and once activated able to shed and activate pro-inflammatory 
cytokines such as TNF-α and IL-1β (Chien et al. 2013). MMP-2 has been consistently shown 
to be upregulated following irradiation in both pre-clinical and clinical studies, occurring 
prior to, or concurrently with, intestinal histopathological damage in acute RIGT (Strup-
Perrot et al. 2006; Angenete et al. 2009; Mangoni et al. 2015).  
1.5.3 MMP-9 
MMP-9 is also a member of the gelatinase group of MMPs, classified as gelatinase B (Yan & 
Boyd 2007). Similarly to MMP-2, MMP-9 is capable of degrading type IV collagen, gelatin 
and elastin, among several other ECM components (Visse & Nagase 2003). Several pre-
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clinical studies have suggested a disruptive effect of MMP-9 in pathological states. MMP-9 is 
predominantly secreted by neutrophils and can impair re-epithelialization (Castaneda et al. 
2005; Biancheri et al. 2013). MMP-9 is also known to alter pro-inflammatory cytokine 
expression, capable of both processing IL-1β from its precursor and degrading it (Visse & 
Nagase 2003). Whilst MMP-9 has been shown to be increased in the large intestine following 
irradiation in some models, its role is slightly less clear than that of MMP-2, and the literature 
is inconsistent in its findings (Strup-Perrot et al. 2006; Angenete et al. 2009). 
1.5.5 MMP-14 
MMP-14 has been shown to cleave the cell adhesion receptor CD44, promoting cell adhesion 
and migration (Yan & Boyd 2007). Additionally, MMP-14 is intricately involved with the 
activation of pro-MMP-2. Active MMP-14 expressed on the cell surface, when bound to 
tissue inhibitor of metalloproteinase 2 (TIMP2),acts as a receptor for pro-MMP-2 after which 
a free MMP-14 molecule is able to cleave and activate pro-MMP-2 (Chien et al. 2013). 
Whilst MMP-14 has remained largely unexplored in RIGT, its involvement with MMP-2 
regulation suggests it may play an important role (Strup-Perrot et al. 2006).  
1.6 Intestinal microvasculature 
The intestinal microvasculature plays an important role in the maintenance and regulation of 
the intestinal tract. It not only regulates blood delivery and perfusion, but also acts as a barrier 
controlling the exchange of fluids and nutrients, while preventing the systemic circulation of 
pathogenic bacteria from the intestinal lumen (Spadoni et al. 2015). Endothelial cells are a 
primary component of the microvasculature, and can regulate mediator expression and 
immune cell infiltration in response to pathological conditions (Cromer et al. 2011). Cell 
culture studies comparing different endothelial cell culture human intestinal microvascular 
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endothelial cells (HIMECs) have been compared with human umbilical vein endothelial cells 
(HUVECs) and have been found to have different inflammatory responses (Nilsen et al. 1998; 
Cromer et al. 2011). HIMECs, unlike HUVECs, when stimulated with lipopolysaccharide 
(LPS), found in the intestine as a major component of gram-negative bacteria, produce IL-1β, 
IL-3, and IL-6 (Nilsen et al. 1998; Cromer et al. 2011). The identification of an intestine-
vascular barrier, similar to the blood-brain barrier, has also recently been described by 
Spadoni and colleagues (2015). In the gastrointestinal tract, permeability of intestinal 
endothelial cells is closely regulated by the presence of intercellular tight junctions, such as 
occludin, zonula occludens-1, and adherens junctions, such as vascular endothelial cadherin 
and β-catenin (Spadoni et al. 2015). Whilst outside the scope of this thesis, the role of tight 
junctions in the development of cancer-treatment related toxicities has been explored in more 
detail by Wardill and colleagues (2014; 2015; 2016; 2016). The intestinal microvasculature is 
known to be involved in RIGT. Clinically, telangiectasis, or the formation of pathological, 
vasodilated microvessels, has been documented in both acute and chronic RIGT (Kruse et al. 
2004; Yeoh et al. 2005). Pre-clinically, endothelial apoptosis, as well as a shift of the 
intestinal microvasculature to a pro-coagulant and pro-thrombotic phenotype, have been 
shown to occur following irradiation (Paris et al. 2001; Wang, J et al. 2002). Despite these 
changes, the pathobiology of microvascular changes during RIGT, particularly the 
relationship between the intestinal microvasculature and MMPs, require further exploration to 
identify targets for novel treatments. Previous literature surrounding the relationship of these 
aspects of RIGT will be explored in chapter 2, forming the basis for the aims of the research 
presented in this thesis. 
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1.7 Aims of Thesis 
Whilst the pathobiology of acute and chronic RIGT continues to be explored, there remains a 
lack of targets for the development of novel treatments. In addition, the relationship between 
some of the newer aspects of RIGT development, the intestinal microvasculature, MMPs, and 
vascular mediators, need to be explored further so that their potential in RIGT treatment can 
be evaluated. Thus, to further elucidate the role of these components in RIGT, the aims and 
hypotheses of this thesis are as below; 
1. I hypothesise that microvascular alteration occurs during both during both acute and 
chronic phases in a rat model of RIGT, and that these changes are associated with 
increases in the vascular mediators VEGF, TGFβ, von willebrand factor (VWF), 
angiostatin, and endostatin. I aim to assess the microvascular response to irradiation, 
and the alteration of vascular mediators, VEGF, TGFβ, VWF, angiostatin, and 
endostatin, in an in vivo model of fractionated radiation-induced RIGT.  
2. An increase in MMPs -2, -9, and -14, and a decreased in MMP-1, is hypothesised to 
occur alongside microvascular alterations and intestinal histopathological changes. 
Thus, I aim to further elucidate the roles of MMPs, particularly MMP-1, -2, -9, and -
14, in the same model of fractionated radiation-induced RIGT.  
3. MMP expression is hypothesised to increase following irradiation of endothelial, and 
the attenuation of these MMPs via specific inhibition is hypothesised to alter 
endothelial viability and regulate VEGF and TGFβ expression. Thus, I aim to assess 
the effect of MMP inhibition using the selective MMP-2 and -9 inhibitor, SB-3CT, on 
tumour-associated microvascular endothelial cells (TAMECs) derived from 
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spontaneous Dark Agouti rat mammary adenocarcinoma, with and without irradiation 
in vitro. 
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Chapter 2 Radiotherapy-induced gut toxicity: Involvement of matrix metalloproteinases 
and the intestinal microvasculature 
[Stansborough et al., (2016) International Journal of Radiation Biology. 92(5): 241-248] 
Referencing has been altered from original publication for consistency between chapters.  
2.1 Abstract 
Purpose: To review the literature surrounding the involvement of the endothelium and matrix 
metalloproteinases (MMP) in radiotherapy-induced gut toxicity (RIGT) and further elucidate 
its complex pathobiology.  
Results: RIGT involves damage to the gastrointestinal mucosa and is associated with 
diarrhoea, pain, and rectal bleeding depending on the area of exposure. The mechanisms 
underpinning RIGT are complex and have not yet been elucidated. Members of the MMP 
family, particularly MMP -2 and -9, have recently been identified as being key markers in 
RIGT and chemotherapy-induced gut toxicity (CIGT).  Furthermore, the microvasculature has 
long been implicated in the development of toxicities following both chemotherapy and 
radiotherapy, however, the mechanisms behind this are yet to be explored.  
Conclusions: It is proposed that matrix metalloproteinases are key regulators of endothelial 










Radiotherapy-induced gut toxicity (RIGT) is a dose-limiting pathology involving damage to 
the gastrointestinal mucosa caused by radiotherapy for cancer. Its symptoms including, but 
not limited to pain, diarrhoea, nausea, and rectal bleeding, are debilitating and significantly 
reduce the patients’ quality of life (Sonis, Stephen T.  & Keefe 2013). The overall incidence 
of RIGT is not well understood, due to discrepancies in the definition of gastrointestinal 
toxicity following radiotherapy, and the classification of symptoms. Acute diarrhea and 
abdominal pain occur in 20-70% of patients receiving radiotherapy for abdominal or pelvic 
malignancies, and acute RIGT affecting quality of life has been shown to occur in 47% of 
women receiving radiotherapy for cervical or endometrial cancer (Classen et al. 1998; 
Abayomi, Kirwan & Hackett 2009; Shadad et al. 2013b). 
2.3 Gastrointestinal response to radiotherapy 
Gastrointestinal toxicities from radiotherapy are classified as being either acute (occurring 
hours after treatment) or delayed (months after treatment) (Al-Dasooqi et al. 2013). Acute 
RIGT occurs shortly after radiation and can continue for up to 3 months following treatment 
(Theis et al. 2010). Symptoms of acute toxicity include, but are not limited to, mucositis, 
nausea and vomiting, pain, and diarrhoea (Al-Dasooqi et al. 2013; Elting et al. 2013; Sonis, 
Stephen T.  & Keefe 2013). Further, acute RIGT is characterised by a plethora of 
histopathological alterations including mucosal atrophy, inflammation, and increased 
intestinal permeability (Theis et al. 2010). Several mediators have been identified as being 
key regulators in the development of acute RIGT, particularly the transcription factor nuclear 
factor-κB (NF-κB); which acts to up-regulate over 200 genes involved in this pathology 
(Bowen et al. 2007). Key downstream mediators of NF-κB include pro-inflammatory 
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cytokines, mitogen-activated protein kinase (MAPK), and matrix metalloproteinases (MMP) 
(Sonis, S. T. 2004; Logan, Gibson, et al. 2008; Logan, Stringer, et al. 2008; Al-Dasooqi et al. 
2010). These mediators act together to cause significant levels of apoptosis, decrease 
proliferation, and degrade the extracellular matrix (Sonis, S. T. 2004). 
Delayed toxicity, also known as chronic radiation enteropathy, occurs between 18 months and 
6 years following irradiation and is reported in up to 20% of patients receiving pelvic 
radiotherapy (Theis et al. 2010). Commonly reported symptoms include changes in stool 
frequency and rectal bleeding (in ~70% of cases); however, lesser reported complications may 
also occur, including small intestinal obstruction and fistulation (occurring in 0.6 and 13% of 
cases, respectively) (Henson 2010; Theis et al. 2010). Histopathologically, delayed RIGT is 
characterised by tissue ischaemia and necrosis, ulceration, telangiectasia, fibrosis of both the 
submucosa and the microvasculature, and mesenchymal cell activation (Richter et al. 1998; 
Theis et al. 2010; Al-Dasooqi et al. 2013). It has been shown that several mediators up-
regulated in the delayed phase of RIGT, such as transforming growth factor-β1 (TGF-β1) and 
thrombomodulin, interact with the extracellular matrix (ECM) to cause deposition of ECM 
components in the intestinal smooth muscle wall and perhaps induce long-term injury to the 
epithelium and endothelium of the gastrointestinal tract (Andreyev 2007; Gervaz, Morel & 
Vozenin-Brotons 2009; Wang, FZ et al. 2012; Al-Dasooqi et al. 2013). Remodelling of the 
ECM has many downstream effects, including the release of sequestered growth factors 
resulting in alterations to the microvasculature, possibly linking back to related symptoms 
such as rectal bleeding and telangiectasis (Imai et al. 1997; Bergers et al. 2000). These studies 
suggest a complex mediator pathway associated with delayed toxicity following radiation. 
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Both acute and delayed toxicities result in a significant reduction of quality of life of patients 
receiving radiotherapy for cancer (Bentzen 2006; Lalla, Saunders & Peterson 2014). Despite 
the clinical significance of RIGT, its pathogenesis remains poorly understood. This lack of 
understanding of the mechanisms by which RIGT occurs hinders the development of effective 
treatments. Previous studies have suggested a complex pathway of mediator release, 
inflammation, and apoptosis, of not only the epithelial mucosa, but the underlying submucosa, 
including microvascular endothelium (Paris et al. 2001; Kruse et al. 2004).   
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2.4 Matrix metalloproteinases (MMP) 
Matrix metalloproteinases, a class of zinc-dependent endopeptidases, have been previously 
shown to be altered in RIGT and chemotherapy-induced gut toxicity (CIGT) (Strup-Perrot et 
al. 2006; Al-Dasooqi et al. 2010). MMP subtypes are classified either functionally or 
structurally, with 24 members of the MMP family currently identified in humans, all of which 
share a catalytic domain coordinated by zinc (Yan & Boyd 2007). Their gene expression is 
predominantly regulated at the transcriptional level, with MMP members being regulated by 
transcription factors such as beta-catenin and NF-κB (Yan & Boyd 2007). However, post-
transcriptional regulation of MMP does occur, with TGF-β, vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), and various pro-inflammatory cytokines 
being capable of activating MMP promoters, particularly in disease states (Yan & Boyd 
2007). MMP family members vary structurally and functionally, with differences also 
occurring in the transcriptional and post-transcriptional regulation (Strongin et al. 1995). 
Whilst the general role of the MMP family is primarily in homeostasis of the extracellular 
matrix, specific MMP members may have different roles and have been identified as altering 
cell growth, immune responses, chemokine and cytokine expression, as well as apoptosis, a 
key histopathological feature of RIGT (Castaneda et al. 2005; Manicone & McGuire 2008). 
The recent implication of the MMP family in RIGT and CIGT suggests a complex and 
intricate involvement with associated mediators and tissue types in RIGT, as summarised in 
previous reviews (Sternlicht & Werb 2001; Al-Dasooqi et al. 2009). 
2.5 Matrix metalloproteinases may be key mediators in RIGT 
Studies by Strup-Perrot et al. (2005; 2006) identified matrix metalloproteinases as regulating 
RIGT. Male Wistar rats received a single dose of radiation (10 Gy) to the abdomen, and gene 
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expression of MMP -2, -3, -9, and -14 in the colon was assessed. MMP -2 was significantly 
increased at 1, 3, and 7 days following irradiation, MMP -3 was significantly increased at 3 
days, MMP -9 at 3 and 9 days, and MMP -14 at 1 and 3 days (Strup-Perrot et al. 2006). Strup-
Perrot et al. (2004) also assessed intestinal gene expression of MMP -2, -9, and -14, as well as 
tissue inhibitor of matrix metalloproteinase (TIMP) -1, and -2, in patients undergoing surgery 
for intestinal occlusion caused by delayed radiation-induced enteritis. MMP -2, -9, and -14, 
and TIMP -1, and -2 mRNA expression were significantly increased compared to healthy 
controls (Strup-Perrot et al. 2004). Conflicting results have been found in later studies. 
Angenete et al. (2009) studied levels of various matrix metalloproteinases in normal and 
tumour tissue from the rectum of rectal cancer patients scheduled for open surgery with or 
without pre-operative radiation. The study recruited 32 patients, 20 of which received short-
term pre-operative fractionated radiotherapy (5 x 5 Gy) with a median time of tissue 
collection following completion of radiotherapy of 3 days. The remaining 12 patients received 
no pre-operative radiation. Patients receiving chemoradiotherapy were excluded and groups 
were matched for age and gender. Whilst MMP -2 levels were significantly increased in the 
rectal mucosa following radiotherapy, no significant changes in MMP -1, MMP -9, or TIMP -
1 levels were observed following radiotherapy in these patients (Angenete et al. 2009). These 
discrepancies may be due to the many differences between the studies, including species 
difference in preclinical vs clinical studies, differences between acute and delayed RIGT, and 
single-dose vs fractionated irradiation. This is particularly relevant in the context of acute vs 
delayed RIGT, in which many differences can be observed at the clinical, histopathological, 
and molecular levels (Theis et al. 2010). It is likely that MMP expression would differ 
depending on time from the last radiotherapy course. Differences in normal tissue response in 
single vs fractionated dose radiotherapy have also been widely observed, with the short breaks 
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between doses in fractionated irradiation thought to lead to an accumulative affect, although 
not always linear (Yeoh et al. 2007; Hauer-Jensen, Denham & Andreyev 2014).  
Recent studies characterizing MMP expression in the development of CIGT have suggested 
particular roles for different MMP members depending on their patterns of expression, and 
their coincidence with stages of CIGT development (Al-Dasooqi et al. 2010). MMP -2, -9, 
and -12 levels have been shown to peak 48 hours following chemotherapy, coinciding with 
maximal mucosal damage in the jejunum of Dark Agouti rats (Al-Dasooqi et al. 2010). This 
implicates these specific MMP subtypes in the progression of inflammation in CIGT. In 
contrast, MMP -1 has been found to be down-regulated early in the development of CIGT, 
however, is later up-regulated at 96 and 144 hours following chemotherapy administration, 
suggesting it may play a role in the healing stages of the pathology (Al-Dasooqi et al. 2010). 
This is supported by the ability of MMP -1 to cleave type-1 collagen to regulate cell migration 
in re-epithelialization (Pilcher et al. 1997; Al-Dasooqi et al. 2010). Alterations in MMP -1 
expression may therefore be involved in the development of delayed RIGT, in which collagen 
deposition and reactive fibrosis commonly occur, also this has not yet been explored (Hauer-
Jensen, Denham & Andreyev 2014).  Such studies are yet to be conducted in RIGT models, 
particularly in regards to the differences between single dose in vivo RIGT studies and the 
fractionated radiation doses commonly used clinically.  
MMP -2 and -9 in particular, have many downstream mediators linked to the pathobiology of 
RIGT. MMP -2 and -9 are capable of up-regulating pro-inflammatory cytokines such as 
tumour necrosis factor-alpha (TNF-α), as well as forming a positive feedback loop with the 
key transcriptional factor NF-κB, (Sengupta & MacDonald 2007). Certain MMP members, 
MMP -2, -7, and -9 in particular, have also been linked with the disruption of endothelial and 
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epithelial tight junctions (Al-Dasooqi, Wardill & Gibson 2014; Wardill et al. 2014). No 
studies to date have assessed changes in endothelial tight junction protein levels in the 
intestinal microvasculature following radiation. However, studies have assessed intestinal 
epithelial tight junctions and blood-brain barrier tight junctions following radiation (Fauquette 
et al. 2012; Shukla et al. 2016). A recent study by Garg et al. (2016) assessed changes in tight 
junction expression in the jejunum, ileum, and colon of non-human primates following total-
body irradiation. Claudin -1 and -10 expression was significantly increased at day 4, and 
claudin -4 and -7 expression was repressed at days 4, 7, and 12. These changes were also 
shown to be segment-specific, with increased expression of claudin-1 occurring only in the 
colon, and repression of claudin-7 expression occurring only in the ileum (Garg et al. 2016). 
Fauquette et al. (2012) assessed permeability and changes to tight junction protein levels 
following irradiation of a bovine brain capillary endothelial cell (BBCEC) monolayer co-
cultured with glial cells. Permeability to fluorescein isothiocyanate (FITC)-dextran (70kDa) 
was significantly increased 8 days following 25 Gy irradiation, and immunoflourescent 
staining of the tight junction protein zonula occludens-1 (ZO-1) was decreased 8 days 
following both 12 Gy and 25 Gy irradiation. Whilst endothelial cells of the blood-brain 
barrier are structurally distinct to those of the intestinal microvascular, alterations to 
endothelial tight junction integrity following irradiation may still lead to increased 
permeability in such vessels. Similarly, a significant loss of junctional distribution of tight 
junction proteins occludin, claudin-3, and ZO-1 was shown to occur in the colon epithelium 2 
hours following a single dose of 4 Gy whole body irradiation in female C57BL6 mice (Shukla 
et al. 2016). Further exploration of tight junction alterations in the intestinal endothelium 
following radiation is warranted, particularly with increasing evidence of the importance of 
the gut-brain axis in many pathologies, including CIGT (Tillisch 2014; Wardill et al. 2015). 
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Despite these implications of the MMP family in RIGT and CIGT, a causative role has not yet 
been confirmed in previous literature, and several aspects of MMP functionality in RIGT 
remain entirely unexplored. 
2.6 Response of intestinal microvasculature to radiotherapy  
The microvasculature, and specifically the endothelium, plays a large role in toxicity 
following radiotherapy. Despite this, the extent of the involvement of the intestinal 
microvasculature, and the mechanisms behind this beyond their direct clinical manifestation 
in RIGT are unknown. Kruse et al. (2004) assessed changes to the microvasculature of the 
rectum of female C3H/HenAF-nu+ mice following a single dose of 20 Gy irradiation. 
Extensive vascular changes in the rectum, particularly tortuous telangiectatic vessels, were 
observed from 10 weeks following irradiation, with increasing severity, and were not resolved 
at 30 weeks post-irradiation (Kruse et al. 2004). Telangiectatic vessels are defined as ‘thin-
walled, tortuous vascular channels that often occur in groups and are accompanied by an area 
of leukocytic infiltration’ (Kruse et al. 2004; Yeoh et al. 2005). Whilst the involvement of 
these telangiectatic vessels in the development of RIGT is unclear, gastrointestinal bleeding is 
one of the primary symptoms in patients with hereditary haemorrhagic telangiectasia 
presenting with intestinal telangiectatic lesions (Kjeldsen & Kjeldsen 2000). Mucosal 
telangiectasia resulting in rectal bleeding is one of the primary dose-limiting factors for 
irradiation of prostate cancer (Kruse et al. 2004). Further understanding of how intestinal 
telangiectasis occurs in response to radiation may lead to potential targets for the treatment or 
prevention of rectal bleeding in RIGT. 
Although few preclinical studies have assessed changes to the intestinal microvasculature 
following irradiation, these changes have been observed clinically in several studies following 
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radiotherapy for cancer (Yeoh et al. 2005; Takeuchi et al. 2012). Takeuchi et al. (2012) 
assessed histopathological features of radiation toxicity of the lower rectum. The study 
included patients with a history of radiation therapy for an intrapelvic malignancy, 
characteristic colonoscopic findings of radiation proctitis, and histopathological exclusion of 
other diseases. Six male patients with radiation proctitis received 70 Gy external irradiation 
for prostate cancer, and 2 female patients received 50 Gy external irradiation and 20 or 27 Gy 
internal irradiation for uterine and vaginal cancers, respectively. Endoscopies and rectal 
biopsies were performed 15.4 ± 10.2 months from the completion of irradiation. 
Telangiectasia was observed in the superficial layer of the rectal mucosa upon endoscopy, and 
was confirmed in the upper layer of the lamina propria upon histological examination of rectal 
biopsies (Takeuchi et al. 2012). These findings are consistent with those of Yeoh et al. (2005) 
who demonstrated telangiectatic, fibrosed, and sclerosed blood vessels in the lamina propria, 
submucosa and fat layer of the gastrointestinal tract following short-term fractionated pelvic 
irradiation (25 Gy total/5 fractions/1 week), or long-term neoadjuvant chemoradiotherapy (45 
Gy total/25 fractions/5 weeks, with concurrent infusions of 5-fluorouracil), in patients with 
colorectal carcinoma. Although these studies have highlighted a key role of the intestinal 
microvasculature during RIGT they have not described the effect these changes have on the 
underlying pathobiology. The formation of telangiectatic vessels in the rectal mucosa 
following radiation has been associated with increased expression of jagged 1 and Kruppel-
like factor 5 (KLF5), both of which are involved in vascular remodeling and have been linked 
to the development of interstitial fibrosis (Kruse et al. 2004). KLF5 in particular is capable of 
upregulating growth factors such as PDGF and TGF-β (Kruse et al. 2004). The upregulation 
of these mediators would suggest a greater involvement of telangiectatic vessels in RIGT 
development than currently understood.  
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Endothelial apoptosis has also been suggested to be an initiating feature in the pathology of 
RIGT (Paris et al. 2001). Several in vivo and in vitro studies have found that endothelial 
apoptosis occurs hours following various radiation doses in several different tissue types, 
including the intestinal, lung, and central nervous system (CNS) microvasculature (Pena, Fuks 
& Kolesnick 2000; Paris et al. 2001; Zhang, Y et al. 2012; Li, G et al. 2014). Li, G et al. 
(2014) assessed apoptosis in the spinal cord of female Fisher 344 rats following a single dose 
of 50 Gy radiation to the spinal cord. Apoptosis was analysed via histology and terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and 3.2 ± 10% of 
apoptotic cells in the spinal cord 10 hours following irradiation were identified as endothelial 
(cells positively stained for factor-VIII-related antigen). A similar study conducted by Pena, 
Fuks and Kolesnick (2000) found 16-20% of endothelial cells in the spinal cord of male mice 
underwent apoptosis at 12 hours following exposure to 50 Gy of irradiation. Zhang, Y et al. 
(2012) observed positive apoptotic staining co-localised to the lung endothelium of C57BL/6J 
mice following a single dose of 15 Gy irradiation to the thorax. It was reported in the study 
that 11% of apoptotic cells in the irradiated lung were endothelial (Zhang, Y et al. 2012). 
Changes to endothelium following irradiation cause significant long-term effects, with 
irradiated endothelium lacking the ability to regulate thrombogenic, inflammatory and 
coagulation processes months to years following irradiation (Boerma et al. 2004; Otterson et 
al. 2012). Many of these effects of radiation on the endothelium are related to changes in 
angiogenic signalling. 
Angiogenic changes have been described in vitro, with the angiogenesis pathway being over-
expressed in primary human endothelial cells from 12 hours to 21 days following a single 
irradiation dose of 2Gy (Heinonen et al. 2015). The angiogenic mediator TGF-β1 has been 
found to be up-regulated preclinically in both early and delayed RIGT and is an upstream 
 Chapter 2 RIGT: MMPs and the microvasculature  
26 
 
mediator of thrombomodulin, capable of reducing thrombomodulin immunoreactivity in the 
endothelium. Thrombomodulin is a transmembrane glycoprotein present on endothelial cells 
which is capable of forming a complex with thrombin, preventing the formation of fibrin and 
the activation of protease activated receptor-1 (PAR-1). This leads to the activation of protein 
C, an anticoagulant and anti-inflammatory protein (Wang, J et al. 2002). When 
thrombomodulin reactivity is reduced following irradiation PAR-1 is up-regulated, decreasing 
thromboresistance and inducing endothelial dysfunction (Wang, J et al. 2002; Wang, FZ et al. 
2012; Boerma et al. 2013). TGF-β1 has also been shown to enhance radiation-induced fibrotic 
thickening of the intestinal wall and subserosa in a rat model of early and delayed RIGT 
following fractionated irradiation (Boerma et al. 2013). Although these microvascular 
changes have been described in several studies, the causal relationship of these changes to 
RIGT pathobiology are yet to be explored, as are the opportunities for novel therapies that 
may arise from this. 
2.7 Matrix metalloproteinases and the intestinal microvasculature following 
radiotherapy 
The MMP family has been strongly linked to endothelial regulation and angiogenesis, and 
could play a direct role in pathological angiogenesis associated with RIGT (Bergers et al. 
2000; Al-Dasooqi et al. 2010). Much of what is known regarding the involvement of MMP in 
the regulation of the endothelium, particularly MMP -2 and -9, is from their involvement in 
tumour invasion and tumour angiogenesis. MMP -9 has been shown to be integral in the 
progression of some cancer types based on its ability to regulate angiogenesis (Bergers et al. 
2000; Bhoopathi et al. 2010). MMP members degrade the basement membrane allowing for 
endothelial proliferation and migration, and remodeling of the extracellular matrix, inducing 
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tube formation (Chidlow et al. 2007; Al-Dasooqi et al. 2011). Members of the MMP family 
also indirectly induce pathological angiogenesis via regulation of angiogenic mediators such 
as vascular endothelial-cadherin (VE-cadherin), TGF-β, chemokines, vascular endothelial 
growth factor (VEGF), platelet-derived growth factor (PDGF), angiostatin, and endostatin 
(Ichikawa et al. 2006; Xu, Yu & Duh 2006; Bendrik et al. 2008; Manicone & McGuire 2008; 
Tolstanova et al. 2011). These mediators contribute to many facets of pathological 
angiogenesis including increased vascular permeability, vasodilation, endothelial 
proliferation, and inhibition of vessel maturation and pericyte stabilization (Kalluri 2003; 
Bendrik et al. 2008; Tolstanova et al. 2011). Due to this cumulative evidence of a role for the 
MMP family in endothelial regulation, MMP inhibitors have been explored for their efficacy 
in the reduction of tumour burden and metastasis. Whilst broad-acting MMP inhibitors such 
as marimastat significantly inhibited tumour angiogenesis and reduced tumour burden 
preclinically, phase II and III clinical trials have been unsuccessful (Zucker, Cao & Chen 
2000; Zucker & Cao 2009). This may be due to the vastly different, and even opposing 
affects, of various MMP types, as well as the exclusion of patients with early stage cancer 
(Zucker & Cao 2009). Specific inhibition of MMP members known to be involved in tumour 
angiogenesis, such as MMP -2 and -9, may be more efficacious in ongoing research, and 
provide insights in to how matrix metalloproteinases may be regulating these endothelial 
changes.  
Few studies have been conducted to assess the role of matrix metalloproteinases in changes to 
the intestinal microvasculature in RIGT, and most have been performed in vitro. Park et al. 
(2012) found MMP -2 and vascular endothelial growth factor receptor (VEGFR)-2 to be 
significantly increased 24 hours following a single radiation dose of 4 Gy in human brain 
microvascular endothelial cells (HBMECs) and human dermal microvascular endothelial cells 
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(HDMECs). In a similar in vitro model, capillary endothelial cells were irradiated with a 
single dose of 10 Gy and displayed significantly increased apoptosis, as well as an increase in 
active MMP -1 and -2 (Vorotnikova, Tries & Braunhut 2004). MMP -2 expression was also 
increased at 24 hours, as was MMP -2 enzyme activity at 24 and 48 hours, following a single 
dose of 4 Gy irradiation in endothelial cells cultured from normal human breast tissue (Oh et 
al. 2014). In contrast, MMP -9 expression decreased in these cells at 24 and 48 hours 
following irradiation (Oh et al. 2014). Whilst these studies suggest MMP, particularly the 
gelatinase MMP -2, are directly involved in the endothelial response to radiation, further in 
vivo studies are warranted. 
2.8 MMP signalling regulates endothelial mediators of RIGT 
2.8.1 MMP and Vascular Endothelial Growth Factor (VEGF) 
VEGF plays a variety of roles in the regulation of microvasculature. It is capable of increasing 
vascular permeability, causing transient vasodilation, and promoting endothelial proliferation, 
migration, and differentiation, all of which stimulate angiogenesis (Ferrara, Gerber & 
LeCouter 2003; Chidlow et al. 2007). The primary ability of the MMP family, particularly 
MMP -2 and -9, to increase VEGF, lies in their ability to cleave collagen IV to release 
sequestered VEGF (Bergers et al. 2000; Kalluri 2003). Once VEGF has been released it is 
able to bind to VEGF receptors on endothelial cells and induce angiogenesis via a tyrosine 
kinase pathway (Lee et al. 2015). MMP -2, and 9 have also been suggested to change the 
structure of VEGF, cleaving larger VEGF isoforms and increasing bioavailability, however, 
Hawinkels et al. (2008) found MMP -9 to have no effect in cleaving VEGF165 to the smaller, 
soluble isoform VEGF121 in HT29 colon carcinoma and fibroblast spheroids (Belotti et al. 
2003; Kalluri 2003; Hawinkels et al. 2008). Hawinkels and colleagues (2008) showed a 
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decrease in extracellular localization of heparan sulphate proteoglycans (HSPG), suggesting a 
release of VEGF from the ECM via cleavage of HSPG by MMP -9. Bergers et al. (2000) 
cultured normal, non-transgenic pancreatic islets from C57/B16 mice with MMP -9. Cells 
were then washed and embedded in collagen gels containing endothelial cells. Whilst control 
islets, with no added MMP -9, failed to elicit an angiogenic response from the endothelial 
cells, islets treated with MMP -9 promoted the endothelial cells to form sprouts towards the 
islet. VEGF levels were 2-fold higher in the medium of MMP -9 treated islets, and MMP -9 
treated islets showed no angiogenic response of endothelial cells when an anti-VEGF 
antibody was added. This suggests that the MMP -9 mediated endothelial response is 
regulated by VEGF (Bergers et al. 2000). A study by Bhoopathi and colleagues (2010) found 
VEGF expression following secreted protein acidic and rich in cysteine (SPARC) 
overexpression to be MMP -9 dependent in human medulloblastoma cell lines. These studies 
highlight a complex involvement of MMP, particularly MMP -9, with VEGF and it is likely 
that differences in the pathway occur based on tissue types and the tissue environment 
(pathological vs normal tissue).  
2.8.2 MMP and Transforming Growth Factor-β 
The effect of TGF-β on the microvasculature is complex, with TGF-β having several different 
effects on the endothelium, depending on the signalling pathway (Goumans et al. 2003). 
Ionizing radiation has been shown to alter the signalling pathways of TGF-β in endothelium, 
reducing the activation of the activin receptor-like kinase 1 (ALK1) pathway and enhancing 
the ALK5 pathway activation (Kruse et al. 2009; Scharpfenecker et al. 2009). This change in 
signalling pathways is thought to alter the way in which endothelial cells respond to TGF-β, 
with ALK5 inhibiting and ALK1 stimulating endothelial cell proliferation and migration 
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(Goumans et al. 2003). The degradation of the small collagen-associated proteoglycan, 
decorin, by several MMP members has been shown in several studies to sequester latent TGF-
β, converting it to its active state (Imai et al. 1997). TGF-β1 and MMP -9 mRNA levels have 
been shown to be significantly increased at 3 and 7 days, as was TGF-β2 from day 1, 
following 10 Gy abdominal X-irradiation (Strup-Perrot et al. 2005). Despite this link between 
MMP -9 and TGF-β, associated changes to the microvasculature are yet to be explored. 
2.8.3 MMP and anti-angiogenic mediators 
Several MMP subtypes have been associated with the anti-angiogenic mediators, endostatin, 
tumstatin, and angiostatin (Kalluri 2003; Tolstanova et al. 2011). Endostatin and tumstatin are 
both anti-angiogenic mediators formed from the c-terminal portions of collagens XVIII and 
IV respectively (Sudhakar et al. 2003). Both collagen IV and XVII, found in vascular 
basement membranes, can be broken down by active forms of MMP -2, cleaving endostatin 
from collagen XVII, and increasing thrombospondin-1, which has been shown to be up-
regulated early and late in an animal model of CIGT (Bowen et al. 2007). MMP -2, -7, -9, and 
-12 are also capable of cleaving plasminogen to form angiostatin (Sternlicht & Werb 2001). 
MMP -9, endostatin, VEGF, and platelet-derived growth factor receptor (PDGFR) were 
increased at different time points in an animal model of ulcerative colitis, with increased 
endostatin and VEGF being correlated with increased size of colonic lesions (Tolstanova et al. 
2011). However, the effects of endostatin and angiostatin on endothelial cells are yet to be 
clarified, with transfection of the MMP -9 gene in vivo inducing endostatin release and 
significantly reducing tumour growth rate and microvessel area in mammary 
adenocarcinomas in mice (Bendrik et al. 2008). This could be due to biphasic effects of 
endostatin, and differential effects depending on cell type (Guan et al. 2003; Folkman 2006). 
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Despite this, COL-3 (Metastat; Collagenex Pharmaceuticals, Newtown, PA, USA), a specific 
inhibitor of MMP -2 and MMP -9, did not increase tumour growth rate of advanced solid 
malignancies in clinical trials and three patients with disease progression prior to treatment 
had prolonged stable disease (>6 months) (Syed et al. 2004). Further studies are now 
warranted to characterise MMP -9 and associated downstream angiogenic mediators in RIGT. 
2.8.4 MMP and endothelial permeability 
MMP -2, -7, and -9 have also been shown to play extensive roles in endothelial permeability 
due to their ability to shed VE-cadherin and cleave occludin; two tight junction proteins with 
essential roles in maintaining tissue permeability. MMP -7 sheds epithelial-cadherin from 
adherens tight junctions to remodel cell-cell contacts and facilitate cell migration (McGuire, 
Li & Parks 2003). VEGF-A, a possible downstream mediator of several MMP subtypes, is 
also capable of increasing junction adhesion molecule -C expression, stimulating occludin and 
VE-cadherin phosphorylation and decreasing occludin and VE-cadherin at endothelial tight 
junctions (Antonetti et al. 1998). This link between matrix metalloproteinases, which have 
been shown to be up-regulated in RIGT, and the phosphorylation of endothelial tight 
junctions, highlights a potential new involvement for the MMP family in intestinal endothelial 
dysfunction and increased permeability in RIGT.  
2.9 Take home messages 
RIGT is one of the most prevalent dose-limiting toxicities manifesting following radiotherapy 
(Sonis, Stephen T.  & Keefe 2013; Lalla, Saunders & Peterson 2014). It involves debilitating 
pain and increases the risk of infection in patients receiving radiotherapy. Due to many of the 
severe side effects of RIGT, it is often necessary to reduce the dosage, or halt anti-neoplastic 
therapies, leading to decreased remission and increased mortality (Lalla, Saunders & Peterson 
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2014). Despite the prevalence and burden of this pathology, there are currently no effective 
treatments for RIGT and its pathobiology remains to be clearly understood. Various MMP 
members have been shown to be altered in the intestine following irradiation, in the settings 
of both acute and delayed RIGT (Strup-Perrot et al. 2004; Strup-Perrot et al. 2006; Angenete 
et al. 2009). The gastrointestinal microvasculature has also been implicated in RIGT 
development, with endothelial apoptosis occurring early in the pathology, and pathological 
angiogenesis being observed in several models of RIGT (Paris et al. 2001; Kruse et al. 2004; 
Yeoh et al. 2005). Several MMP subtypes are capable of regulating many angiogenic and 
anti-angiogenic endothelial mediators, such as VEGF, TGF-β, endostatin, and angiostatin, 
highlighting a strong link for their role in RIGT-associated microvascular changes. Thus the 
present review proposes a vascular mediator pathway, regulated by altered MMP expression 
or activation following irradiation, as being involved in intestinal microvascular changes seen 
in both acute and delayed RIGT. Although further study is necessary, the MMP family 
presents a unique target in the development of novel therapies for RIGT. Due to the complex 
nature of members of the MMP family, and differential effects based on the type of MMP, 
tissue type, and pathology, extensive studies are required. As RIGT is a prevalent and 
debilitating adverse effect of anti-neoplastic therapies, any future studies focusing on the 
biological basis of this pathology will aid in the development of anti-mucotoxic therapies of 
much clinical value. 
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Chapter 3 Fractionated abdominal irradiation induces intestinal microvascular changes 
in an in vivo model of radiotherapy-induced gut toxicity 
[Stansborough R.L. et al., (2017) Supportive Care in Cancer. 25(6): 1793-1983] Included in 
this thesis with permission of Springer © Springer-Verlag Berlin Heidelberg 2017 
Referencing has been altered from original publication for consistency between chapters. 
3.1 Abstract 
Purpose: Radiotherapy-induced gut toxicity (RIGT) is associated with diarrhoea, pain and 
rectal bleeding and can occur as an acute or chronic toxicity. The microvasculature has been 
shown to be altered in the development of RIGT; however, the features are not yet 
characterized. We hypothesized that apoptosis of microvascular cells would occur early in the 
gastrointestinal tract following fractionated irradiation, followed by late microvascular 
changes, including sclerosis and telangiectasis. 
Methods: Female Dark Agouti rats were treated with a 6-week fractionated radiation schedule 
of 3 × 2.5 Gy doses per week localized to the abdomen. At 3, 6 and 15 weeks, the intestines 
were assessed for markers of acute and chronic injury including morphological changes, 
collagen deposition, apoptosis and proliferation. 
Results: Apoptosis of microvascular cells significantly increased at 6 and 15 weeks in the 
jejunum (p = 0.0026 and p = 0.0062, respectively) and at 6 and 15 weeks in the colon (p < 
0.0001 and p = 0.0005, respectively) in rats receiving fractionated radiation to the abdomen. 
Histopathological changes of the colon microvasculature were also seen from week 3, 
including thickening of the lamina propria and dilated, thickened, telangiectatic vessels. 
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Conclusions: Findings of this study provide evidence of regional and timing-specific changes 
in the intestinal microvasculature in response to fractionated radiotherapy which may play a 
role in development of both acute and chronic RIGT. 




Radiotherapy-induced gut toxicity (RIGT) is an adverse effect of radiotherapy for cancer, 
which may occur as an acute toxicity (also referred to as gastrointestinal mucositis or acute 
radiation enteropathy) or chronic toxicity (also chronic radiation enteropathy) (Hauer-Jensen, 
Denham & Andreyev 2014; Stansborough et al. 2016). In patients receiving radiotherapy for 
abdominal or pelvic tumours, approximately 60–80% develop symptoms of acute gut toxicity, 
including, but not limited to, nausea, diarrhoea, pain and fatigue (Hauer-Jensen, Denham & 
Andreyev 2014). Chronic gut toxicity may also occur following radiotherapy and includes 
symptoms such as altered intestinal transit, gut dysmotility and less commonly intestinal 
obstruction or fistulae formation (Hauer-Jensen, Denham & Andreyev 2014). Despite these 
symptoms, there remain few treatment options for RIGT, largely hindered by a lack of 
understanding of the underlying pathobiology (Hauer-Jensen, Denham & Andreyev 2014; 
Lalla et al. 2014). This is particularly true for the endothelium. Late rectal bleeding is one of 
the most common symptoms of RIGT following high-dose radiotherapy for prostate cancer, 
occurring in up to 70% patients (Akimoto et al. 2004; Kruse et al. 2004). This points to a 
likely impact of radiation on the normal intestinal microvasculature. Whilst intestinal 
epithelial cell apoptosis (Potten et al. 1994; Qiu et al. 2010), activation of transcription factors 
such as NF-κB (Yeoh et al. 2005) and a cascade of inflammatory mediators including pro-
inflammatory cytokines and matrix metalloproteinases (Strup-Perrot et al. 2005; Strup-Perrot 
et al. 2006) are well known to be involved in RIGT, these pathways are yet to be 
characterized in the endothelium.  
Paris and colleagues (2001) assessed changes to endothelial apoptosis in the jejunum of 
C57BL/6 mice who received 8–15 Gy whole body irradiation. Whilst this study showed that 
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endothelial apoptosis occurred early (4 h) following irradiation, the model was largely based 
on GI syndrome, in which doses are not clinically translatable in the context of radiotherapy 
for cancer (Paris et al. 2001). Additionally, later preclinical studies showed conflicting results, 
in which endothelial apoptosis did not to occur early during GI syndrome and did not 
contribute to the severity of toxicity (Schuller et al. 2007; Kirsch et al. 2010). Abderrahmani 
and colleagues (2012) found a significant increase in endothelial apoptotic cells in the villus 
lamina propria 4 and 5 h following 19 Gy intestinal irradiation in mice (Abderrahmani et al. 
2012). This was significantly lower in plasminogen activator inhibitor-1 (PAI-1) knockout 
mice, which had significantly reduced acute and late radiation-induced intestinal injury when 
compared to wild-type mice (Abderrahmani et al., 2012). Whilst this again suggests a link 
between early endothelial apoptosis and intestinal injury, epithelial apoptosis was also 
significantly lower in PAI-1 knockout mice at the 5-h time point, making it difficult to 
suggest which may be contributing to the reduced toxicity (Abderrahmani et al. 2012). 
Despite the lack of consensus of the literature on endothelial apoptosis in RIGT, changes to 
intestinal microvasculature have been identified, both clinically and pre-clinically (Kruse et 
al. 2004; Yeoh et al. 2005). Yeoh and colleagues (2005) assessed histological changes of 
archived colorectal tissue samples from 28 patients with colorectal carcinoma who had 
received either preoperative short term pelvic irradiation or long-term neoadjuvant 
chemoradiotherapy. Short-term radiation involved a total dose of 25 Gy using the 4 field box 
technique, over 5 fractions in 1 week. Long-term neoadjuvant chemoradiotherapy involved 
concurrent 5-FU (300 mg/m2/day) and pelvic irradiation with 45 Gy in 25 fractions over 5 
weeks. Yeoh et al. (2005) demonstrated telangiectatic, fibrosed and sclerosed blood vessels in 
the lamina propria, submucosa and fat layer of the gastrointestinal tract following abdominal 
radiation. The study did not assess these changes in direct relation to the occurrence of RIGT 
 Chapter 3 Intestinal microvascular changes in RIGT  
40 
 
in the patients; however, 16 out of 28 of recruited patients did experience symptoms of 
gastrointestinal toxicity during treatment (Yeoh et al. 2005). In pre-clinical studies, tortuous 
telangiectatic vessels have been seen in the rectum of mice irradiated with a single dose of 20 
Gy. These did not resolve at the completion of the study (30 weeks following irradiation); 
however, these changes were not investigated in relation to clinical parameters of 
gastrointestinal toxicity in these mice (Kruse et al. 2004). 
Despite the observation of pathological blood vessels in RIGT, few studies have investigated 
specific vascular changes in an in vivo model of fractionated irradiation. Several studies, 
however, have assessed thrombogenic changes to the microvasculature in an attempt to 
characterize mediator pathways underpinning vascular-related symptoms such as rectal 
bleeding, including changes to levels of vascular mediators such as thrombomodulin, 
protease-activated receptor-1 (PAR-1) and von Willebrand factor (vWF) (Jahroudi, Ardekani 
& Greenberger 1996; Wang, J et al. 2002; Hauer-Jensen, Fink & Wang 2004). Wang and 
colleagues (2002) found a statistically significant decrease in the number of thrombomodulin-
positive blood vessels in the intestines of Sprague-Dawley rats who had received fractionated 
radiation (33.6 Gy in 8 daily fractions or 67.2 Gy in 16 daily fractions) to a surgically induced 
scrotal hernia. Irradiated rats also displayed mucosal ulceration and inflammation during early 
RIGT (1 day and 2 weeks following cessation of radiation), vascular sclerosis and reactive 
fibrosis of the subserosa and submucosa in delayed RIGT (6 and 26 weeks following 
radiation). 
Decreases in thrombomodulin are known to increase PAR-1 and decrease protein C 
activation, leading to upregulation of inflammatory mediators and endothelial dysfunction 
(Wang, J et al. 2002; Hauer-Jensen, Fink & Wang 2004). These changes in vascular mediator 
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upregulation following radiotherapy suggest a change in pathophysiological state of the 
intestinal microvasculature; however, further studies are needed to determine how this is 
affecting microvascular cell kinetics.  
Thus, the present study aimed to determine changes to microvascular apoptosis and 
proliferation following fractionated abdominal radiation in an animal model of RIGT. The 
study also aimed to assess clinical and histopathological parameters of RIGT including 
changes to body weight and epithelial apoptosis to assess the timeline of these changes in the 
context of microvascular damage. In the present study, we demonstrate for the first time 
significantly increased intestinal microvascular apoptosis and significantly reduced 
microvascular proliferation following fractionated radiation in rats. 
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3.3 Materials and Methods 
3.3.1 Ethics 
This study was conducted in accordance with ethics approved by the Animal Ethics 
Committees at both The University of Adelaide (M-041-2006) and the Institute of Medical 
and Veterinary Science (IMVS) (78/05) and complied with the National Health and Medical 
Research Council (Australia) Code of Practice for Animal Care in Research and Teaching 
(2007). 
3.3.2 Animals and Experimental Design  
Seventy female Dark Agouti (DA) rats, weighing 155 to 170 g on arrival, were housed under 
controlled conditions with 12 h dark and 12 h light cycles. Rats had ad libitum access to water 
and standard rat chow. The experimental design was based on our previously published pilot 
study (Yeoh et al. 2007). Briefly, rats (n = 5 per time point) were randomly assigned into 
three groups receiving radiation and three groups receiving sham irradiation. Prior to 
irradiation, rats in both treatment and control groups were anaesthetized with 4% isofluorane 
and placed into a custom-built container (Yeoh et al. 2007). Rats in the treatment groups were 
irradiated, limited to the abdomen by lead shielding, at a dose of 2.5 Grey (Gy)/fraction three 
times a week to a total of 45 Gy/18 fractions/6 weeks prescribed to depth of 3.3 cm using a 
Varian Clinac Linear Accelerator (Varian Medical Systems) with focus-skin distance of 130 
cm. Control rats received sham irradiation in the same course as treated rats. Groups of rats 
were killed at the ends of weeks 1 to 6, representing acute toxicities from short- and long-
course radiation, and at 15 weeks, representing a delayed, or chronic, toxicity. Animals were 
closely monitored in the immediate recovery period (30 min from radiation) and were then 
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monitored daily for weight change, diarrhoea, dull/ ruffled coat, change in temperament, 
reluctancy to move and skin reaction to radiation, throughout the experimental time course. 
3.3.3 Gastrointestinal Tissue collection 
Gastrointestinal tissue was collected as previously described by Yeoh and colleagues (2007). 
Following flushing of the small and large intestine with cold isotonic saline, sections of 
jejunum (at 25% length of small intestine from the pylorus) and colon (at 50% length of large 
intestine) were resected into 2-cm sections, fixed in 10% neutral formalin and embedded in 
paraffin for further analysis. In preparation for staining, sections were cut using a rotary 
microtome (Leica) to 4 μm and were mounted on uncoated slides for haemotoxylin & eosin 
(H&E) and Picro sirius red staining or FLEX immunohistochemistry (IHC) microscope slides 
(Dako) for IHC. 
3.3.4 Histology 
H&E staining was conducted to determine morphological changes to the jejunum and colon 
following irradiation as described previously (Yeoh et al. 2007), including villous blunting or 
fusion, crypt loss, inflammation, vessel dilation and oedema. Picro Sirius red staining was 
used to determine total tissue collagen levels as described previously (Al-Dasooqi et al. 
2011). Briefly, sections were dewaxed in xylene and hydrated in a series of graded ethanol. 
Picro Sirius red solution (0.5 g Sirius red F3B in 500-ml saturated aqueous picric acid 
solution) was applied to sections and left at room temperature for 1 h. Sections were then 
washed using acid water (0.5% acetic acid in H2O), dehydrated, cleared and coverslipped. 
Images of H&E and Picro Sirius red-stained tissue were taken using NanoZoomer scanning 
equipment (Hamamatsu, Japan), and images were analysed using NanoZoomer Digital 
Pathology software (NDP.view2, Hamamatsu). H&E-stained tissue was assessed using a 
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previously validated damage scoring method in which sections were given a score of either 0 
or 1 for the presence of the following factors: disruption of the brush border, crypt 
loss/architectural disruption, disruption of crypt cells, infiltration of polymorphonuclear cells 
and lymphocytes, dilation of lymphatics and capillaries, oedema and villous fusion and 
atrophy in the jejunum. Picro Sirius red-stained tissue was assessed qualitatively. All 
assessments were conducted in a blinded fashion by one assessor (RLS). 
3.3.5 Immunohistochemistry (IHC) 
Activated caspase 3 and Ki67 proteins were visualized by IHC staining in intestinal tissue 
from rats killed at the end of weeks 3, 6 and 15 to determine levels of apoptosis, proliferation 
and microvascular cell dysfunction, respectively. Caspase 3 and Ki67 primary antibodies 
were utilized as previously published (Marshman et al. 2001; Al-Dasooqi et al. 2011). A 
Dako-automated staining system (Autostainer link 48 and PT Link, Dako) was used to 
conduct IHC for caspase 3 (Abcam #ab44976, 0.200 mg/ml), Ki67 (Abcam #ab16667, 
concentration not provided) at dilutions of 1:1000 and 1:1200, respectively. IHC was 
conducted according to manufacturer’s instructions using the EnVision™ FLEX kit for Dako 
autostainer link systems (Dako) and as previously described (Wardill et al. 2015). Briefly, 4-
μm sections of jejunum and colon mounted on IHC microscope slides (Dako) were dewaxed 
in histolene and rehydrated through a series of graded ethanols. Antigen retrieval was 
conducted using a Tris/EDTA antigen retrieval buffer (0.37 g/l EDTA, 1.21 g/l Tris; pH 9.0) 
in the PT link antigen retrieval system (Dako) in which the buffer was preheated to 65 °C 
following which slides were added then heated to 97 °C for 20 min. Slides were placed in the 
autostainer, and sections were blocked for 5 min using the FLEX 0.3% hydrogen peroxide 
block (Dako). A protein block (0.25% casein in PBS, containing stabilizing protein and 0.015 
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mol/l sodium azide, Dako) was then applied for 30 min to reduce non-specific background 
staining of tissue, followed by application of the primary antibody for 60 min. Rabbit HRP-
labelled polymer conjugated to goat anti-rabbit or goat anti-mouse (Dako), depending on the 
specifications of the antibody, was then applied for 30 min as a labelling and secondary 
antibody system. Sections were visualized using DAB (EnVision™ FLEX kit, Dako) and 
counterstained with Harris’ haematoxylin for 20 s, dehydrated in 100% ethanol, cleared with 
histolene and coverslipped. Images were taken using NanoZoomer scanning equipment 
(Hamamatsu) and DAB staining of villi (jejunum only), crypts, and microvasculature was 
analysed on NanoZoomer Digital Pathology software (NDP.view2, Hamamatsu). Cell counts 
per crypt (average of 15 crypts per section) were taken for caspase 3 and Ki67 staining in the 
jejunum and colon mucosa as well as in the villi of the jejunum. Cell counts of caspase 3 and 
Ki67-immunostained cells were also performed on the microvasculature in the lamina propria 
and submucosa in which stained cells were counted in 15 microvessels per section and were 
then averaged to give stained cells per vessel. All sections were assessed in a blinded fashion 
by one assessor (RLS). 
3.3.6 Statistical Analysis 
Group means for histological damage scoring and apoptotic and proliferative cell counts were 
compared between sham irradiated and irradiated rats per time point. All statistical analysis 
was conducted using the program Graphpad Prism (version 6). Differences between study 
group means were analysed using a two-way ANOVA with Sidak’s multiple comparison. 
Asterisks denote significance compared to control at the time point, where *<0.05, **<0.01, 
***<0.001 and ****<0.0001. Bars on graphs represent standard error of the mean. 
  




3.4.1 Response of animals to fractionated radiation 
Animals receiving fractionated irradiation to the abdomen three times a week displayed 
significantly lower weight gain (represented as a % from baseline) at weeks 3 (p = 0.0055) 
and from 6 weeks onwards (p < 0.05) when compared to animals receiving sham irradiation 
(Fig. 1). Whilst some rats were observed to have a dull/ruffled coat raised around the neck 
following irradiation, no significant differences were observed in any other clinical 
parameters including diarrhoea, change in temperament, reluctancy to move or skin reaction 
to radiation (data not shown). Small intestinal weight was significantly higher in irradiated 
rats at 15 weeks (p < 0.0001) (Table 1). There were no significant differences in large 
intestinal weight between irradiated and control rats (Table 1).   





Figure 1. Percentage body weight change from baseline (day 0) of DA rats following 
fractionated abdominal irradiation. Percentage body weight gain was significantly lower in 
irradiated rats when compared to controls at week 3 (p < 0.0001) and every week from week 6 
until study completion in week 15 (6–9 weeks, p < 0.05; 10–15 weeks, p < 0.01). Shaded area 
of graph represents course of fractionated or sham irradiation. Asterisk denotes significances 
compared to control where *p < 0.05, **p < 0.01  
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3.4.2 Fractionated radiation induced microvascular changes to the jejunum and colon 
Jejunum 
Damage scoring was not significantly altered in the jejunum at any time point (Suppl. 1). 
Despite this, thickening of the lamina propria and dilated, thickened, telangiectatic vessels 
were seen at week 6 in H&E-stained sections (Fig. 2). This thickening of the intestinal 
microvasculature was confirmed using Picro Sirius red in which fibrotic thickening of the 
microvasculature was also seen, extending from weeks 3 to 15 (Fig. 2). No significant 
difference was seen in the villus height or crypt depth (data not shown). 
Colon 
Damage scoring of the colon was significantly increased compared to controls at week 3 (p = 
0.043) (Suppl. 1). Histopathological changes of the colon microvasculature were seen in rats 
receiving irradiation from week 3. Thickening of the lamina propria and dilated, thickened, 
telangiectatic vessels were seen from 3 weeks after the first radiation dose and had resolved 
by week 6 (Fig. 2). This thickening of the intestinal microvasculature was confirmed using 
Picro Sirius red staining and vasodilation, and fibrosis of the microvasculature was observed 6 
weeks from the first radiation dose (Fig. 2). Crypt depth was significantly higher in the colon 
of rats receiving radiation when compared to control rats at 5 weeks (p = 0.022). No 
significant differences were noted at any other time point (data not shown). 
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Table. 1 Small intestinal weight and large intestinal weight of DA rats following fractionated 
































Small intestinal weight was significantly higher in irradiated rats at week 15 (p < 0.0001) 
when compared to time matched controls. Large intestinal weight did not significantly differ 
between groups at any time point. Data presented as mean ± standard deviation. * denotes 
significance compared to time matched control where ****p < 0.0001 
 




Figure 2 Morphological changes to jejunum and colon microvasculature following 
fractionated irradiation. A H&E-stained jejunal microvasculature with dilated, telangiectatic 
vessels indicated by arrows. B Picro Sirius red-stained jejunal microvasculature in which 
fibrotic thickening of vessels can be seen from week 3 following irradiation (indicated by 
arrowheads). C H&E-stained colonic microvasculature displaying formation of telangiectatic 
vessels (indicated by arrows) following fractionated irradiation. D Picro Sirius red-stained 
colonic microvasculature with a thickened vessel indicated by arrowhead. ×40 magnification. 
Scale bar = 30 μm 
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3.4.3 Fractionated radiation induced microvascular cell apoptosis and reduced 
microvascular proliferation in the jejunum and colon 
Jejunum 
Apoptosis of microvascular cells significantly increased at 6 and 15 weeks in the jejunum (p = 
0.0026 and p = 0.0062, respectively) in rats receiving fractionated radiation to the abdomen 
(Fig. 3). Cell proliferation, measured by Ki67 immunostaining, was not significantly altered at 
any time point in the jejunal microvasculature (Fig. 4). 
Colon 
Colonic microvascular cell apoptosis was significantly increased at 6 weeks (p < 0.0001) and 
15 weeks (p = 0.0005) in rats receiving fractionated radiation when compared to control (Fig. 
3). No significant changes in microvascular apoptosis were seen between groups at 3 weeks. 
Microvascular cell proliferation was significantly decreased 3 weeks from first dose in the 
colon (p = 0.0072) and was not significantly altered at week 6 (Fig. 4). In contrast, 
proliferation significantly increased at 15 weeks in the colon microvasculature (p = 0.0041).  
3.4.4 Fractionated radiation induced apoptosis in the epithelial cells of the crypts of the 
jejunum and colon 
Jejunum 
Apoptosis, as determined by caspase 3 immunostaining, was significantly higher in the 
epithelial cells of the jejunum crypts of irradiated rats at 3 and 6 weeks (p = 0022 and p < 
0.0001, respectively) (Fig. 5). Jejunal crypt apoptosis was not significantly altered at the 15-
week time point. There were also no significant changes in apoptosis in the villi of the 
jejunum at any time point assessed. 




Apoptosis was also significantly increased in the epithelial cells lining the colonic crypts at 6 
weeks when compared to control (p = 0.014) (Fig. 5). Again, no significant changes were 
seen at any other time point. 
3.4.5 Fractionated radiation induced proliferation in the epithelial cells of the jejunum and 
colon 
Jejunum 
There were no significant changes seen to proliferation indices in the jejunal crypts or villi at 
any time point after irradiation (data not shown). 
Colon 
Proliferative cells in the colon crypts, as determined by Ki67 immunostaining, were 
significantly higher in the radiation group at 6 weeks when compared to control (p = 0.026) 









Figure 3. Caspase 3 immunostaining of the jejunum and colon microvasculature. A Caspase 
3 significantly increased in the micro vessel of the jejunum at 6 and 15 weeks. B Caspase 3 
staining increased in the colon microvasculature at 6 and 15 weeks. C Caspase 3 staining of 
the jejunal microvasculature. Arrow indicates apoptotic microvascular cells, with arrowhead 
indicating unstained red blood cells. D Caspase 3 staining of the colonic microvasculature 
with arrows indicating apoptotic microvascular cells at 6 and 15 weeks. Scale bar = 30 μm, 
×40 magnification. * Significance compared to control where **p < 0.01, ***p < 0.001, 
****p < 0.0001 




Figure 4. Ki67 immunostaining of the colon microvasculature. A Ki67-stained microvascular 
cells significantly decreased in the colon at week 3 and significantly increased at week 15. B 
Ki67 staining of the colon microvasculature. Scale bar = 30 μm, ×40 magnification. * 
Significance compared to control where **p < 0.01 
 




Figure 5. Apoptosis of jejunal and colonic crypts following fractionated irradiation. A 
Caspase 3-immunostained cells significantly increased in the jejunal crypts at 3 (p = 0.0029) 
and 6 weeks (p < 0.0001) when compared to control. B Caspase 3-immunostained cells were 
significantly increased in the colon crypts at 6 weeks in the irradiated group (p = 0.0145). C 
Caspase 3 immunostaining in the jejunal crypts with apoptotic cells indicated by arrows. D 
Caspase 3 immunostaining in the colonic crypts with apoptotic cells visible at week 6. Scale 
bars = 40 μm. Asterisk denotes significance compared to controls where *p < 0.05, ****p < 
0.0001 





RIGT is a debilitating adverse effect of radiotherapy for cancer; however, RIGT pathobiology 
is not entirely understood, hindering the development of novel treatments. Key findings from 
this study demonstrate an increase in apoptotic cells of the microvasculature following 
fractionated abdominal radiation in rats. Of particular interest, apoptosis of the colon 
microvasculature was shown to occur 15 weeks following initial irradiation in the colon, 9 
weeks following the last dose of radiation. Although previous studies have assessed changes 
in vascular mediator expression and histopathological features of endothelial dysfunction in 
RIGT (Richter et al. 1998; Wang, J et al. 2002), this is the first study showing microvascular 
apoptosis to be occurring in the delayed, or chronic, phase of RIGT, as displayed in the 15-
week time point of the current study. This late microvascular apoptosis in the colon may be 
linked to mediators previously known to contribute to intestinal endothelial dysfunction 
following irradiation such as transforming growth factor beta (TGFβ), PAR-1 and von 
willebrand factor (Jahroudi, Ardekani & Greenberger 1996; Wang, J et al. 2002). 
RIGT was shown to occur in the present study, with irradiated rats gaining significantly less 
weight compared to sham irradiated controls and increased apoptosis in crypts of both the 
jejunum and colon. This is in support of previous studies assessing RIGT following 
fractionated radiation in vivo (Al-Dasooqi et al. 2011). Yeoh and colleagues (2007) described 
significantly increased apoptosis in crypts of both the jejunum and colon from weeks 1–6 in 
DA rats administered a 6-week course of fractionated radiation to the abdomen (3 × 2.5 
Gy/week). The studies did, however, differ with regard to proliferation of cells in the crypts. 
The present study showed an increase in proliferation at 6 weeks in the colonic crypts, as 
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opposed to a significant decrease in proliferating cells throughout the course of radiation in 
the aforementioned study (Al-Dasooqi et al. 2011). This could be explained in part by the 
differences between assessments of proliferating cells, with the present study using 
immunostaining of Ki67, a protein expressed in all active phases of the cell cycle, as opposed 
to mitotic cell count. Apoptosis was also shown to be highest at 6 weeks in both the jejunum 
and colon, indicating an accumulative effect of fractionated radiation on damage to the 
gastrointestinal mucosa. This is consistent with what has previously been seen in models of 
fractionated irradiation, in which it is proposed that the epithelial cells are able to regenerate 
due to breaks in the course of radiation (Al-Dasooqi et al. 2011). This is reflected in the 
relatively unchanged levels of proliferation in the jejunum and colon throughout the time 
course of the study. 
The significant increase in wet weight of the small intestine is most likely explained by 
changes associated with chronic, or delayed, RIGT. In this late phase, reactive fibrosis often 
occurs, leading to fibrotic thickening of the muscle layer, submucosa and vascular walls 
(Wang, J et al. 2002). Several studies have assessed this in in vivo models of delayed 
radiation-induced enteropathy, and increases in collagen deposition and upregulation of 
fibrotic mediators including TGFβ have been shown (Jahroudi, Ardekani & Greenberger 
1996; Wang, J et al. 2002). These changes, coupled with oedema and inflammatory infiltrate, 
could be leading to this increased wet weight of the small intestine, although parameters of 
histopathological damage, including oedema and presence of neutrophils, were not 
significantly increased in the jejunum at any time point in the current study. 
This study is the first to show changes to microvascular apoptosis and proliferation in an in 
vivo fractionated radiation model. Of particular interest is the sustained microvascular cell 
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apoptosis occurring 9 weeks following the cessation of irradiation in the colon (week 15 of 
the study). Despite this, numbers of apoptotic cells in the crypts of the colon were not 
significantly higher than controls at the 15-week time point. Whilst this long-term 
microvascular apoptosis has not previously been shown, changes to the intestinal 
microvasculature have been observed many months following chemotherapy, and the biology 
of these cells has shown to be altered (Richter et al. 1998; Wang, J et al. 2002). 
Wang and colleagues (2002) have shown an increase in thrombomodulin, an endothelial 
transmembrane glycoprotein and a decrease in protein C, an anticoagulant and anti-
inflammatory protein, in a rat model of chronic radiation enteropathy. This increase in 
thrombomodulin leads to endothelial dysfunction, involving decreased thromboresistance and 
the activation of protease-activated receptor 1 (PAR-1) (Wang, J et al. 2002; Hauer-Jensen, 
Fink & Wang 2004). These mediator changes, particularly thrombomodulin and activated 
protein C, could play a role in the microvascular cell apoptosis seen in this delayed toxicity 
phase in the present study. Both thrombomodulin and protein C have been shown to be 
protective in models of endothelial apoptosis, thought to be due to the ability of protein C to 
decrease the expression and activation of transcription factor NF-kB and downregulate pro-
apoptotic proteins p53 and Bax (Cheng et al. 2003; Mosnier, Zlokovic & Griffin 2007; Li, Y-
H et al. 2012), however, this link has not yet been explored in the context of RIGT. 
The current study provides a link between the development of RIGT, particularly late RIGT, 
and intestinal microvascular changes, including microvascular cell apoptosis, early 
senescence and late proliferation. Whilst mucosal damage was significantly increased in the 
colon 3 and 6 weeks into the fractionated radiation schedule, as shown by various indices 
including damage scoring, apoptosis and decreased proliferation, apoptosis and proliferation 
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were observed in the microvascular cells in the delayed RIGT time point of 15 weeks, 9 
weeks following the last dose of fractionated irradiation. Despite this, weight gain of 
irradiated rats was significantly lower than control rats from 6 weeks onwards. These results 
indicate that changes to the intestinal microvasculature may be driving toxicity observed in 
the later time points, indicative of chronic, or delayed, RIGT. In order to determine whether 
these factors are causally related, the effects of endothelial damage on the intestinal response 
to RIGT need to be explored in more depth. Preliminary, in vitro studies have indicated that 
the endothelial cell response to radiation may induce epithelial dysfunction, independent of 
the BAX-mediated apoptosis of epithelial cells following direct irradiation (Gaugler, MH et 
al. 2007). If this pathway could be attenuated, it may lessen gastrointestinal toxicity, thus 
reducing the severity of RIGT. However, this distinct mechanism needs to be further explored 
to determine possible mediators of this response, thus providing targets for the development 
of novel treatments.  
Apoptosis of endothelial cells following radiation has also been shown to occur in endothelial 
cells of other tissues, including lung, brain, spinal cord and kidney (Pena, Fuks & Kolesnick 
2000; Yeoh et al. 2007; Li, G et al. 2014). Whilst few studies have assessed changes to 
intestinal endothelium following irradiation, endothelial apoptosis of the intestinal 
microvasculature has been shown to occur shortly following single-dose irradiation in vivo 
(Sung et al. 2006; Abderrahmani et al. 2012). Endothelial apoptosis in vascular endothelial 
cells in the lamina propria of intestinal crypts was observed 4 h following 14 Gy whole-body 
irradiation of C57BL/6 J mice (Sung et al. 2006). In a similar study by Abderrahmani and 
colleagues (2012), C57BL/6 J mice received a single dose of 19 Gy gamma irradiation to a 
segment of exposed intestine. Endothelial apoptosis in the lamina propria of the villi was 
shown to be significantly increased at 4 and 5 h following irradiation when compared to 
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control (Abderrahmani et al. 2012). Whilst microvascular apoptosis was not observed in the 
earliest time point of the present study (3 weeks), this may be due to the differences between 
fractionated and single-dose radiation. These studies, together with common clinical 
symptoms including rectal bleeding and late reactive fibrosis, and results of the present study, 
highlight a role of the intestinal microvasculature in the pathophysiology of RIGT. 
3.6 Conclusion 
Changes in cell kinetics, specifically apoptosis and proliferation, were observed in the 
intestinal microvasculature throughout the entire time course of fractionated irradiation in 
vivo. Findings of this study highlight a role for intestinal microvasculature in both acute and 
chronic RIGT and implicate intestinal endothelium as being a potential target for the 
development of novel treatments.  




Supplementary Figure 1 Damage scoring of the colon and jejunum of irradiated rats. * 
denotes significances compared to control where * (p < 0.05).  





Supplementary figure 2 Ki67 immunostaining of the colon crypts. A Proliferation was 
significantly higher in the colon crypts at 6 weeks in the irradiated group (p = 0.0260) B Ki67 
immunostaining of the colon crypts.  * = p < 0.05.
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Chapter 4 Matrix metalloproteinase expression is altered in the small and large intestine 
following fractionated radiation in vivo 
[Stansborough R.L. et al., (2018). Supportive Care in Cancer (Available at: 
https://doi.org/10.1007/s00520-018-4255-5)] 
4.1 Abstract 
Purpose: Radiotherapy-induced gut toxicity (RIGT) is associated with significant diarrhoea, 
pain, and rectal bleeding. Matrix metalloproteinases (MMPs) have been reported to be involved 
in chemotherapy-induced gut toxicity and RIGT following single-dose irradiation in vivo. We 
therefore proposed MMPs would be involved in the pathobiology of RIGT following 
fractionated irradiation. 
Methods: Dark Agouti rats were treated with fractionated radiation (3 x 2.5 Gy/week for 6 
weeks). Rats were killed at 3, 6 and 15 weeks to represent acute and chronic toxicities. Section 
of jejunum and colon were immunostained for MMP-1, -2, -9, and -14. Relative mRNA 
expression in jejunum and colon was quantified by RT-PCR for MMP-1, -2, -9, and -14. 
Western blotting was also conducted on jejunum and colon tissue collected at week 6 to 
determine protein levels of pro- and active- MMP-2. 
Results: MMP-2 total protein levels, determined by western blotting, significantly increased in 
both the jejunum (p = 0.0359), and the colon (p = 0.0134) 6 weeks into the fractionated radiation 
schedule. MMP-1, -2, and -14 mRNA expression significantly increased in the jejunum. MMP-
2 mRNA expression was also significantly increased in the colon. Immunostaining of MMP-2 
was observed to be increased in both crypt enterocytes and the lamina propria. 
Conclusions: MMP-2 plays a role in the pathobiology of gastrointestinal toxicities following 
fractionated irradiation. Whilst MMP-1 and -14 mRNA expression was increased, this occurred 
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only in the jejunum, suggesting MMPs are differentially involved in RIGT depending on the 
intestinal region. Further studies are needed to elucidate the role these mediators play in the 
development and potentiation of RIGT.  




Radiotherapy-induced gut toxicity (RIGT) is a debilitating side effect of radiotherapy for 
cancer, estimated to affect over 80% of patients depending on target area and radiation schedule 
(Theis et al. 2010; Shadad et al. 2013b). Symptoms differ depending on time from last dose, 
and can be generally divided into acute and chronic toxicities, with acute toxicities involving 
diarrhoea, pain, rectal bleeding, and histopathological changes to the gut, including villous 
blunting, crypt disruption, and telangiectasia (Yeoh et al. 2007; Stansborough et al. 2016). 
Chronic symptoms include incontinence, rectal bleeding, and ulceration, often due to reactive 
fibrotic thickening of the muscle layer and microvascular walls in the small and large intestines 
(Theis et al. 2010). Both acute and chronic RIGT lead to significant decreases in quality of life, 
and can lead to radiotherapy dose reductions or cessation of treatment (Sonis, Stephen T.  & 
Keefe 2013). Despite this, limited treatment options remain, and most target individual 
symptoms alone (Lalla et al. 2014).  
Matrix metalloproteinases (MMPs), a 24-member family of zinc-dependent endopeptidases, 
have recently been identified in the development of RIGT (Strup-Perrot et al. 2005; Strup-Perrot 
et al. 2006; Angenete et al. 2009). Expression of MMPs can be increased at the transcriptional 
level by mediators known to contribute to the pathogenesis of RIGT, including pro-
inflammatory cytokines and the activation of p53 by NF-κB (Yeoh et al. 2005; Nagase, Visse 
& Murphy 2006; Strup-Perrot et al. 2006; Yue et al. 2015). MMPs are synthesized as pro-
zymogens and can either be secreted, or in the case of membrane type-MMPs (MT-MMPs), 
expressed on the cell surface (Sternlicht & Werb 2001; Yan & Boyd 2007). Pro-MMPs require 
proteolytic activation to allow for degradation of the extracellular matrix. Activation of pro-
MMPs can be induced via the plasminogen-plasmin cascade, or in the case of MMP-2 
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specifically, by MT1-MMP (also known as MMP-14) (Strup-Perrot et al. 2004). MMP 
activation is also regulated by tissue inhibitors of matrix metalloproteinases (TIMPs), which 
are capable of inhibiting active MMPs (Strup-Perrot et al. 2004; Al-Dasooqi et al. 2010).  
Following activation, MMPs are capable of altering cell growth, inflammation, cell death, or 
angiogenesis via the upregulation of downstream mediators such as pro-inflammatory 
cytokines, growth factors, and chemokines (Castaneda et al. 2005; Manicone & McGuire 
2008; Stansborough et al. 2016). MMP-2, -3, and -9, for example, are capable of activating 
the pro-inflammatory cytokine interleukin-1β (Schonbeck, Mach & Libby 1998). Many of 
these mediators are known to be involved in the development of RIGT, with pro-
inflammatory cytokines such as tumour necrosis factor alpha (TNFα), and interleukin-1beta 
(IL-1β) being involved in the propagation of inflammation and eventually ulceration, 
implicating MMPs in this pathobiology (Strup-Perrot et al. 2006; Logan, Stringer, et al. 
2008). 
Due to these widespread effects and possible link to RIGT, Strup-Perrot and colleagues 
(2006) assessed levels of MMP-2, -3, -9, and -14 in the colon of rats irradiated with a single 
abdominal dose of 10 Gy. mRNA expression of all assessed MMPs were significantly 
increased in the colon, and protein levels of both pro- and active MMP-2 were also 
significantly increased 1, 3, and 7 days following irradiation (Strup-Perrot et al. 2006). Few 
studies have assessed changes in MMP expression in RIGT clinically, however protein 
expression of MMP-2, but not -1 or -9, has been shown to be significantly increased in the 
irradiated normal rectal tissue of patients who had received short-term preoperative 
fractionated radiotherapy for rectal cancer (Angenete et al. 2009). These studies clearly 
highlight possible differences in MMP expression dependent on intestinal region, time since 
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last dose, and single dose vs fractionated radiation schedules. Thus further research 
investigating MMPs in different intestinal regions is required in order to better clarify our 
understanding of the role of the MMP pathway in RIGT. 
Whilst studies have linked increases in MMPs to RIGT, no study to date has assessed MMPs 
in multiple regions of the gut following fractionated irradiation in a clinically relevant model 
of RIGT. As it is clear from the aforementioned studies that MMP expression is dependent on 
many factors, including intestinal region and radiation schedule, the present study aimed to 
assess expression and localization of MMPs -1, -2, -9, and -14, in both the jejunum and colon 
in a rat model of fractionated RIGT. The Dark Agouti rat model of RIGT has been utilized in 
this study due to prior characterisation of the histopathological response to RIGT in this 
model, the fractionated radiation schedule reflecting clinical schedules, and the inclusion of 
both acute and chronic time points (Yeoh et al. 2007; Stansborough et al. 2017). 
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4.3 Materials and Methods 
4.3.1 Ethics 
This study was conducted in accordance with ethics approved by the Animal Ethics 
Committees at the University of Adelaide (M-041-2006) and the Institute of Medical and 
Veterinary Science (78/05) and complied with the National Health and Medical Research 
Council (Australia) Code of Practice for Animal Care in Research and Teaching at the time of 
the study. 
4.3.2 Animals and Experimental Design  
Experimental design was as previously described (Yeoh et al. 2007; Stansborough et al. 
2017). Briefly, thirty female Dark Agouti (DA) rats were randomly assigned into groups 
receiving radiation, and groups receiving sham irradiation ). Prior to irradiation, rats in 
treatment and control groups were anaesthetised and placed into a custom-built container, 
limiting radiation to the abdomen (Yeoh et al. 2007; Stansborough et al. 2017). Rats in the 
radiation group were irradiated at a dose of 2.5 Gray (Gy)/fraction three times a week for 6 
weeks prescribed to a depth of 3.3 cm using a Varian Clinac Linear Accelerator (Varian 
Medical Systems, USA) with focus-skin distance of 130 cm. Rats in both sham irradiated and 
irradiated groups were killed at the ends of weeks 3, 6, and 15 (n=5 per treatment group at 
each time point). These time points corresponded to total accumulated doses of 0 Gy (sham 
irradiated controls), 22.5 Gy (3 week time point), or 45 Gy (6 and 15 week time points). 
These time points and doses were calculated to represent acute toxicity (< 12 weeks from start 
of abdominal irradiation) and delayed toxicity (≥12 weeks from start of abdominal 
irradiation). Gastrointestinal tissue was collected following flushing, with two 2 cm sections 
of jejunum (at 25 % length of small intestine from the pylorus) and colon (at 50 % length of 
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large intestine) resected. One section of tissue was formalin-fixed and paraffin-embedded, and 
the other was snap frozen in liquid nitrogen and stored at -80 °C.  
4.3.3 RNA isolation and reverse transcription 
RNA isolation was performed using the Nucleospin® RNA II kit (Macherey-Nagel, Duren, 
Germany) as previously described (Stansborough et al. 2017). Briefly, ~15 mg of tissue was 
homogenized in cell lysis buffer and beta-mercaptoethanol using the TissueLyser LT 
(Qiagen) with stainless steel beads (Qiagen). The lysate was filtered through silica membrane 
filter columns, 70 % ethanol was added, the silica membrane was desalted, and DNA was 
digested using the DNAse reaction mixture. Following washing and drying of the silica 
membrane RNA was eluted in 60 µl of RNase-free water. RNA concentration and purity was 
determined using the TAKE3 plate and Synergy My Reader (BioTek). RNA was converted to 
cDNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according to 
manufacturers’ protocol. Total cDNA concentration and purity was quantified using the 
TAKE3 plate and Synergy My Reader. Stock cDNA was diluted to 100 ng/µl with nuclease-
free water.  
4.3.4 Real-time polymerase chain reaction (qRT-PCR) 
Quantitative RT-PCR was performed using the Rotor Gene 3000 (Corbett Research, Sydney, 
Australia). Reaction mixtures contained 1 µl of cDNA, 5 µl of SYBR green PCR Master Mix 
(Applied Biosystems), 5 µl of nuclease-free water, and 0.5 µl each of 50 pmol/µl forward and 
reverse primers (table 1). Thermal cycling conditions were optimised for each target gene and 
melt curve analysis was performed to determine presence of any dimers. Conditions included 
a denaturation step at 95 °C for 10 minutes, and 40 cycles at 95 °C (15 seconds), annealing 55 
°C (MMP-1 and -9), 56°C (MMP-14), or 60 °C (MMP-2) (15 seconds), and acquiring at 72 
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°C (20 seconds). The housekeeping gene used was 18S, which was determined to be stable 
throughout treatment groups. Primer efficiency was between 90-110 % for each target gene 
against 18S, and thus the 2-∆∆CT method was used to determine fold change in gene expression 
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Table 1. Primer sequences for housekeeping and target genes. 




Tm (°C) Ref 
18S F; CAT TCG AAC GTC TGC CCT AT 
R; GTT TCT CAG GCT CCC TCT CC 
344-452 109 52 56 (Uchida et al. 
2010) 
MMP-1 F; CCT TCC TTT GCT GTT GCT TC 
R; CTG AAA CAC GGG GAA ACT GT 
51-108 58 52 52 Designed in 
Primer3 
MMP-2 F; CTG ATA ACC TGG ATG CAG TGCT 
R; CCA GCC AGT CCG ATT TGA 
2138-2272 135 55 50 (Al-Dasooqi et 
al. 2010) 
MMP-9 F; AAG CCT TGG TGT GGC ACG AC 
R; TGG AAA TAC GCA GGG TTT GC 




MMP-14 F; GTG GAT GGA CAC CGA GAA CT 
R; CTT TGT GGG TGA CCC TGA CT 
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4.3.5 Immunohistochemistry (IHC) 
MMP proteins were visualised using immunohistochemical (IHC) staining in jejunal and 
colonic tissue from rats killed at the end of weeks 3, 6, and 15 to determine protein 
localization. An automated staining system (Autostainer link 48 and PT Link, Dako) was used 
to conduct IHC for MMP-1 (#PAB12708, Abnova), MMP-2 (#ab37150, Abcam), MMP-9 
(#ab58803, Abcam), and MMP-14 (#ab53712, Abcam), at concentrations of 2 µg/ml (MMP-
1), 1.25 µg/ml (MMP-2 and MMP-9), 2.5 µg/ml (MMP-14). The EnVision™ FLEX kit for 
Dako autostainer link systems (Dako) was used as previously described (Wardill et al. 2015). 
Slides were scanned using the Nanozoomer (Hamamatsu Photonics) and protein localization 
was qualitatively assessed for each slide and stain.    
4.3.6 Western blot 
Protein Extraction 
Protein was extracted from 30 mg sections of snap frozen jejunum and colon. Sections were 
homogenized in cooled Eppendorf tubes with homogenizing beads at 50 GHz for 5 minutes 
with 250 µl of 1:10 protease inhibitor cocktail (10 µg/ml in sterile PBS, EDTA free; #P8340, 
Sigma) in RIPA buffer (#R0278, Sigma) using the TissueLyser LT (Qiagen). Beads were 
removed and tubes were centrifuged at 10,000 x g for 15 minutes at 4 ºC. Supernatant was 
collected and protein was quantified using the BCA protein quantification assay (#23227, 
Thermo Scientific) according to manufacturer’s protocol, after which it was stored at -80 ºC. 
Western blotting  
Western blotting was performed to quantify levels of pro- and active forms of MMP-2 protein 
in the jejunum and colon following fractionated irradiation. The iBlot™ 2 dry blotting system 
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(Invitrogen) was used to perform the western blot according to manufacturer’s protocol. 
Samples were prepared with 30 µg of total protein, 10 µl Bolt LDS Sample Buffer (#B0008, 
ThermoFisher), 4 µl of Bolt Reducing Agent (#B0009, ThermoFisher) and dH2O to yield a total 
sample volume of 40 µl. Samples were vortexed, heated at 70 ºC for 10 minutes, and pipetted 
into lanes of a 4-12 % Bis-Tris plus 12-well gel (#NW04122, ThermoFisher) in the iBlot™ 
mini gel tank with 1x SDS Running buffer (20x Bolt MES Running Buffer in dH2O, #B0002, 
ThermoFisher). 5 µl BioRad Precision Plus Protein™ dual colour standard (#1610374, BioRad) 
was used as a standard ladder. Electrophoresis was run at a constant 150V for 45 minutes. The 
iBlot transfer system was used with copper transfer stacks to transfer from gel to a PVDF 
membrane (#IB24002, ThermoFisher). The membrane was washed with TBST, re-activated 
with methanol, rinsed with dH20 and immersed in 1x iBind fluorescent detection (FD) solution 
(iBindTM FD Solution Kit, #SLF1019, ThermoFisher). Primary antibodies for MMP-2 
(#ab37150, Abcam) and beta-actin (#ab8224, Abcam) were diluted in iBind FD solution at 5 
µg/ml and 0.167 µg/ml, respectively. The secondary antibody (IRDye 800CW goat anti-Rabbit, 
#925-32211, Li-Cor) was diluted in iBind FD solution at a concentration of 0.33 µg/ml. The 
iBind system (#SLF1010, ThermoFisher) was used, with iBind FD solution applied to the card, 
to add the primary and secondary antibodies to the membrane. The membrane was left 
overnight and scanned using the LI-COR Odyssey CLx imager at 800 nM with an intensity of 
3.0. MMP-2 bands were quantified against the beta-actin housekeeping band using Image 
Studio™ software (Li-Cor).  
Statistical Analysis 
Means for each treatment group (sham irradiated and irradiated) were compared at each time 
point. Following normality testing, differences between treatment group means were analysed 
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using either a two-way ANOVA with Sidak’s multiple comparison or a Kruskal-Wallis test 
with multiple comparison. Asterisks denote significance compared to control at the time point, 








4.4.1 Fractionated irradiation induced intestinal upregulation of MMP -1, -2, and -14 at 
the transcriptional level 
Jejunum 
RT-qPCR was performed to determine mRNA expression of MMP-1, -2, -9, and -14 
following fractionated irradiation. MMP-1 mRNA expression was significantly increased in 
the jejunum 3 weeks into the fractionated radiation schedule (p=0.0086), but not at the 6- or 
15-week time points (figure 1A). MMP-2 mRNA expression increased 172 fold at week 3 in 
the jejunum (p<0.0001) but was not sigificantly different at other timepoints (figure 1B). 
MMP-9 mRNA expression was not significantly altered at any time point under investigation 
(figure 1C). MMP-14 mRNA expression was significantly increased in the jejunum at week 3, 
by 26-fold, and at week 6, by 24-fold (p=0.0002, and p=0.0065, respectively). There was no 
significant difference seen at 15 weeks following radiation (Figure 1E).  
Colon 
There were no significant changes to MMP-1 mRNA expression in the colon (figure 2A) at 
any time point under investigation. MMP-2 mRNA expression significantly increased by 14- 
and 24-fold at 3 and 6 weeks in the colon (p=0.0313, and p=0.0001, respectively) (Figure 2B). 
However, no significant change was seen at 15 weeks after radiation. MMP-9 mRNA 
expression was not significantly altered at any of the time points investigated (Figure 2C). In 
contrast to what was observed in the jejunum, MMP-14 was not significantly altered at any 
time point in the colon (Figure 2E).   




Figure 1. Expression of MMP -1, -2, -9, and -14 in the jejunum following abdominal 
irradiation.  A mRNA expression of MMP-1 was significantly increased by 3.5-fold at week 
3 (p=0.0086). B MMP-2 was significantly increased by 172-fold 3 weeks into the fractionated 
radiation course (p<0.0001). C MMP-9 mRNA expression was not significantly altered at any 
time point in the jejunum. D MMP-14 expression was significantly increased by 26-fold and 
24-fold at the 3- and 6-week time points, respectively (p=0.0002; p=0.0065). Dotted line 
represents baseline fold change. Data shown is mean + standard error of the mean (SEM). 
Asterisks denote significance compared to controls at each time point, where **<0.01, 
***<0.001, and ****<0.0001, n=5. 




Figure 2. Expression of MMP-1, -2, -9, and -14 in the colon following abdominal irradiation. 
A Colonic MMP-1 mRNA expression was not significantly altered at any time point (p>0.05). 
B Colonic MMP-2 mRNA expression was significantly increased at week 3, with a 14--fold 
increase (p=0.0313). MMP-2 expression was also significantly increased at week 6 by 24-fold 
(p=0.0001). Colonic mRNA expression of MMP-9 (C) and -14 (D) were not significantly 
altered at any time point. Dotted line indicates baseline fold change. Data shown is mean + 
SEM. Asterisks denote significance compared to controls at each time point, where *<0.05, 
and ***<0.001, n=5. 
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4.4.2 Protein expression and localization of MMP-2 was altered in the colon following 
fractionated irradiation 
As changes in mRNA expression of MMP-1, -2, and -14 were observed, 
immunohistochemistry was qualitatively assessed to initially determine any changes in 
protein localization or staining intensity prior to conducting western blotting. MMP-2 had an 
increase in total immunostaining represented by an increase in cytoplasmic staining in crypt 
enterocytes observed at weeks 3 and 6 (figure 3). There was also a slight increase in 
localization of MMP-2 to the lamina propria, particularly of the microvasculature, at weeks 3 
and 6 (Supplementary figure 1). Staining intensity of the other MMPs assessed, -1, -9, and -
14, was not altered in the jejunum or colon at any time point under investigation.  
4.4.3 Pro- and active forms of MMP-2 protein were significantly increased in the jejunum 
following fractionated irradiation 
As increases in immunostaining of MMP-2 were seen at 6 weeks, but unable to be quantified, 
western blotting was undertaken for MMP-2 in both the jejunum and colon at the 6-week time 
point. The 6-week time point was chosen due to a maximum radiation dose at this time point 
(45 Gy), as well as significant histopathological damage, including apoptosis of both the jejunal 
and colonic crypts and microvascular cells as previously reported [17]. Levels of both pro- and 
active- MMP-2 were able to be quantified via western blotting, as these forms have different 
molecular weights and thus present as separate bands. Pro-MMP-2 was significantly increased 
in both the jejunum (p<0.0001) and colon (p<0.0001) when compared against housekeeping 
band intensity (β-actin) and average intensity of controls (figure 4). Active MMP-2 was 
significantly increased following irradiation in the jejunum (p=0.0011) but not in the colon 
(figure 4).  




Figure 3. MMP -1, -2, and -9 immunostaining in the colonic crypts following fractionated 
irradiation. A MMP-1 staining intensity in the colonic crypts was not altered at any time point 
following fractionated irradiation B MMP-2 immunostaining was increased in the colonic 
crypts following 22.5 Gy and 45 Gy fractionated irradiation (weeks 3 and 6, respectively) C 
MMP-9 immunostaining was not altered in the colonic crypts 10x magnification, scale bar = 
30 µm (applies to all images in same row), n=5. 




Figure 4. MMP-2 protein expression was significantly increased in the jejunum and colon 6 
weeks into the fractionated radiation schedule. A Jejunal levels of pro-MMP-2 were 
significantly increased at 6 weeks (p<0.0001) B Jejunal levels of active MMP-2 were 
significantly increased at 6 weeks (p=0.0011) C Colonic levels of pro-MMP-2 were 
significantly increased at week 6 (p<0.0001) D Colonic levels of active MMP-2 were not 
significantly altered at 6 weeks (p>0.05). Data shown is mean + SEM. Asterisks denote 
significance compared to controls at each time point, where **<0.01, ***<0.001, and 
****<0.0001, n=5. 




The current study assessed mRNA and protein expression of several MMPs thought to be 
involved in the development of RIGT in a model of fractionated irradiation. A key finding of 
this study suggests MMP -2 mRNA expression is upregulated in both the small and large 
intestine in response to abdominal fractionated irradiation. MMP-1 and -14 mRNA expression 
was also significantly increased in the jejunum only. The increases in these MMPs occurred 
alongside loss of body weight, increases in histopathological damage and microvascular 
changes previously shown in the same model (Stansborough et al. 2017).  
The key finding of a significant increase in MMP-2 mRNA expression in both the jejunum and 
colon early in the fractionated radiation schedule accords with the consistent upregulation of 
MMP-2 reported in both clinical and preclinical studies of RIGT (Strup-Perrot et al. 2006; 
Angenete et al. 2007). MMP-2 expression was increased 172-fold at the 3-week time point in 
the jejunum, but not significantly altered at 6-weeks, despite an increase in cumulative dose. It 
is possible that the fractionated schedule of radiation is a contributor to this, with repeated 
healing occurring between doses over the 6-week radiation schedule, possibly leading to a 
decrease in MMP-2 expression. As MMP-2 immunohistochemical staining was also increased 
in the colonic crypts at the 3 and 6-week time points, protein levels were further quantified 
using western blotting to ascertain differences in pro and active forms. Whilst MMPs are 
expressed in their latent forms, activation is essential to many of the downstream effects 
(Hofmann 2000). Both pro- and active- MMP -2 were significantly increased in the jejunum 
following irradiation, however, only pro-MMP-2 was significantly increased in the colon. Rats 
receiving fractionated irradiation had significantly lower weight gain, significantly increased 
histopathological damage scoring in the colon, telangiectatic vessel formation, and apoptosis in 
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the crypts of the jejunum and colon occurring at the same time points as significant increases 
in MMP-2 mRNA and protein expression (Stansborough et al. 2017). 
Strup-Perrot and colleagues (2006) showed protein levels of pro- and active MMP-2 to be 
increased 1, 3, and 7 days in the colon following 10 Gy abdominal irradiation in rats. However, 
the jejunum was not assessed in the aforementioned study. MMP-2 protein expression has been 
correlated with decreased mean bursting pressure and breaking strength during anastomic 
healing 3 and 7 days following 40 Gy fractionated irradiation in Wistar rats (Bedirli et al. 2007). 
Clinically, active MMP-2 levels have correlated to poor outcomes in RIGT and radiation 
enteritis (Angenete et al. 2007). Angenete and colleagues (2007) found increased levels of 
MMP-2 in both tumour tissue and tumour-adjacent normal rectal tissue within the radiation 
field to correlate with fistula formation in patients who had received pre-operative fractionated 
irradiation (5x 5 Gy) for rectal cancer. This increase of MMP-2 following radiation, in both 
pre-clinical and clinical studies, supports the findings of the present study. Correlation of this 
increase with poor outcomes such as impaired anastomic healing, and fistula formation, 
suggests MMP-2 may be a clinical target for the treatment of RIGT.  
Following transcriptional upregulation and activation of secreted pro-MMP-2, MMP-2 is 
capable of degrading several ECM components, such as collagen IV and VXII, plasminogen, 
and decorin, to active downstream products such as vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGFβ), and form angiostatin, endostatin, and tumstatin 
(Stansborough et al. 2016). Active MMP-2 is also able to shed and activate pro-inflammatory 
cytokines such as TNF-α and IL-1β (Chien et al. 2013). Active MMP-2 is thus able to indirectly 
alter cell signalling, altering cell growth, migration, and angiogenesis, and in the present study 
is upregulated at the same time point as apoptosis in both the jejunum and colon (Yan & Boyd 
 Chapter 4 MMP-2 is increased in RIGT 
86 
 
2007; Stansborough et al. 2017). Previous studies have confirmed significantly increased 
expression of proinflammatory mediators, such as TNFα and IL-1β, in animal models of RIGT 
(Ong et al. 2010; Gerassy-Vainberg et al. 2018). This supports a possible pathway in which 
MMP-2 may be contributing to the exacerbation of acute RIGT through the activation of these 
proinflammatory mediators. Future studies assessing specific inhibition of MMPs, particularly 
MMP-2, as a possible treatment for RIGT should investigate the potential involvement of 
proinflammatory cytokines in this pathway. From the results of the present study, when 
considered in the context of previous literature, it is likely that the upregulation and activation 
of intestinal MMP-2 following irradiation plays an important role in the pathogenesis of RIGT 
(Strup-Perrot et al. 2006; Angenete et al. 2009; Chien et al. 2013). 
MMP-14 was also significantly upregulated in the jejunum following irradiation in the present 
study. As previously mentioned, MMP-14 is intricately involved with the activation of pro-
MMP-2 (Chien et al. 2013). Active MMP-14 expressed on the cell surface binds to TIMP-2 via 
the N-terminal domain. This complex then acts as a receptor for pro-MMP-2 after which a free 
MMP-14 molecule is able to cleave and activate pro-MMP-2 (Chien et al. 2013). This 
mechanism of MMP-2 activation by MMP-14 may be reflected in the present study, in which 
levels of both pro- and active MMP-2 were concurrently increased with MMP-14 expression in 
the jejunum. However, pro-, but not active MMP-2 was increased in the colon, in which MMP-
14 mRNA expression was not significantly altered. Differences between the response of the 
jejunum and colon to radiation have been characterized in previous studies (Cameron et al. 
2012; Stansborough et al. 2017). Loss of epithelial cell lining and villi have been noted 6-24 
hours following single-dose irradiation in rats (Cameron et al. 2012). In contrast, damage to the 
structure of the colonic crypts occurs from 24 hours following irradiation (Cameron et al. 2012). 
The upregulation of MMP-14 at acute time points in the jejunum corresponds to significantly 
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lower weight gain, and apoptosis in both epithelial and endothelial apoptosis in the same model 
(Stansborough et al. 2017). Apoptosis has also been shown to occur earlier in the jejunum than 
in the colon in the model of fractionated irradiation used in the present study (Stansborough et 
al. 2017). Whilst the timing of these events is likely altered in a fractionated radiation schedule, 
this reflects a differing profile of RIGT in the different intestinal regions. Additionally, the 
increase in MMP-14 expression in the present study does not appear to correspond to increased 
cumulative doses, with relative expression similar at both 3 and 6 week time points. However, 
the direction of the relationship between the increase in MMP expression and the 
histopathological damage in the gut remains unclear. The pattern of MMP-2 and MMP-14 
expression following radiation potentially supports the role of MMP-14 in the activation of 
MMP-2, which should be considered when exploring MMP inhibition as a treatment for RIGT.  
In the present study MMP-1 mRNA expression was found to be significantly increased in the 
jejunum following 22.5 Gy fractionated abdominal irradiation. This was not reflected in protein 
localization, with no changes in MMP-1 immunostaining in the jejunum or colon. MMP-1 is 
classified as a collagenase due to its ability to degrade collagen and gelatin, however it is also 
capable of activating pro-MMP-9 (Mittal et al. 2016). Transcription of MMP-1 can be increased 
in response to proinflammatory cytokines, epidermal growth factor, as well as following 
activation of p38 mitogen-activated protein kinases (MAPK), which has previously been shown 
to be increased in RIGT (Sonis, S. T. 2002; Salmela et al. 2004; Mittal et al. 2016). Al-Dasooqi 
and colleagues (2010) found MMP-1 protein expression to be down-regulated early, and 
upregulated late during chemotherapy-induced gut toxicity (CIGT), suggesting a role for MMP-
1 in healing. MMP-1 could be playing a similar role in the present study as it is known to 
regulate cell migration and re-epithelialization, however MMP-1 was not altered in the chronic 
RIGT time point of the present study, 6 weeks following the cessation of radiation 
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(Stansborough et al. 2016). It is possible that any increase in MMP-1 could have returned to 
baseline at this point. 
In contrast with the Strup-Perrot and colleagues (2006) study assessing MMP levels following 
irradiation in rats we found no significant difference in MMP-9 mRNA expression. MMP-1 and 
-14 mRNA expression, like MMP-2, were significantly increased in the jejunum. Despite the 
significantly increased mRNA expression of these MMPs, no changes in immunostaining 
intensity or localisation were observed. This lack of post-translational modification of the 
remaining MMPs may be due to the time points of the present study in which all tissue was 
collected 24 hours following irradiation, despite different cumulative radiation doses at the 3- 
and 6-week time points. MMP-9 has been shown to be increased 3-7 days following irradiation 
in rats, however this has been assessed in models of single-dose irradiation (Strup-Perrot et al. 
2006; Angenete et al. 2009). Changes in mRNA expression do not always correlate strongly 
with protein expression so it is also possible that these changes had no molecular manifestation 
(de Sousa Abreu et al. 2009). Additional studies are required to further assess the role of these 
MMPs in RIGT in different regions, models and with different treatment schedules.  
4.6 Conclusion 
Whilst this study is consistent with previous studies assessing MMP expression following 
radiation, this is the first study to assess the MMP expression in multiple regions of the gut in 
a fractionated radiation model of RIGT. Key findings of this study suggest MMP-2 to be 
involved in the development of RIGT in both the small and large intestine following 
abdominal fractionated radiation. MMP-2 is widely understood to be overexpressed in many 
human cancer and levels of active MMP-2 have been shown to increase risk of metastasis of 
head and neck cancer (Chien et al. 2013). This study presents a unique possibility for specific 
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MMP inhibitors to improve radiotherapy-induced gastrointestinal toxicities whilst not 
reducing efficacy of cancer treatment. Further studies are now warranted to assess these 
inhibitors for their therapeutic potential in RIGT.   




Supplementary Figure 1. MMP -1, -2, -9, and -14 immunostaining in the colonic lamina 
propria following fractionated irradiation. A MMP-1 staining intensity in the colonic lamina 
propria was not altered at any time point following fractionated irradiation B MMP-2 
immunostaining was increased in the colonic lamina propria at weeks 3 and 6 C MMP-9 
immunostaining was not altered in the colonic lamina propria, although staining of red blood 
cells was increased at weeks 3 and 6 D MMP-14 immunostaining was not increased in the 
colonic lamina propria at any time point. 20x magnification, scale bar = 20 µm (applies to all 
images in same row).
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Chapter 5 Vascular endothelial growth factor (VEGF), transforming growth factor beta 
(TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced 
gastrointestinal toxicity  
[Stansborough R.L. et al., (2018). International Journal of Radiation Biology (Available at: 
https://doi.org/10.1080/09553002.2018.1483588)] 
5.1 Abstract 
Purpose: Radiotherapy-induced gut toxicity (RIGT) is a debilitating effect of radiotherapy for 
cancer, often resulting in significant diarrhoea and pain. Previous studies have highlighted 
roles of the intestinal microvasculature and matrix metalloproteinases (MMPs) in the 
development of RIGT. We hypothesized vascular mediators would be significantly altered in 
a dark agouti (DA) rat model of RIGT. Additionally, we aimed to assess the effect of MMP-2 
and -9 inhibition on the response of tumour-associated microvascular endothelial cells 
(TAMECs) to radiation.  
Methods: Dark Agouti (DA) rats were administered 2.5 Gy abdominal irradiation (3 
times/week over 6 weeks). Vascular endothelial growth factor (VEGF), transforming growth 
factor beta (TGFβ), von Willebrand factor (VWF), angiostatin, and endostatin expression was 
assessed at 3, 6 and 15 weeks. Additionally, DA rat mammary adenocarcinoma tumour-
associated microvascular endothelial cells (TAMECs) were used to assess the effects of 
radiation (12 Gy) and the MMP inhibitor SB-3CT on MMP, VEGF, and TGFβ expression, 
and cell viability.  
Results: VEGF mRNA expression was significantly increased in the colon at week 15 (p = 
0.0012), and TGFβ mRNA expression was significantly increased in both the jejunum and 
colon at week 3 (p = 0.0280, and p = 0.0310, respectively). Endostatin immunostaining was 
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significantly increased at week 3 (p = 0.0046), and angiostatin at 3 and 6 weeks (p = 0.0022, 
and p = 0.0135, respectively). MMP-2 and -9 mRNA and total protein levels were 
significantly increased following irradiation of TAMECs. Although this increase was 
significantly attenuated by SB-3CT, it did not significantly alter endothelial cell viability or 
VEGF and TGFβ mRNA expression.  
Conclusions: Findings of this study support the involvement of VEGF, TGFβ, angiostatin, 
endostatin, and MMP-2 in the pathobiology of RIGT. However, the relationship between 
these mediators is complex and needs further investigation to improve understanding of their 
therapeutic potential in RIGT.   




Radiotherapy-induced gut toxicity (RIGT), estimated to affect 60-80% of patients receiving 
radiotherapy for abdominal or pelvic tumours, induces debilitating symptoms including, but 
not limited to, diarrhoea, pain, rectal bleeding, and incontinence (Theis et al. 2010; Shadad et 
al. 2013a; Hauer-Jensen, Denham & Andreyev 2014). RIGT is often divided into acute and 
chronic toxicity, with acute changes involving histopathological damage to villi and crypts, 
and chronic involving reactive fibrotic thickening (Yeoh et al. 2007; Theis et al. 2010). 
Previous research has suggested the involvement of the intestinal microvasculature in the 
development of RIGT, and several mediators have been investigated (Kruse et al. 2004; Yeoh 
et al. 2007; Stansborough et al. 2017). NFκB, proinflammatory cytokines, and matrix 
metalloproteinases (MMPs) are all upregulated in the intestine following radiation, and have 
downstream effects on vascular mediators such as vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGFβ), von Willebrand factor (VWF), and the 
antiangiogenic mediators endostatin and angiostatin (Stansborough et al. 2016). Whilst a link 
has been proposed in RIGT (Stansborough et al. 2016) there is limited research which has 
investigated changes in these mediators in the intestinal microvasculature during a 
fractionated radiation schedule.  
Our previous studies have shown the intestinal microvasculature to be involved in RIGT, with 
apoptosis, cytostasis, telangiectasis, and fibrotic thickening occurring early and late following 
fractionated irradiation in dark agouti (DA) rats (Yeoh et al. 2005; Stansborough et al. 2017). 
In addition, several regulators of angiogenesis and vascular physiology including, but not 
limited to, TGFβ, VEGF, and VWF, are known to be altered in the intestine following 
irradiation (Wang, J, Zheng & Hauer-Jensen 2001; Wang, J et al. 2002; Milliat et al. 2006; 
Lenting et al. 2012; Boerma et al. 2013). VEGF, bound to heparin in the extracellular matrix, 
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is able to be released by matrix metalloproteinases (MMPs) such as MMP-2, and MMP-9 
(Carmeliet 2005). The anti-angiogenic mediators angiostatin and endostatin have also been 
shown to increase in response to irradiation of cancer endothelial cells derived from human 
breast cancer tissue (Oh et al. 2014). A reduction in angiostatin via knockdown of 
plasminogen restored tube formation of these cells, suggesting angiostatin is involved in 
endothelial regulation following irradiation (Oh et al. 2014). Although it appears angiostatin 
and endostatin are involved in endothelial response to irradiation this connection is yet to be 
explored in RIGT. With the increasing investigation of the possible use of anti-angiogenic 
agents as adjuvant cancer therapies alongside chemotherapy or radiotherapy, targeting 
mediators such as vascular endothelial growth factor (VEGF) and endostatin, the role of these 
mediators in RIGT needs to be further explored. 
Previous research has clearly shown MMPs are involved in RIGT, with MMP-2 in particular 
shown to be significantly increased during RIGT (Strup-Perrot et al. 2006). It has also been 
hypothesised MMPs are involved in microvascular changes and alteration to vascular 
mediators such as VEGF, TGFβ, and VWF in RIGT (Stansborough et al. 2016). MMPs are 
able to regulate the expression of several of these mediators via the degradation of the 
extracellular matrix (ECM) leading to the release of latent VEGF and TGFβ, as well as 
forming angiostatin and endostatin by cleaving plasminogen and collagen XVIII respectively 
(Sternlicht & Werb 2001; Kalluri 2003; Carmeliet 2005). In degrading the ECM, MMPs also 
promote endothelial migration, proliferation and tube formation (Kalluri 2003). Despite 
previous literature, a direct link has not been established between MMPs and vascular 
mediator expression following radiation, and the effect of these changes on endothelial cells. 
Thus the present study aimed to first confirm the alteration of vascular mediators VEGF, 
TGFβ, VWF, angiostatin, and endostatin in the jejunum and colon following fractionated 
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irradiation in DA rats. We then aimed to determine whether inhibition of MMP-2 and -9 with 
SB-3CT altered endothelial viability and expression of these vascular mediators in primary 
tumour-associated microvascular endothelial cells (TAMECs) derived from DA rat mammary 
adenocarcinomas. TAMECs have been successfully cultured for previous, similar 
experiments, have been phenotyped, and their cultivation in DA rats allows for consistency 
between both components of the study (Bateman et al. 2013). In utilising this primary in vitro 
model we aimed to assess the effects of SB-3CT on tumour endothelial response to irradiation 
as an initial investigation into the response of tumour endothelium to MMP-2 and -9 
inhibition. As the cell type used in the in vitro component of the study does not directly 
translate to RIGT, further studies are required to assess the effects of SB-3CT on intestinal 
endothelium following irradiation. However, results of the present study form a foundation 
for further investigation into the possible use of SB-3CT following irradiation. 
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5.3 Materials and Methods 
5.3.1 Ethics 
Both studies were conducted in accordance with ethics approved by the Animal Ethics 
Committees at the University of Adelaide (M-041-2006; M-2015-117) and complied with the 
National Health and Medical Research Council (Australia) Code of Practice for Animal Care 
in Research and Teaching (2013). 
5.3.2 Animals and Experimental Design  
Archival tissue from a prior study was utilised in the in vivo component of the present study, 
and experimental design has been previously described (Yeoh et al. 2007; Stansborough et al. 
2017). Briefly, 30 female Dark Agouti (DA) rats were randomly assigned into two groups, 
one group receiving sham irradiation, and one group receiving a schedule of fractionated 
irradiation. Both groups of rats were anaesthetised using 3% halothane in 100% oxygen and 
placed into a custom-built container, with rats in the treatment group receiving fractionated 
abdominal irradiation using a Varian Clinac Linear Accelerator (Varian Medical Systems, 
USA) at a dose of 2.5 Gray (Gy) (depth = 3.3 cm, focus-skin distance = 130 cm) 3x per week 
for a total dose of 22.5 Gy in 9 fractions and 45 Gy in 18 fractions over 3 and 6 weeks, 
respectively (Yeoh et al. 2007). Rats were killed at 3, 6, or 15 weeks from first irradiation 
dose (n = 5 per time point). Animals were monitored daily and clinical record sheets kept. 
Sections of jejunum (30% of small intestinal length when measured from the pylorus) and 
colon (midlength of the large intestine) were collected as previously described and either 
formalin-fixed and paraffin-embedded, or snap frozen and stored at -80º (Yeoh et al. 2007; 
Stansborough et al. 2017).  
 Chapter 5 Vascular mediators increased in RIGT 
100 
 
5.3.3 RNA isolation and reverse transcription 
RNA isolation was performed using the Nucleospin® RNA II kit (Macherey-Nagel, 
Germany) according to manufacturers’ protocol. Briefly, 15-20 mg of jejunal and colonic 
tissue was homogenized using the TissueLyser LT (Qiagen) and Nucleospin® RNA II kit 
reagents (Macherey-Nagel, Germany). The lysate was filtered through silica membrane filter 
columns, desalted, DNA was digested using the DNAse reaction mixture, and the silica 
membrane was washed and dried. RNA was eluted in 60 µl RNase-free water. The TAKE3 
plate and Synergy MyReader (BioTek) was used to determine RNA concentration and purity. 
RNA (1 µg) was converted to cDNA using the iScript cDNA synthesis (Bio-Rad, USA) 
according to manufacturers’ protocol. The TAKE3 plate and Synergy MyReader was again 
used to determine total cDNA concentration and purity and stock cDNA was diluted to 100 
ng/µl with nuclease-free water.  
5.3.4 Real-time polymerase chain reaction (RT-PCR) 
RT-PCR was performed using the Rotor Gene 3000 (Corbett Research, Sydney, Australia) 
according to manufacturer’s protocol. Reaction mixtures contained 1 µl of cDNA, 5 µl of 
SYBR green (Applied Biosystems, Foster City, CA), 5 µl of nuclease-free water, and 0.5 µl 
each of 50 pmol/µl forward and reverse primers (Table 1). Thermal cycling conditions were 
as described; denaturation step at 95°C for 10 min, and included 40 cycles at 95°C for 10 s, 
annealing at 60ºC (VWF, TGFβ, and MMP-2), or 55ºC (VEGF and MMP-9), for 15 s, and 
extension and acquiring at 72°C for 20 s. 18S was used as the housekeeping gene. Primer 
efficiency was calculated to be between 90-110% for each target gene against 18S, and thus 
the 2-∆∆CT method was used to determine fold change in gene expression relative to the 
housekeeping gene and sham irradiated controls from each time point. 
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5.3.5 Immunohistochemistry (IHC) 
Angiostatin and endostatin proteins were visualised by IHC staining in the colon at 3, 6, and 
15 week time points. A Dako automated staining system (Autostainer link 48 and PT Link, 
Dako, Denmark) was used with the EnVision™ FLEX kit for Dako autostainer link systems 
(Dako, Denmark) as previously described (Stansborough et al. 2017). The anti-angiostatin 
primary antibody (#ab2904, Abcam), and anti-endostatin primary antibody (#GTX37706, 
GeneTex), were used at 6.66 µl/ml and 20 µl/ml, respectively. Slides were scanned using the 
Nanozoomer (Hamamatsu Photonics, Japan) at 40x magnification. ImageScope imaging 
software (Leica Biosystems, Germany) was used to analyse angiostatin and endostatin in 
which percentage of positively stained cells was calculated in the lamina propria of each 
section (averaged from ten randomly selected 40x sections per slide). 
5.3.6 Isolation of tumour-associated microvascular endothelial cells (TAMECs) 
Tumour-associated microvascular endothelial cells were isolated and cultured as previously 
described (Bateman et al. 2013). Briefly, Dark Agouti (DA) rats were injected subcutaneously 
with DA mammary adenocarcinoma cells, and 8 days following, tumours were removed and 
processed under sterile conditions. Surrounding connective tissue was removed and tissue was 
mechanically disrupted into 1 mm fragments. The tissue was enzymatically digested in 
collagenase/dispase (Sigma), and incubated with 0.25% trypsin/EDTA (Bateman et al. 2013). 
Following this, the tissue was centrifuged and resuspended in complete growth medium, 
consisting of supplemented Dulbecco’s Modified Eagle Media (DMEM) (28% HEPES buffer, 
10% foetal bovine serum (FBS), and 1% L-glutamine, penicillin, streptomycin) and filtered 
through a 100 µm nylon cell strainer (Corning). The resultant suspension was added to 
gelatinised culture flasks and incubated at 37ºC. Tumour-conditioned medium (TCM) was 
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added to the TAMECs every 24-48 h to maintain the endothelial cell culture. Endothelial 
culture was confirmed using immunostaining for endothelial cell markers, as previously 
described (Bateman et al. 2013).  
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Table 1. 18S, VEGF, TGFβ, VWF, MMP-2, and MMP-9 primer sequences 







18S F CATTCGAACGTCTGCCCTAT 
R GTTTCTCAGGCTCCCTCTCC 





VEGF F AGGCGAGGCAGCTTGAGTTA 
R CTGTCGACGGTGACGATGGT 
1601-1766 166 62 
64 
(Zhang, 
M et al. 
2014) 
TGFβ F ATGACATGAACCGACCCTTC 
R ACTTCCAACCCAGGTCCTTC 




u & Reh 
2005) 
VWF F GCCTCTACCAGTGAGGTTTTGAAG 
R ATCTCATCTCTTCTCTGCTCCAGC 





MMP-2 F CTG ATA ACC TGG ATG CAG TGCT 
R CCA GCC AGT CCG ATT TGA 






MMP-9 F AAG CCT TGG TGT GGC ACG AC 
R TGG AAA TAC GCA GGG TTT GC 
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5.3.7 Treatment of TAMECs 
TAMECs at passages 1-2 were detached with trypsin, pelleted, counted, diluted to 1 x 109 
cells/mL, and split evenly across 4 x 50 ml falcon tubes to represent the four treatment groups 
(vehicle control, SB-3CT alone, irradiation alone, and irradiation and SB-3CT combined). 
Cells were then treated for 24 hours with either 0.01% DMSO in H20 (vehicle control), or 1 
µm SB-3CT. SB-3CT concentration was determined by dose response assays (data not 
shown) and was determined to be within the Ki range of inhibiting MMP-2 and MMP-9 (Ki = 
14 nM and Ki = 600 nM, respectively), without inhibiting MMP-1, -3, or -7 (Ki = 206 µM, Ki 
= 15 µM, Ki = 96 µM, respectively) (Brown et al. 2000). Following this, falcon tubes 
containing the cells were either sham irradiated, or received 12 Gy gamma irradiation using a 
Cs137 source (IBL-437 Blood Irradiator). Cells were immediately plated according to 
individual experimental conditions. An XTT assay was used to conduct a radiation dose 
response assay and was based on an initial dose range of 0-12 Gy. 12 Gy resulted in a 
significant decrease in cell viability without causing excessive cell death (data not shown). 
Dosimetry was calculated prior to radiation and based on dose rate calculations, calibrated 
monthly based on degradation constant. 
5.3.8 Protein and RNA extraction from TAMECs 
Following irradiation and/or SB-3CT pre-treatment, TAMECs were seeded into 6-well plates 
at a cell density of 1 x 105 cells/well, and incubated for 24 h. Following incubation, the media 
was collected and immediately placed on ice. Cells were pelleted and supernatant collected 
and stored at -80ºC. Lysis buffer (Macherey-Nagel RNA kit) was added to each well. Wells 
were scraped and cells and buffer were collected and disrupted using a 26-gauge needle. β-
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mercaptoethanol (3.5 µl) was added to each tube, vortexed, and further RNA extraction and 
cDNA conversion was performed according to kit protocols, as described earlier. 
5.3.9 MMP 2 and 9 activity assays 
MMP-2 and -9 activity was assessed in supernatant collected from treatment TAMECs, using 
MMP-2 and -9 activity assay kits (QuickZyme). Experiments were conducted according to kit 
protocol. Briefly, duplicate diluted samples (1:2 dilution with assay buffer), serially diluted 
standards, and assay buffer controls, were pipetted into the assay plate. The plate was covered 
and incubated at 4ºC overnight. The wells were aspirated and washed with assay buffer, and 
50 µl of P-Aminophenyl mercuric acetate (APMA) solution (0.5 mM APMA in 0.05% 
DMSO/assay buffer) was added to wells containing standards, and to one of the two duplicate 
sample wells. Assay buffer was added to the remaining sample wells, and detection reagent 
was added to all wells. The plate was shaken for 20 s and read at 405 nm to obtain the 
baseline value, repeated at 6 and 22 h. Data was analysed by subtracting the average blank 
value from each sample value, creating a standard curve based on the 6 h data and plotting the 
standard concentration against the blank subtracted standard values, applying a best-fit curve, 
and calculating the sample concentrations graphically.    
5.3.10 XTT Assay 
In preparation for XTT assay, 1x105 treated TAMECs were passaged intro 96-well flasks and 
were left to adhere for 24 h. Following adhering, XTT was performed according to kit 
protocol (Cell Proliferation Kit II (XTT, Sigma), with labelling and electron coupling reagents 
being prepared immediately before removing media from wells, replacing with 100 µl fresh 
media, and adding 50 µl per well of the prepared XTT reagent. The plates were incubated for 
6 h and the plate was read at 490 nm using the TAKE3 plate and Synergy MyReader.  
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5.3.11 Immunocytochemistry (ICC) 
Prior to experimentation of TAMECs, expression of VEGF, VWF, TGFβ, MMP-2, and 
MMP-9 under normal conditions was confirmed using immunocytochemistry (Supplementary 
Figure 1). Briefly, treated TAMECs were passaged into 8-well chamber slides at 2x105 
cells/well and left to adhere for 24 h. Following this, cells were fixed with 4% 
paraformaldehyde for 30 minutes at 4ºC, washed twice with PBS, incubated with 3% H2O2 in 
PBS for 5 min to reduce non-specific staining, washed, and incubated with Triton-X block 
(100 µl TX-100 and 0.1 g sodium citrate in 100 mL H20) for 8 min to permeate the cell 
membrane. The cells were washed and blocked using the normal serum blocking reagent 
(Level 2 USA™ Ultra Streptavidin Detection System kit, Signet Laboratories). Primary 
antibodies (MMP-2; #ab37150, Abcam, MMP-9; #ab58803, Abcam, VEGF; #ab46154, 
Abcam, VWF; #ab6994, Abcam, TGFβ; #ab92486, Abcam) were prepared at previously 
optimised concentrations of 2 µl/ml (VWF & MMP-2), 4 µl/ml (VEGF & MMP-9), and 10 
µl/ml (TGFβ), and added to each well for 60 min. Cells were washed and a linking reagent 
(Level 2 USA™ Ultra Streptavidin Detection System kit, Signet Laboratories) was applied for 
20 min. A peroxidase-labelled ultra-streptavidin labelling reagent (Signet Laboratories) was 
applied for 20 min, followed by a 1 min incubation with diaminobenzidine (DAB) chromogen 
in 0.03% hydrogen peroxidase (Signet Laboratories) for visualization. Cells were washed, 
chambers were removed, and slides were counterstained with Lillie Meyers haematoxylin 
(1:10), washed, dehydrated, and coverslipped. 
5.3.12 Statistical Analysis 
Graphpad Prism (version 6) software was used to perform statistical analysis. Normality was 
determined and differences between study group means were analysed using either a one-way 
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or two-way ANOVA with Sidak’s multiple comparison, or a Kruskal-Wallis test with 
multiple comparison. Asterisks denote significance compared to control at the time point, 
where * <0.05, ** <0.01, *** <0.001, and **** <0.0001. Bars on graphs represent standard 
error of the mean. 
  




5.4.1 Fractionated irradiation induced changes in weight gain and histopathological 
damage 
Clinical and histological response to fractionated irradiation for this study has been previously 
published (Stansborough et al. 2017). Briefly, rats receiving fractionated irradiation had 
significantly lower weight gain at week 3 (p = 0.0055), and from week 6 until the completion 
of the study (p < 0.05), when compared to sham irradiated controls (Stansborough et al. 
2017). Histopathological damage scoring was significantly increased in the colon, but not in 
the jejunum, at week 3 (p = 0.043). However, thickening of the lamina propria, telangiectatic 
vessel formation, and apoptosis were observed in both the jejunum and colon following 
irradiation (Stansborough et al. 2017). 
 
5.4.2 VEGF and TGFβ were significantly increased in the colon following irradiation in 
DA rats 
Despite no significance effect in the jejunum, VEGF mRNA expression was significantly 
increased in the colon at the 15-week time point (p = 0.0012) (Figure 1A+B). TGFβ mRNA 
expression significantly increased in both the jejunum and colon 3 weeks into the radiation 
schedule (p = 0.0280 and p = 0.0310, respectively), however was not significantly increased 
at 6- or 15-weeks in either region (Figure 1C+D). VWF mRNA expression was not 
significantly altered at any time point following fractionated irradiation in jejunum or colon 
(Figure 1E + 1F). 
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5.4.3 Angiostatin and endostatin immunostaining was significantly increased in the colon 
following fractionated irradiation 
Endostatin was immunostaining significantly increased in the lamina propria of the colon at 
the 3-week time point only (p = 0.0046) (Figure 2A + 2C). Angiostatin immunostaining was 
significantly increased at 3- and 6-weeks in the colon lamina propria (p = 0.0022, and p = 
0.0135, respectively) (Figure 2B + 2C). There were no significant alterations at week 6 or 15.  
  




Figure 1. VEGF, TGFβ, and VWF expression in the jejunum and colon following fractionated 
radiation. A VEGF mRNA expression in the jejunum following fractionated irradiation B 
VEGF mRNA expression in the colon following fractionated irradiation C TGFβ mRNA 
expression in the jejunum fractionated irradiation. D TGFβ expression in the colon following 
fractionated irradiation. E Relative mRNA expression of VWF in the jejunum following 
fractionated irradiation F VWF mRNA expression in the colon. Dotted line represents 
baseline fold change. * = significance compared to control. * <0.05, ** <0.01, n=5. Data = 
mean + standard error of the mean (SEM). 




Figure 2. Endostatin (A) and angiostatin (B) immunostaining in the lamina propria of the 
colon following fractionated irradiation. Cell positivity was calculated using ImageScope 
software and is determined as number of positively stained cells/number of total cells. * 
denotes significance compared to controls at the same time-points, ** <0.01, *** <0.001. 
Data = mean + SEM, n=5. Scale bars = 20 µm, 40x original magnification.  
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5.4.4 SB-3CT significantly attenuated the expression of MMP-9 following irradiation of 
TAMECs 
Relative mRNA expression of MMP-2 was not significantly altered following irradiation of 
TAMECs when compared to controls (p = ns; Figure 3A). However, TAMEC MMP-2 
expression following irradiation was significantly reduced when pre-treated with SB-3CT, as 
compared to the radiation only group (p = 0.0034) (Figure 3A). MMP-9 mRNA expression 
was significantly increased following irradiation of TAMECs (0.0022). This was significantly 
attenuated by SB-3CT (p < 0.0001). Despite this attenuation of MMP-2 and -9, SB-3CT did 
not significantly alter cell viability following irradiation, compared to radiation alone (p = ns; 
figure 5).  




Figure 3. MMP-2 (A) and -9 (B) mRNA expression following irradiation of TAMECs, 
with/without SB-3CT. Dotted line represents baseline fold change. * = significance compared 
to control. * <0.05, ** <0.01, **** <0.0001. Data = mean + SEM. n=12 
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5.4.5 SB-3CT significantly attenuated MMP-2 and -9 protein expression following 
irradiation 
Total protein levels of both MMP-2 and MMP-9 were significantly increased in TAMEC 
supernatant following 12 Gy irradiation (p = 0.046, and p = 0.0401, respectively) (Figure 4A 
and 4C). This increase in total MMP-2 and -9 protein levels was significantly attenuated by 
the administration of SB-3CT (p = 0.0119, and p = 0.0209, respectively). The ratio of active: 
total MMP-2 and -9 were not significantly altered following irradiation of TAMECs. 
However the ratio of active: total MMP-2 was significantly increased in the radiation + SB-
3CT group, compared to control (p = 0.0379). The ratio of active: total MMP-9 was not 
significantly altered in the radiation + SB-3CT group when compared to all other groups (p = 
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ns; Figure 4D). 
 
Figure 4. Total and active: total ratio of secreted MMP-2 and -9 protein concentration 
following irradiation and MMP inhibition in TAMECs. A Total MMP-2 protein concentration 
B Ratio of active: total MMP-2 protein levels C Total MMP-9 protein concentration D Ratio 
of active: total MMP-9 protein levels. * = significance compared to control. * <0.05. Data = 
mean + SEM. n = 12 
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5.4.6 SB-3CT did not alter tumour-associated microvascular endothelial cell viability 
following irradiation 
SB-3CT alone did not significantly alter cell viability; as measured via XTT assay; both 
irradiation (12 Gy), and irradiation + SB-3CT significantly reduced cell viability of TAMECs 
(p = 0.0236, and p = 0.0003, respectively) (Figure 5). There was no significant difference 
between the radiation alone, and radiation + SB-3CT groups (p = ns; Figure 5).  
5.4.7 VEGF and TGFβ mRNA expression were not significantly altered following 
irradiation of TAMECs 
RT-PCR was used to assess relative mRNA expression of VEGF and TGFβ following 
irradiation and MMP inhibition in TAMECs. VEGF and TGFβ mRNA expression were 
unaltered by both irradiation and SB-3CT treatment (Figure 6).   




Figure 5. Cell viability of TAMECs following irradiation and MMP inhibition. * = 
significance compared to control. * <0.05, *** <0.001. Data = mean + SEM. n = 8 
 
  





Figure 6. VEGF and TGFβ mRNA expression following irradiation of TAMECs with or 
without SB-3CT. VEGF (A) and TGFβ (B) mRNA expression were not significantly altered 
following irradiation of TAMECs, with or without the presence of SB-3CT. Dotted line 
represents baseline fold change. Data = mean + SEM. n = 12 
  




Although the pathobiology of RIGT is complex, MMPs, the intestinal microvasculature, and 
associated vascular mediators have been shown to be involved (Stansborough et al. 2016). 
Key findings from this study show mRNA expression of VEGF and TGFβ mRNA expression 
to be significantly increased in the intestines following RIGT, and is the first study to show an 
increase in angiostatin and endostatin during RIGT. However, the pattern of upregulation of 
these mediators was different, occurring at different time points and in different intestinal 
regions. Further, this study assessed the effect of the MMP-2 and -9 inhibitor, SB-3CT, on 
tumour-associated microvascular endothelial cells (TAMECs) following irradiation. Both 
mRNA and protein expression of MMP-2 and -9 were significantly upregulated in TAMECs 
following irradiation, however irradiation did not significantly alter VEGF or TGFβ 
expression in these cells. SB-3CTsignificantly attenuated MMP-2 and -9 mRNA and protein 
expression, however, it did not alter cell viability of TAMECs following irradiation.  
VEGF mRNA expression was significantly increased in the colon at the 15 week time point 
of the DA rat RIGT model. VEGF may have a protective role in gastrointestinal injury, with 
higher levels of VEGF expression correlating with less severe gastric ulcers in murine models 
of stress-induced gastric ulceration (Malara et al. 2005). VEGF has also been shown to 
regulate normal vasculature in the small intestinal villi, with excessive inhibition resulting in 
regression of normal microvasculature, and reduced vascular density (Howdieshell et al. 
2001; Saif, Elfiky & Salem 2007; Pollom et al. 2015). Clinically, the inhibition of VEGF has 
been shown to delay healing of gastric erosions, reduce vascular density in the small intestinal 
villi, and induce epithelial ulceration, supporting a role for VEGF in healing (Mangoni et al. 
2012; Pollom et al. 2015). This regulatory role could be consistent with the timing of VEGF 
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upregulation seen in the present study, occurring at the 15 week time-point in the colon only. 
At this time point, 9 weeks following the last radiation dose, we have clearly documented and 
reported on a transition from acute to chronic RIGT phenotype which is able to be seen 
histologically (Stansborough et al. 2017). This effect is likely due to alteration of the wound 
healing process, as well as vascular changes resulting in impaired delivery of healing agents 
to the damaged tissue (Mangoni et al. 2012). This study, in combination with findings of 
previous literature, suggests a role for VEGF in the progression to chronic RIGT, possibly 
playing a part in wound healing following acute RIGT. This potential role of VEGF in RIGT 
needs to be further explored, particularly with the increased study of anti-VEGF as adjuvant 
cancer therapies (Barney et al. 2013; Pollom et al. 2015). When VEGF inhibitors (VEGFIs) 
are combined with radiotherapy, gastrointestinal toxicity has been shown to significantly 
increase (Barney et al. 2013; Pollom et al. 2015). This potential for increased intestinal 
toxicity needs to be considered when determining the clinical potential of these agents. 
Whilst TGFβ expression was significantly increased 3 weeks into the fractionated radiation 
schedule in our rat model of RIGT, consistent with previous literature, it was not significantly 
upregulated at 6 and 15 weeks, nor was it altered following irradiation of TAMECs (Richter 
et al. 1998; Wang, J, Zheng & Hauer-Jensen 2001). The lack of increase in TGFβ at the 
chronic RIGT time point was somewhat unexpected and in contrast with previous literature 
(Kleifeld et al. 2001). This may be explained by the different models used in the study by 
Wang and colleagues (2001, in which a scrotal hernia is surgically induced and the 
fractionated schedule uses higher doses over a shorter period of time (Wang, J, Zheng & 
Hauer-Jensen 2001). Our previous studies have shown fibrotic changes to the lamina propria 
and microvasculature at both the 6 and 15 week time points (Stansborough et al. 2017). With 
the complex interactions of TGFβ it is possible that the early upregulation of TGFβ, or 
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alterations in the receptors of TGFβ are involved in these fibrotic changes. It is also unclear 
what the potential consequences of TGFβ involvement in RIGT may be, with TGFβ being 
capable of opposing angiogenic effects, highly dependent on conditions and tightly regulated 
in the endothelium by the receptors ALK1 and ALK5 (Goumans et al. 2003). Whilst TGFβ 
binding with ALK5 has an anti-angiogenic effect, inhibiting endothelial cell migration and 
proliferation, ALK1 binding has the opposite effect (Goumans et al. 2003). Thus the ratio of 
ALK5 to ALK1 seems to be key to the functional role of TGFβ in pathological conditions. 
Further studies, both in vitro and in vivo, are needed to investigate the ALK5 to ALK1 ratio 
and determine where this balance lies in endothelial response to irradiation, and during RIGT, 
in order to determine the role of TGFβ in its pathobiology.  
Angiostatin and endostatin immunostaining was shown to be significantly elevated in the 
lamina propria of both the jejunum and colon. This occurred only during the acute time 
points, with angiostatin increasing at 3 and 6 weeks, and endostatin at 3 weeks. The anti-
angiogenic mediators angiostatin and endostatin, fragments of plasmin and type XVIII 
collagen, respectively, are responsible for inhibiting endothelial cell proliferation and 
migration, as well as inducing apoptosis in the case of endostatin (Ribatti 2009). Endostatin is 
also known to directly inhibit MMP-2 (Abdollahi et al. 2004). Although this current study is 
the first to assess angiostatin and endostatin in an animal model of RIGT, response of 
angiostatin to radiation has previously been assessed in vitro (14). Oh and colleagues (2014) 
finding angiostatin protein levels to be significantly increased in human breast tissue derived 
cancer endothelial cells following 4 Gy irradiation (Oh et al. 2014). Whilst endostatin has not 
yet been investigated in RIGT, Endostar, a recombinant human endostatin, has been shown to 
significantly decrease MMP-2, -9, -14, and VEGF immunostaining in nasopharyngeal 
carcinoma xenografts in mice following 6 Gy irradiation (Peng et al. 2012). Although the 
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roles of angiostatin and endostatin likely differ in normal vs tumour tissue response to 
radiation, these studies, in combination with the present study, suggest a role of these anti-
angiogenic mediators in radiation response, likely linked to the MMP pathway.  
MMP-2 and -9 mRNA and protein expression was significantly increased following 
irradiation of TAMECs. The significant increase in MMP-2 expression is consistent with 
previous studies finding an increase in MMP-2 24 hours following 4 Gy irradiation of human 
normal endothelial cells and TAMECS (NECs and CECs, respectively) derived from breast 
tissue (Oh et al. 2014). However, the same study found MMP-9 not to be altered by 
irradiation of TAMECs in contrast to the findings of our current study (Oh et al. 2014). This 
is not entirely unexpected, due to species and tissue differences between the two studies, with 
MMP-9 regulation known to depend on cell type (Vincenti & Brinckerhoff 2007). Despite 
these conflicting results, the similarities between the studies highlight a role for MMP-2, in 
particular, in endothelial regulation following irradiation.  
The increase in MMP-2 and -9 expression was also significantly attenuated, both at the 
mRNA and protein level, by the pre-treatment of TAMECs with SB-3CT. SB-3CT is the first 
mechanism-based MMP inhibitor, potently and selectively inhibiting MMP-2 and -9. The 
effect of SB-3CT is unique in its selectivity, as it forms a reactive species within the active 
sites of MMP-2 and -9 (Kruger et al. 2005) and was developed in response to a lack of 
efficacy of broad-spectrum, synthetic MMP inhibitors when used as anti-cancer therapies in 
clinical trials.  
An unexpected finding in the present study was the significant decrease in mRNA expression 
of MMP-2 and MMP-9 following pre-treatment with SB-3CT in TAMECs following 
irradiation, as the mechanism of action of SB-3CT is in inhibiting activation. Additionally, 
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SB-3CT significantly increased MMP-2 activity in TAMECs when combined with irradiation, 
having no effect on activity of MMP-9. The significant decrease in proMMP expression by 
SB-3CT is not unprecedented, with SB-3CT significantly decreasing proMMP-9 levels in a 
mouse model of transient focal cerebral ischemia (37). The study hypothesized this decrease 
was likely due to a positive feedback mechanism between MMP activity and gene 
transcription (Gu et al. 2005).  
To our knowledge, this is the first study to assess mRNA expression of MMP-2 and -9 
following SB-3CT administration. There are endogenous mediators that can be regulated by 
active MMP-2 and -9, such as TGFβ, and pharmacological reagents, such as doxycycline, that 
have been shown to regulate the mRNA expression of MMP-2 and -9 by altering mRNA 
stability (Yan & Boyd 2007). Whether SB-3CT is regulating transcription via a similar 
process, by affecting the promotor regions of these MMPs, or through disruption of a positive 
feedback mechanism, is unclear. The regulation of mRNA expression of both MMP-2 and 
MMP-9 by SB-3CT should be investigated further and current studies are underway in our 
laboratory. 
The use of a single cell type in this study is a limitation as normal and tumour endothelial 
cells are phenotypically different and subsequently respond differently to irradiation; 
therefore it is likely that the response of normal gut endothelial to SB-3CT would differ to the 
findings of the present study (Oh et al. 2014). Thus, in order to further assess the possible 
effects of MMP inhibition in RIGT, future studies assessing SB-3CT in an in vivo model of 
RIGT are warranted. However, the findings of this study highlight a relationship between 
radiation, MMP expression and tumour endothelium. Due to the potential use of specific 
MMP inhibitors as cancer therapies, and with the involvement of both MMP’s and the 
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endothelium in the development and progression of RIGT, the findings of this study highlight 
the need for further research and consideration as to possible dual effects of MMP inhibitors 
in this setting (Strup-Perrot et al. 2006; Angenete et al. 2009; Stansborough et al. 2017). 
5.6 Conclusion 
The findings of this study support a role for the vascular mediators VEGF, TGFβ, angiostatin, 
and endostatin in RIGT following fractionated irradiation. Additionally, MMP-2 and -9 were 
shown to be involved in endothelial response to radiation in vitro, however inhibition by SB-
3CT did not alter cell viability. The findings of the in vitro component of the present study 
elucidate the effects of SB-3CT on the endothelium, with unexpected findings of significantly 
inhibited proMMP expression, but not active MMP expression, and confirm the role of MMP-
2 in particular in the endothelial response to irradiation.  These results highlight the need for 
further pre-clinical studies to assess the effect of MMP inhibitors and anti-angiogenic drugs in 
RIGT, particularly as these drugs are currently being investigated as adjuvant cancer 
therapies.  
  




Supplementary Figure 1. Conformational staining of MMP-2, MMP-9, VWF, and VEGF in 
tumour-associated microvascular endothelial cells (TAMECs). 100x magnification 
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Chapter 6 General Discussion 
6.1 Introduction 
RIGT encompasses both acute, and chronic, intestinal toxicity following radiotherapy for 
cancer, with symptoms developing in 33-72% of patients during, or following radiotherapy, 
depending on target area and treatment regime (Roszak et al. 2012; Kim, Huh & Park 2013; 
Shadad et al. 2013b). RIGT incorporates the previously defined acute radiation enteropathy, 
chronic radiation enteropathy, radiation enteritis, radiation proctitis, and radiation-induced 
gastrointestinal mucositis (Theis et al. 2010). This thesis explored new facets of the 
pathobiology of RIGT, clarifying and expanding on the existing understanding of the role of 
intestinal microvasculature, vascular mediators, and matrix metalloproteinases (MMPs) (Paris 
et al. 2001; Wang, J et al. 2002; Strup-Perrot et al. 2006; Stansborough et al. 2016).  
Throughout this thesis I aimed to assess each of these components, beginning with changes to 
the intestinal microvasculature (chapter 3), expression of MMPs (chapter 4), and expression 
of vascular mediators (chapter 5) in a well-established in vivo model of fractionated radiation-
induced gastrointestinal toxicity. My studies were the first to show apoptosis and cytostasis in 
the intestinal microvasculature in a fractionated radiation model of RIGT, which preceded 
peak epithelial damage, and telangiectasis and fibrotic thickening of the microvasculature 
(Stansborough et al. 2017). I then assessed MMPs and found MMP-2 was associated with 
these changes, with increases in both mRNA and protein expression occurring during RIGT. 
Consistent with my hypothesised link between MMPs, vascular mediators, and subsequent 
vascular modification in RIGT (chapter 2), I also found VEGF, TGFβ, angiostatin, and 
endostatin, were significantly increased in the same model (chapter 5). Finally, I developed a 
novel in vitro model of endothelial response to irradiation to assess the effect of MMP 
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inhibition on endothelial cell viability, MMP expression, and the subsequent expression of 
VEGF and TGFβ. Using this model I demonstrated irradiation of tumour-associated 
microvascular endothelial cells (TAMECs) significantly upregulated both MMP-2 and MMP-
9, suggesting a direct effect of radiation on endothelial regulation of MMPs. Whilst SB-3CT 
did significantly attenuate their upregulation and translation of MMP-2 and -9, it did not 
significantly alter TAMEC viability. Additionally, VEGF and TGFβ were not significantly 
upregulated following irradiation in the in vitro model, possibly due to the required 
involvement of other tissue components, not present in the single cell model.  
6.2 Intestinal Microvasculature in RIGT 
Previous research has shown an involvement of the intestinal microvasculature in the 
development of RIGT, however, to date the interpretation of the findings of these studies has 
been controversial (Richter et al. 1998; Paris et al. 2001; Gaugler, M-H et al. 2007). Paris et 
al. (2001) reported endothelial apoptosis occurs hours following irradiation in a mouse model 
of GI syndrome, in which extensive intestinal damage is caused by high-dose of radiation. 
Despite this finding, endothelial response to the large doses of irradiation in GI syndrome 
may not be consistent with that during RIGT, in which radiotherapy is typically administered 
in a fractionated schedule consisting of smaller doses over time. Since the Paris (2001) study, 
findings of endothelial involvement in RIGT have been conflicting, with some studies finding 
no endothelial apoptosis in GI syndrome (Schuller et al. 2007; Kirsch et al. 2010), and another 
finding endothelial apoptosis to occur within hours of intestinal irradiation in mice 
(Abdderahmani et al 2012). Key findings in this thesis (chapter 3) support the role of 
endothelial apoptosis in RIGT, with apoptosis of small and large intestinal microvascular cells 
occurring in the acute (24 hours following last radiation dose of a 3 or 6 week fractionated 
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radiation schedule) and chronic (9 weeks following last radiation dose of a 6 week 
fractionated radiation schedule) RIGT stages, in an in vivo rat model of fractionated radiation-
induced gastrointestinal toxicity (Stansborough et al. 2017). Cytostasis was shown to precede 
apoptosis of these cells in the colon and was significantly increased compared to control at the 
chronic point. My findings coincided with increased damage scoring in the colon, epithelial 
apoptosis in both the jejunum and colon, significantly reduced weight gain, and 
histopathological changes to the lamina propria and microvasculature, including fibrotic 
thickening and telangiectasis (Stansborough et al. 2017). These results reflect the clinical 
presentation of RIGT, with telangiectatic, fibrosed vasculature occurring in colorectal tissue 
following short-term fractionated pelvic irradiation or long-term neoadjuvant 
chemoradiotherapy for colorectal cancer (Yeoh et al. 2005). These findings of similarities 
between the rat model used in this study and clinical presentation of RIGT support the 
validity of this RIGT model for further experimental use. Taken together, my suggest changes 
to the intestinal microvasculature may be key drivers in the progression of acute RIGT.  
Although the microvascular changes I demonstrated in chapter 3 coincided with significantly 
lower weight gain, the clinical implications of endothelial apoptosis and telangiectasis in 
RIGT require further study (Stansborough et al. 2017). Determining the transition from acute 
to chronic RIGT is key in developing treatments and preventative measures. This transition 
has previously been explained in a model of consequential late effects, in which acute toxicity 
directly induces chronic toxicities (Peters, Ang & Thames 1988). Although findings of 
chapter 3 appear to support a relationship between intestinal microvascular alteration in acute 
RIGT and microvascular sclerosis and telangiectasis in chronic RIGT, this link is difficult to 
confirm. It is possible apoptosis and cytostasis of the microvasculature in acute RIGT, as 
shown in chapter 3, with the altered expression of tissue factors and vascular mediators in 
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chapter 5, may create a pro-coagulant endothelial surface and drive the development of 
chronic RIGT (Denham & Hauer-Jensen 2002). The role of intestinal telangiectasis in this 
shift, however, is particularly unclear. Previously telangiectasis has been shown to be more 
common after acute radiation toxicities (Turesson et al. 1996); it seems acute inflammatory 
damage to microvasculature is important in the development of telangiectasia, but not in the 
induction of post-irradiation fibrosis (Denham & Hauer-Jensen 2002). Although the findings 
of chapter 3 suggest intestinal microvasculature alteration plays some role in the shift from 
acute to chronic RIGT, it is likely to involve several other factors. Recent literature finding 
mast cell deficiency, sensory-nerve ablation, and TGFβ modulation in rats produce 
dissociations between acute and chronic toxicity (Hauer-Jensen, Denham & Andreyev 2014).  
Further studies are required, to build on these findings, assessing a possible link in processes 
inducing microvascular changes and driving the shift from acute to chronic RIGT. In 
particular, in vivo models of RIGT assessing the inhibition of MMPs or vascular mediators 
such as VEGF, angiostatin and endostatin should also include assessment of intestinal 
microvascular changes to determine any affect of inhibition of these mediators on the shift 
from acute to chronic RIGT. 
6.3 MMPs in RIGT 
Utilizing the same model as chapter 3, in which histopathological characteristics of RIGT, 
particularly the response of the microvasculature, were explored, allowed me to investigate 
possible links between MMP alteration and RIGT development. Results of my study 
highlighted an involvement of MMP-2 in RIGT, having been upregulated in the jejunum and 
colon, both at the protein and mRNA levels following 6 weeks of fractionated irradiation. 
When considering the results of chapters 3 and 4, with telangiectasis, microvascular apoptosis 
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and cytostasis, and epithelial damage, occurring alongside an increase in MMP-2 expression, 
a relationship between these factors is possible. MMPs are regulated at the transcriptional 
level by several transcription factors, primarily including β-catenin, and NFκB. MMPs are 
also regulated post-transcriptionally via transforming growth factor-β (TGFβ), vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and pro-
inflammatory cytokines (Yan & Boyd 2007; Stansborough et al. 2016). These mediators are 
capable of increasing the half-life of MMP mRNAs by binding to the coding regions of the 
transcript and regulating mRNA stability, and possibly regulating translation efficiency via 
the recruitment of mRNA to membrane-bound ribosomes (Yan & Boyd 2007). It is likely this 
increase in expression of MMP-2 is an indirect result of the effect of radiation on 
transcriptional regulators, such as NFκB, and pro-inflammatory cytokines, including TNF and 
IL-1β (Yeoh et al. 2007). Whilst these mediators were not assessed in this thesis, they are well 
known to be involved in the pathogenesis of RIGT, including the same in vivo model of RIGT 
as in chapters 3-5 of this thesis (Yeoh et al. 2005; Boerma et al. 2013; Yue et al. 2015). 
Additionally, MMP-2 degrades the capillary basement membrane, primarily via the 
degradation of type IV collagen (Kalluri 2003). This allows for endothelial migration and 
proliferation; this function possibly contributes to the telangiectasis seen in chapter 3, 
particularly at the chronic time point, week 15, in which endothelial proliferation was 
significantly increased. Alternatively, it is possible MMP-2 may have dual functions in 
regulating the intestinal microvascular changes in RIGT. This may be through sequestering 
the anti-angiogenic mediators angiostatin and endostatin (Kalluri 2003; Tolstanova et al. 
2011), increased in the same model (chapter 5), via the digestion of plasminogen and type 
XVIII collagen, which could contribute to endothelial cytostasis (Cauwe et al., 2007). 
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The demonstrated increase in both MMP-2 and MMP-14 at the transcriptional level in this 
thesis (chapter 4) is one which should be considered when investigating the role of MMP-2, 
or the inhibition of MMP-2, in future models of RIGT. This increase in both MMP-2 and -14 
expression is consistent with previous findings of intestinal upregulation of these same MMPs 
following abdominal irradiation in rats (Strup-Perrot et al. 2005). As MMP-2 is uniquely 
controlled by a mechanism of enzyme activation in which MMP-2 and MMP-14 are co-
regulated (Sternlicht & Werb 2001), combined with the findings of chapter 4 that both MMP-
2 and -14 are upregulated in RIGT, development of specific inhibitors of MMPs for the 
treatment of RIGT should consider MMP-14 as a possible target. 
6.4 Vascular mediators in RIGT 
A link between MMP-2, shown to be significantly increased in chapter 4, and microvascular  
alteration, seen in chapter 3, was hypothesised in chapter 2 (Stansborough et al. 2017). 
Chapter 5 aimed to explore this hypothesised link, assessing the vascular mediators VEGF, 
TGFβ, VWF, angiostatin, and endostatin. As discussed in chapter 2, all of these vascular 
mediators are able to be sequestered from the ECM by MMP-2, shown to be increased in 
chapter 4 (Yan & Boyd 2007; Stansborough et al. 2016). mRNA expression of VEGF, TGFβ, 
angiostatin, and endostatin were found to be increased; primarily in the acute phases of the 
fractionated radiation schedule. The exception was VEGF, which was significantly increased 
during the chronic phase, in the colon only. These findings support the hypothesised pathway 
of MMP inducing microvascular alteration in RIGT via the regulation of vascular mediators 
(Stansborough et al. 2016). Additionally, my study was the first pre-clinical study to assess 
intestinal VEGF expression following fractionated irradiation. An increase during the chronic 
RIGT time point may suggest a role in healing, supported by evidence from the literature 
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which show the inhibition of VEGF to significantly enhance intestinal damage when 
combined with total body irradiation in mice (Mangoni et al. 2012). VEGF acts to maintain 
immature vasculature and enhance angiogenesis, thus it is likely an increase in VEGF weeks 
following the last radiotherapy dose is also contributing to telangiectasis in chronic RIGT 
(Carmeliet 2005). This is supported by a study by Trzcinski and colleagues (2017) in which 
VEGF expression significantly correlated with chronic radiation proctitis in patients who had 
undergone radiotherapy for prostate, cervical, or uterine cancers. Clarity is needed in the 
implications of VEGF inhibition on acute and chronic RIGT, and intestinal toxicity should be 
investigated further in future clinical trials in which VEGF inhibitors are combined with 
abdominal irradiation. 
My study also demonstrated TGFβ was significantly increased in both the jejunum and colon 
early in the DA rat model of RIGT (chapter 5). TGFβ has previously been shown to increase 
in the small intestine following irradiation in both pre-clinical and clinical studies (Wang, J, 
Zheng & Hauer-Jensen 2001; Milliat et al. 2006). This increase has largely been associated 
with fibrotic changes occurring during chronic RIGT, rather than acute RIGT (Wang, J, 
Zheng & Hauer-Jensen 2001). However, this early increase is not entirely unexpected as it has 
been suggested ionizing radiation may directly induce TGFβ1 release via reactive oxygen 
species (Boerma et al. 2013). Additionally, MMP-2, coinciding with TGFβ upregulation, 
increases the bioavailability of TGFβ (Egeblad & Werb 2002). Both MMP-2 and -9 have been 
shown to proteolytically cleave latent TGFβ, sequestering its inactive extracellular complex 
and thus leading to the activation of TGFβ (Yu & Stamenkovic 2000). Clinically, enhanced 
rectal expression of TGFβ has been shown to correlate with radiation injury score, 
highlighting TGFβ as a possible target for the treatment of acute RIGT, and even the 
prevention of the development of chronic RIGT (Milliat et al. 2006). The findings of this 
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thesis suggest a link between MMP-2 expression and acute TGFβ, and further investigations 
are now necessary to determine whether the inhibition of MMP-2 alters TGFβ expression and 
to elucidate the role of TGFβ during acute RIGT. 
This is the first study to assess intestinal angiostatin and endostatin protein expression using 
immunostaining during RIGT. Both angiostatin and endostatin were found to be significantly 
increased in the lamina propria of the colon 3 weeks into the fractionated radiation schedule, 
with angiostatin also significantly increased at week 6. Angiostatin and endostatin, when 
increased in early RIGT, may contribute to the endothelial apoptosis and cytostasis observed 
in chapter 3 (Itasaka et al. 2007). Angiostatin and endostatin are both sequestered by MMP-2, 
from plasmin and collagen type XVIII respectively (Ribatti 2009). When the findings of 
chapter 5 are considered with the increase in MMP-2 in chapter 4, the role of MMP-2 in 
endothelial apoptosis and cytostasis in RIGT is further supported (Stansborough et al. 2017). 
With this implication of anti-angiogenic mediators in the development of RIGT, particular 
consideration should be given to intestinal toxicity when these angiogenic mediators are used 
in combination with radiation as anti-cancer therapies. 
6.5 Modulation of microvascular changes in RIGT via MMP inhibition 
As a link could be seen between microvascular changes, MMP expression, and vascular 
mediator expression in chapters 3-5, primary tumour-associated microvascular endothelial 
cells (TAMECs) isolated from DA rat mammary adenocarcinoma were used to assess the 
direct effects of radiation and MMP inhibition on endothelial cells. I found MMP-2 and -9 
expression was significantly increased in these endothelial cells following 12 Gy irradiation. 
Further, MMP-2 and -9 were significantly inhibited by the addition of the inhibitor SB-3CT. 
The increase in MMP-9 in the in vitro model, not seen in the in vivo model of RIGT, is likely 
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due to the differences between tumour and normal endothelium. Although MMP-9 plays an 
important role in tumour response to irradiation, it does not seem to be involved in 
gastrointestinal damage from fractionated irradiation (Bergers et al. 2000; Angenete et al. 
2009). This highlights a limitation in the model used in this study, in that MMPs are highly 
tissue-specific in their upregulation and downstream effects, thus changes observed in tumour 
endothelium may not reflect those seen in normal endothelium following irradiation.  
Radiation significantly reduced cell viability of TAMECs. However, despite the significantly 
inhibited expression of MMP-2 and -9 by SB-3CT in irradiated TAMECs, this inhibition did 
not alter cell viability of TAMECs. Whilst the presence of TGFβ and VEGF expression was 
confirmed in the present study, they were not significantly altered following irradiation of 
TAMECs as seen in both my in vivo studies and also supported by previous literature (Wang, 
J, Zheng & Hauer-Jensen 2001). Regulation of endothelium by MMPs is largely due to the 
sequestering of ECM components, and subsequent release and activation of growth factors 
such as TGFβ and VEGF (Hawinkels et al. 2008; Manicone & McGuire 2008; Stansborough 
et al. 2016). Thus, it is likely the lack of ECM components in the TAMEC model which 
would normally be present in the intestinal submucosa may have hindered the effect of MMP 
inhibition on endothelial cell regulation. However, the lack of alteration of VEGF expression 
is consistent with findings of Oh and colleagues (2014) in which VEGF and VEGFR2 
expression was not altered in human breast tissue-derived endothelial cells following 4 Gy 
irradiation.  
Despite some limitations, my study confirmed a direct effect of radiation on MMP-2 and -9 in 
endothelial cells, supporting a link between the significant increase in MMP-2 observed in 
chapter 4, and the microvascular changes observed in chapter 3. Future in vivo studies should 
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now be conducted to determine the effect of MMP-2 and -9 inhibition, or even knockout, in 
RIGT, with a particular focus on the intestinal microvasculature. This is increasingly 
important with the continued development of MMP inhibitors as anti-cancer agents, 
particularly when combined with radiation, as the implications on intestinal toxicity are 
currently unknown.  
6.6 Therapeutic implications 
The findings of this thesis, when taken together, support a role for MMPs and the vascular 
mediators VEGF, TGFβ, angiostatin, and endostatin, in the development of RIGT. These 
mediators are likely part of a larger pathway and contribute to the microvascular changes seen 
in chapter 3 (Stansborough et al. 2017). Due to these findings, both MMP-2 and the 
aforementioned vascular mediators appear to be attractive targets for the development of 
novel RIGT treatments. This section of the general discussion provides context, and discusses 
possible considerations, for the development of these treatments, particularly as similar agents 
have additional implications in cancer treatment. 
6.6.1 MMP inhibition 
Whilst MMP inhibitors are yet to be investigated for the treatment of RIGT, they have a long, 
and tumultuous path in their use as anti-cancer therapies (Pavlaki & Zucker 2003; Syed et al. 
2004; Chu et al. 2007). Although MMP inhibitors have shown a great deal of promise in 
reducing tumour burden and invasion, and preventing metastases in pre-clinical studies, the 
majority of these inhibitors failed to produce objective anti-tumour responses in early clinical 
trials and their development has been halted (Syed et al. 2004; Chu et al. 2007). This is 
largely due to two factors; 1. the use of broad-spectrum MMP inhibitors, and 2. their use in 
patients with treatment-resistant, advanced malignancies (Syed et al. 2004). With increased 
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specificity of MMP inhibitors, such as that used in chapter 5, SB-3CT, their use in early 
stages of tumour progression, or in the prevention of further metastases, warrants further 
investigation. MMP-2, and -14, upregulated in RIGT (chapter 4), and MMP-9, upregulated in 
endothelial cells following irradiation (chapter 5), have been shown to be involved in tumour 
angiogenesis, with specific inhibition of these MMPs reducing endothelial migration and 
invasion, and impairing tumour angiogenesis in pre-clinical studies (Egeblad & Werb 2002). 
If clinical development of specific inhibitors of these MMPs shows therapeutic potential, it is 
possible their combination with radiotherapy may not only enhance the anti-tumour effects of 
irradiation, but reduce associated intestinal toxicity. Thus, the investigation of the role of 
MMPs in RIGT, and the effects of their inhibition on its pathobiology is increasingly 
important.  
Li and colleagues (2017) conducted the first study to assess the effect to MMP inhibition on 
radiation toxicity, determining the effects of the broad-spectrum MMP inhibitor, Ilomastat, on 
radiation-induced pulmonary toxicity in mice. Despite differences in pathology, increases in 
MMPs, cytokines, and reactive fibrosis are all characteristic features of both RIGT and 
radiation-induced pulmonary toxicity (Li, X et al. 2017). Ilomastat significantly reduced 
MMP-2 and -9 expression, attenuated pulmonary toxicity, fibrosis, inflammation, and 
apoptosis, and significantly increased survival time (Li, X et al. 2017). This very recent study, 
combined with the findings of this thesis, suggesting the involvement of MMP-2 in RIGT, 
highlight the need to further investigation and development of specific MMP inhibitors in the 
treatment of RIGT.  
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6.6.2 Vascular mediator inhibition 
Due to the role of VEGF in the ‘angiogenic switch’ during tumorigenesis, inhibitors of VEGF 
(VEGFIs) are currently being investigated as cancer therapies. Despite promising results of 
VEGFIs in clinical trials, adverse effects, including hypertension, haemorrhage, 
thromboembolism, and GI perforation, have severely limited their use, leading to them 
primarily being investigated as adjuvant therapies (Hapani, Chu & Wu 2009; Pollom et al. 
2015). When VEGFIs are combined with radiotherapy, gastrointestinal toxicity has been 
shown to significantly increase (Barney et al. 2013; Pollom et al. 2015). The inhibition of 
VEGF has been shown to delay healing of gastric erosions, reduce vascular density in the 
small intestinal villi, induce epithelial ulceration. Specifically, in the case of inhibition using 
bevacizumab, a monoclonal antibody against VEGF, induces platelet aggregation and 
degranulation, possibly resulting in ischemia and GI perforation (Mangoni et al. 2012; Pollom 
et al. 2015). Barney and colleagues (2013) retrospectively assessed patients with primary or 
metastatic abdominal tumours who had undergone stereotactic body radiation therapy 
(SBRT), in which highly precise, high-dose fractionations of radiotherapy are used, and found 
the rate of serious bowel injury (SBI) in patients who had received post-SBRT VEGFI to be 
35%, with no SBI reported in patients undergoing SBRT alone (Barney et al. 2013). These 
SBI included gastric/duodenal ulceration, gastric ulceration, stomach perforation, small bowel 
perforation, and duodenal perforation leading to sepsis and death (Barney et al. 2013). The 
findings of chapter 5, in which VEGF was significantly increased during chronic RIGT in DA 
rats, support the findings of a protective role for VEGF during RIGT. Although the 
involvement of VEGF in tumorigenesis and tumour angiogenesis prevents the targeting of this 
mediator for the treatment of chronic RIGT, it is important to better understand its role in the 
 Chapter 6 General discussion 
138 
 
pathology in order to better understand the enhancement of RIGT caused by VEGFI’s 
clinically.  
6.7 Conclusions and future directions 
The studies conducted in this thesis aimed to elucidate the role of the intestinal 
microvasculature, and the potential mediators of these microvascular changes, matrix 
metalloproteinases, and associated vascular mediators, in the development of radiotherapy-
induced gastrointestinal toxicity. Chapter 3 is the first study to assess intestinal endothelial 
apoptosis and cytostasis following fractionated irradiation. The findings of this thesis help 
clarify the role of the microvasculature in acute RIGT, and support the role of telangiectasis 
and microvasculature fibrosis in chronic RIGT. MMP-2 was found to be significantly 
increased in the same model of RIGT in chapter 4, and was associated with these 
microvascular changes and intestinal damage, supporting the hypothesis developed in the 
review of the literature (chapter 2). MMP-2 and -9 were also shown to be involved in 
endothelial response to radiation in vitro (chapter 5). Additionally, the importance of MMP-2 
in tumorigenesis, when combined with the findings of a significant increase in RIGT, 
encourage the use of MMP-2 inhibitors in the treatment of RIGT, with the possibility of 
enhancing the efficacy of radiotherapy.  
The additional findings of increased expression of VEGF, TGFβ, angiostatin, and endostatin 
during RIGT present a possible link between the increased MMP-2 observed in chapter 4, and 
the microvascular changes observed in chapter 3, with MMP-2 acting to sequester ECM 
components, thus releasing these mediators. When taken together, the findings of this thesis 
support the proposed mechanism of MMP and microvascular involvement in RIGT. Although 
further studies are now required to elucidate this pathway, these results have greatly 
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contributed to the knowledge of the pathobiology of RIGT, and have highlighted MMPs, and 
the microvasculature, as targets for novel RIGT treatments. 
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the intestinal microvasculature
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ABSTRACT
Purpose To review the literature surrounding the involvement of the endothelium and matrix metallo-
proteinases (MMP) in radiotherapy-induced gut toxicity (RIGT) and further elucidate its complex
pathobiology.
Results RIGT involves damage to the gastrointestinal mucosa and is associated with diarrhoea, pain,
and rectal bleeding depending on the area of exposure. The mechanisms underpinning RIGT are com-
plex and have not yet been elucidated. Members of the MMP family, particularly MMP-2 and -9, have
recently been identified as being key markers in RIGT and chemotherapy-induced gut toxicity (CIGT).
Furthermore, the microvasculature has long been implicated in the development of toxicities following
both chemotherapy and radiotherapy, however, the mechanisms behind this are yet to be explored.
Conclusions It is proposed that matrix metalloproteinases are key regulators of endothelial mediators,
and may play a key role in inducing damage to intestinal microvasculature following radiotherapy.
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Radiotherapy-induced gut toxicity (RIGT) is a dose-limiting
pathology involving damage to the gastrointestinal mucosa
caused by radiotherapy for cancer. Its symptoms including,
but not limited to, pain, diarrhoea, nausea, and rectal bleed-
ing, are debilitating and significantly reduce the patients’
quality of life (Sonis and Keefe 2013). The overall incidence of
RIGT is not well understood, due to discrepancies in the def-
inition of gastrointestinal toxicity following radiotherapy, and
the classification of symptoms. Acute diarrhea and abdominal
pain occur in 20–70% of patients receiving radiotherapy for
abdominal or pelvic malignancies, and acute RIGT affecting
quality of life has been shown to occur in 47% of women
receiving radiotherapy for cervical or endometrial cancer
(Classen et al. 1998, Abayomi et al. 2009, Shadad et al. 2013).
Gastrointestinal response to radiotherapy
Gastrointestinal toxicities from radiotherapy are classified as
being either acute (occurring hours after treatment) or
delayed (months after treatment) (Al-Dasooqi et al. 2013).
Acute RIGT occurs shortly after radiation and can continue for
up to 3 months following treatment (Theis et al. 2010).
Symptoms of acute toxicity include, but are not limited to,
mucositis, nausea and vomiting, pain, and diarrhoea (Al-
Dasooqi et al. 2013, Elting et al. 2013, Sonis and Keefe 2013).
Further, acute RIGT is characterized by a plethora of histo-
pathological alterations including mucosal atrophy, inflamma-
tion, and increased intestinal permeability (Theis et al. 2010).
Several mediators have been identified as being key
regulators in the development of acute RIGT, particularly the
transcription factor nuclear factor-jB (NF-jB); which acts to
upregulate over 200 genes involved in this pathology (Bowen
et al. 2007). Key downstream mediators of NF-jB include pro-
inflammatory cytokines, mitogen-activated protein kinase
(MAPK), and matrix metalloproteinases (MMP) (Sonis 2004,
Logan et al. 2008a, 2008b, Al-Dasooqi et al. 2010). These
mediators act together to cause significant levels of apop-
tosis, decrease proliferation, and degrade the extracellular
matrix (Sonis 2004).
Delayed toxicity, also known as chronic radiation enterop-
athy, occurs between 18 months and 6 years following irradi-
ation and is reported in up to 20% of patients receiving
pelvic radiotherapy (Theis et al. 2010). Commonly reported
symptoms include changes in stool frequency and rectal
bleeding (in 70% of cases); however, lesser reported compli-
cations may also occur, including small intestinal obstruction
and fistulation (occurring in 0.6 and 13% of cases, respect-
ively) (Henson 2010, Theis et al. 2010). Histopathologically,
delayed RIGT is characterized by tissue ischaemia and necro-
sis, ulceration, telangiectasia, fibrosis of both the submucosa
and the microvasculature, and mesenchymal cell activation
(Richter et al. 1998, Theis et al. 2010, Al-Dasooqi et al. 2013).
It has been shown that several mediators upregulated in the
delayed phase of RIGT, such as transforming growth factor-b1
(TGF-b1) and thrombomodulin, interact with the extracellular
matrix (ECM) to cause deposition of ECM components in the
intestinal smooth muscle wall and perhaps induce long-term
injury to the epithelium and endothelium of the gastrointes-
tinal tract (Andreyev 2007, Gervaz et al. 2009, Wang et al.
2012, Al-Dasooqi et al. 2013). Remodelling of the ECM has
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many downstream effects, including the release of seques-
tered growth factors resulting in alterations to the microvas-
culature, possibly linking back to related symptoms such as
rectal bleeding and telangiectasis (Imai et al. 1997, Bergers
et al. 2000). These studies suggest a complex mediator path-
way associated with delayed toxicity following radiation.
Both acute and delayed toxicities result in a significant
reduction of quality of life of patients receiving radiotherapy
for cancer (Bentzen 2006, Lalla et al. 2014). Despite the clin-
ical significance of RIGT, its pathogenesis remains poorly
understood. This lack of understanding of the mechanisms by
which RIGT occurs hinders the development of effective treat-
ments. Previous studies have suggested a complex pathway
of mediator release, inflammation, and apoptosis, of not only
the epithelial mucosa, but the underlying submucosa, includ-
ing microvascular endothelium (Paris et al. 2001, Kruse et al.
2004).
Matrix metalloproteinases (MMP)
Matrix metalloproteinases, a class of zinc-dependent endopep-
tidases, have been previously shown to be altered in RIGT and
chemotherapy-induced gut toxicity (CIGT) (Strup-Perrot et al.
2006, Al-Dasooqi et al. 2010). MMP subtypes are classified
either functionally or structurally, with 24 members of the
MMP family currently identified in humans, all of which share a
catalytic domain coordinated by zinc (Yan and Boyd 2007).
Their gene expression is predominantly regulated at the tran-
scriptional level, with MMP members being regulated by tran-
scription factors such as beta-catenin and NF-jB (Yan and
Boyd 2007). However, post-transcriptional regulation of MMP
does occur, with TGF-b, vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), and various pro-
inflammatory cytokines being capable of activating MMP pro-
moters, particularly in disease states (Yan and Boyd 2007).
MMP family members vary structurally and functionally, with
differences also occurring in the transcriptional and post-tran-
scriptional regulation (Strongin et al. 1995). Whilst the general
role of the MMP family is primarily in homeostasis of the extra-
cellular matrix, specific MMP members may have different roles
and have been identified as altering cell growth, immune
responses, chemokine and cytokine expression, as well as
apoptosis, a key histopathological feature of RIGT (Castaneda
et al. 2005, Manicone and McGuire 2008). The recent implica-
tion of the MMP family in RIGT and CIGT suggests a complex
and intricate involvement with associated mediators and tissue
types in RIGT, as summarized in previous reviews (Sternlicht
and Werb 2001, Al-Dasooqi et al. 2009).
Matrix metalloproteinases may be key mediators in
RIGT
Studies by Strup-Perrot et al. (2005,2006) identified matrix
metalloproteinases as regulating RIGT. Male Wistar rats
received a single dose of radiation (10 Gy) to the abdomen,
and gene expression of MMP-2, -3, -9, and -14 in the colon
was assessed. MMP-2 was significantly increased at 1, 3, and
7 days following irradiation, MMP-3 was significantly
increased at 3 days, MMP-9 at 3 and 9 days, and MMP-14 at 1
and 3 days (Strup-Perrot et al. 2006). Strup-Perrot et al. (2004)
also assessed intestinal gene expression of MMP-2, -9, and -14,
as well as tissue inhibitor of matrix metalloproteinase (TIMP)-1,
and -2, in patients undergoing surgery for intestinal occlusion
caused by delayed radiation-induced enteritis. MMP-2, -9, and
-14, and TIMP-1, and -2 mRNA expression were significantly
increased compared to healthy controls (Strup-Perrot et al.
2004). Conflicting results have been found in later studies.
Angenete et al. (2009) studied levels of various matrix metallo-
proteinases in normal and tumour tissue from the rectum of
rectal cancer patients scheduled for open surgery with or with-
out pre-operative radiation. The study recruited 32 patients, 20
of which received short-term pre-operative fractionated radio-
therapy (5 5 Gy) with a median time of tissue collection fol-
lowing completion of radiotherapy of 3 days. The remaining
12 patients received no pre-operative radiation. Patients
receiving chemoradiotherapy were excluded and groups were
matched for age and gender. Whilst MMP-2 levels were signifi-
cantly increased in the rectal mucosa following radiotherapy,
no significant changes in MMP-1, MMP-9, or TIMP-1 levels
were observed following radiotherapy in these patients
(Angenete et al. 2009). These discrepancies may be due to the
many differences between the studies, including species differ-
ence in preclinical vs. clinical studies, differences between
acute and delayed RIGT, and single-dose vs. fractionated irradi-
ation. This is particularly relevant in the context of acute vs.
delayed RIGT, in which many differences can be observed at
the clinical, histopathological, and molecular levels (Theis et al.
2010). It is likely that MMP expression would differ depending
on time from the last radiotherapy course. Differences in nor-
mal tissue response in single vs. fractionated dose radiother-
apy have also been widely observed, with the short breaks
between doses in fractionated irradiation thought to lead to
an accumulative affect, although not always linear (Yeoh et al.
2007, Hauer-Jensen et al. 2014).
Recent studies characterizing MMP expression in the devel-
opment of CIGT have suggested particular roles for different
MMP members depending on their patterns of expression, and
their coincidence with stages of CIGT development (Al-
Dasooqi et al. 2010). MMP-2, -9, and -12 levels have been
shown to peak 48 h following chemotherapy, coinciding with
maximal mucosal damage in the jejunum of Dark Agouti rats
(Al-Dasooqi et al. 2010). This implicates these specific MMP
subtypes in the progression of inflammation in CIGT. In con-
trast, MMP-1 has been found to be down-regulated early in
the development of CIGT, however, is later upregulated at 96
and 144 h following chemotherapy administration, suggesting
it may play a role in the healing stages of the pathology (Al-
Dasooqi et al. 2010). This is supported by the ability of MMP-1
to cleave type-1 collagen to regulate cell migration in re-
epithelialization (Pilcher et al. 1997, Al-Dasooqi et al. 2010).
Alterations in MMP-1 expression may therefore be involved in
the development of delayed RIGT, in which collagen depos-
ition and reactive fibrosis commonly occur, also this has not
yet been explored (Hauer-Jensen et al. 2014). Such studies are
yet to be conducted in RIGT models, particularly in regards to
the differences between single dose in vivo RIGT studies and
the fractionated radiation doses commonly used clinically.

























































MMP-2 and -9 in particular, have many downstream media-
tors linked to the pathobiology of RIGT. MMP-2 and -9 are cap-
able of upregulating pro-inflammatory cytokines such as
tumour necrosis factor-alpha (TNF-a), as well as forming a posi-
tive feedback loop with the key transcriptional factor NF-jB,
(Sengupta and MacDonald 2007). Certain MMP members,
MMP-2, -7, and -9 in particular, have also been linked with the
disruption of endothelial and epithelial tight junctions (Al-
Dasooqi et al. 2014, Wardill et al. 2014). No studies to date
have assessed changes in endothelial tight junction protein
levels in the intestinal microvasculature following radiation.
However, studies have assessed intestinal epithelial tight junc-
tions and blood-brain barrier tight junctions following radi-
ation (Fauquette et al. 2012, Shukla et al. 2015). A recent study
by Garg et al. (2016) assessed changes in tight junction expres-
sion in the jejunum, ileum, and colon of non-human primates
following total-body irradiation. Claudin-1 and -10 expression
was significantly increased at day 4, and claudin-4 and -7
expression was repressed at days 4, 7, and 12. These changes
were also shown to be segment-specific, with increased
expression of claudin-1 occurring only in the colon, and repres-
sion of claudin-7 expression occurring only in the ileum (Garg
et al. 2016). Fauquette et al. (2012) assessed permeability and
changes to tight junction protein levels following irradiation of
a bovine brain capillary endothelial cell (BBCEC) monolayer co-
cultured with glial cells. Permeability to fluorescein isothio-
cyanate (FITC)-dextran (70 kDa) was significantly increased 8
days following 25 Gy irradiation, and immunoflourescent stain-
ing of the tight junction protein zonula occludens-1 (ZO-1) was
decreased 8 days following both 12 Gy and 25 Gy irradiation.
Whilst endothelial cells of the blood-brain barrier are structur-
ally distinct to those of the intestinal microvascular, alterations
to endothelial tight junction integrity following irradiation may
still lead to increased permeability in such vessels. Similarly, a
significant loss of junctional distribution of tight junction pro-
teins occludin, claudin-3, and ZO-1 was shown to occur in the
colon epithelium 2 h following a single dose of 4 Gy whole
body irradiation in female C57BL6 mice (Shukla et al. 2015).
Further exploration of tight junction alterations in the intestinal
endothelium following radiation is warranted, particularly with
increasing evidence of the importance of the gut-brain axis in
many pathologies, including CIGT (Tillisch 2014, Wardill et al.
2015). Despite these implications of the MMP family in RIGT
and CIGT, a causative role has not yet been confirmed in previ-
ous literature, and several aspects of MMP functionality in RIGT
remain entirely unexplored.
Response of intestinal microvasculature to
radiotherapy
The microvasculature, and specifically the endothelium, plays
a large role in toxicity following radiotherapy. Despite this,
the extent of the involvement of the intestinal microvascula-
ture, and the mechanisms behind this beyond their direct
clinical manifestation in RIGT are unknown. Kruse et al. (2004)
assessed changes to the microvasculature of the rectum of
female C3H/HenAF-nuþ mice following a single dose of 20 Gy
irradiation. Extensive vascular changes in the rectum,
particularly tortuous telangiectatic vessels, were observed
from 10 weeks following irradiation, with increasing severity,
and were not resolved at 30 weeks post-irradiation (Kruse
et al. 2004). Telangiectatic vessels are defined as ‘thin-walled,
tortuous vascular channels that often occur in groups and are
accompanied by an area of leukocytic infiltration’ (Kruse et al.
2004, Yeoh et al. 2005). Whilst the involvement of these tel-
angiectatic vessels in the development of RIGT is unclear,
gastrointestinal bleeding is one of the primary symptoms in
patients with hereditary haemorrhagic telangiectasia present-
ing with intestinal telangiectatic lesions (Kjeldsen and
Kjeldsen 2000). Mucosal telangiectasia resulting in rectal
bleeding is one of the primary dose-limiting factors for irradi-
ation of prostate cancer (Kruse et al. 2004). Further under-
standing of how intestinal telangectasis occurs in response to
radiation may lead to potential targets for the treatment or
prevention of rectal bleeding in RIGT.
Although few preclinical studies have assessed changes to
the intestinal microvasculature following irradiation, these
changes have been observed clinically in several studies fol-
lowing radiotherapy for cancer (Yeoh et al. 2005, Takeuchi
et al. 2012). Takeuchi et al. (2012) assessed histopathological
features of radiation toxicity of the lower rectum. The study
included patients with a history of radiation therapy for an
intrapelvic malignancy, characteristic colonoscopic findings of
radiation proctitis, and histopathological exclusion of other
diseases. Six male patients with radiation proctitis received
70 Gy external irradiation for prostate cancer, and two female
patients received 50 Gy external irradiation and 20 or 27 Gy
internal irradiation for uterine and vaginal cancers, respect-
ively. Endoscopies and rectal biopsies were performed
15.4 6 10.2 months from the completion of irradiation.
Telangiectasia was observed in the superficial layer of the rec-
tal mucosa upon endoscopy, and was confirmed in the upper
layer of the lamina propria upon histological examination of
rectal biopsies (Takeuchi et al. 2012). These findings are con-
sistent with those of Yeoh et al. (2005) who demonstrated tel-
angiectatic, fibrosed, and sclerosed blood vessels in the
lamina propria, submucosa and fat layer of the gastrointes-
tinal tract following short-term fractionated pelvic irradiation
(25 Gy total/5 fractions/1 week), or long-term neoadjuvant
chemoradiotherapy (45 Gy total/25 fractions/5 weeks, with
concurrent infusions of 5-fluorouracil), in patients with colo-
rectal carcinoma. Although these studies have highlighted a
key role of the intestinal microvasculature during RIGT they
have not described the effect these changes have on the
underlying pathobiology. The formation of telangiectatic ves-
sels in the rectal mucosa following radiation has been associ-
ated with increased expression of jagged 1 and Kruppel-like
factor 5 (KLF5), both of which are involved in vascular remod-
eling and have been linked to the development of interstitial
fibrosis (Kruse et al. 2004). KLF5 in particular is capable of
upregulating growth factors such as PDGF and TGF-b (Kruse
et al. 2004). The upregulation of these mediators would sug-
gest a greater involvement of telangiectatic vessels in RIGT
development than currently understood.
Endothelial apoptosis has also been suggested to be an ini-
tiating feature in the pathology of RIGT (Paris et al. 2001).
Several in vivo and in vitro studies have found that endothelial

























































apoptosis occurs hours following various radiation doses in
several different tissue types, including the intestinal, lung,
and central nervous system (CNS) microvasculature (Pena
et al. 2000, Paris et al. 2001; Zhang et al. 2012, Li et al.
2004). Li et al. (2004) assessed apoptosis in the spinal cord
of female Fisher 344 rats following a single dose of 50 Gy
radiation to the spinal cord. Apoptosis was analysed via
histology and terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) assay and 3.2 6 10% of apoptotic
cells in the spinal cord 10 h following irradiation were iden-
tified as endothelial (cells positively stained for factor-VIII-
related antigen). A similar study conducted by Pena et al.
(2000) found 16–20% of endothelial cells in the spinal cord
of male mice underwent apoptosis at 12 h following expos-
ure to 50 Gy of irradiation. Zhang et al. (2012) observed
positive apoptotic staining co-localized to the lung endo-
thelium of C57BL/6J mice following a single dose of 15 Gy
irradiation to the thorax. It was reported in the study that
11% of apoptotic cells in the irradiated lung were endothe-
lial (Zhang et al. 2012). Changes to endothelium following
irradiation cause significant long-term effects, with irradiated
endothelium lacking the ability to regulate thrombogenic,
inflammatory and coagulation processes months to years
following irradiation (Boerma et al. 2004, Otterson et al.
2012). Many of these effects of radiation on the endothe-
lium are related to changes in angiogenic signalling.
Angiogenic changes have been described in vitro, with the
angiogenesis pathway being over-expressed in primary
human endothelial cells from 12 h to 21 days following a sin-
gle irradiation dose of 2Gy (Heinonen et al. 2015). The angio-
genic mediator TGF-b1 has been found to be upregulated
preclinically in both early and delayed RIGT and is an
upstream mediator of thrombomodulin, capable of reducing
thrombomodulin immunoreactivity in the endothelium.
Thrombomodulin is a transmembrane glycoprotein present
on endothelial cells which is capable of forming a complex
with thrombin, preventing the formation of fibrin and the
activation of protease activated receptor-1 (PAR-1). This
leads to the activation of protein C, an anticoagulant and
anti-inflammatory protein (Wang et al. 2002). When thrombo-
modulin reactivity is reduced following irradiation PAR-1 is
upregulated, decreasing thromboresistance and inducing
endothelial dysfunction (Wang et al. 2002, 2012, Boerma
et al. 2013). TGF-b1 has also been shown to enhance radi-
ation-induced fibrotic thickening of the intestinal wall and
subserosa in a rat model of early and delayed RIGT following
fractionated irradiation (Boerma et al. 2013). Although these
microvascular changes have been described in several stud-
ies, the causal relationship of these changes to RIGT pathobi-
ology are yet to be explored, as are the opportunities for
novel therapies that may arise from this.
Matrix metalloproteinases and the intestinal
microvasculature following radiotherapy
The MMP family has been strongly linked to endothelial
regulation and angiogenesis, and could play a direct role in
pathological angiogenesis associated with RIGT (Bergers
et al. 2000, Al-Dasooqi et al. 2010). Much of what is known
regarding the involvement of MMP in the regulation of the
endothelium, particularly MMP-2 and -9, is from their
involvement in tumour invasion and tumour angiogenesis.
MMP-9 has been shown to be integral in the progression
of some cancer types based on its ability to regulate
angiogenesis (Bergers et al. 2000, Bhoopathi et al. 2010).
MMP members degrade the basement membrane allowing
for endothelial proliferation and migration, and remodeling
of the extracellular matrix, inducing tube formation
(Chidlow et al. 2007, Al-Dasooqi et al. 2011). Members of
the MMP family also indirectly induce pathological angio-
genesis via regulation of angiogenic mediators such as vas-
cular endothelial-cadherin (VE-cadherin), TGF-b, chemokines,
vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), angiostatin, and endostatin (Ichikawa
et al. 2006, Xu et al. 2006, Bendrik et al. 2008, Manicone
and McGuire 2008, Tolstanova et al. 2011). These mediators
contribute to many facets of pathological angiogenesis
including increased vascular permeability, vasodilation,
endothelial proliferation, and inhibition of vessel maturation
and pericyte stabilization (Kalluri 2003, Bendrik et al. 2008,
Tolstanova et al. 2011). Due to this cumulative evidence of
a role for the MMP family in endothelial regulation, MMP
inhibitors have been explored for their efficacy in the
reduction of tumour burden and metastasis. Whilst broad-
acting MMP inhibitors such as marimastat significantly
inhibited tumour angiogenesis and reduced tumour burden
preclinically, phase II and III clinical trials have been unsuc-
cessful (Zucker et al. 2000, Zucker and Cao 2009). This may
be due to the vastly different and even opposing effects of
various MMP types, as well as the exclusion of patients
with early stage cancer (Zucker and Cao 2009). Specific
inhibition of MMP members known to be involved in
tumour angiogenesis, such as MMP-2 and -9, may be more
efficacious in ongoing research, and provide insights in to
how matrix metalloproteinases may be regulating these
endothelial changes.
Few studies have been conducted to assess the role of
matrix metalloproteinases in changes to the intestinal micro-
vasculature in RIGT, and most have been performed in vitro.
Park et al. (2012) found MMP-2 and vascular endothelial
growth factor receptor (VEGFR)-2 to be significantly increased
24 h following a single radiation dose of 4 Gy in human brain
microvascular endothelial cells (HBMEC) and human dermal
microvascular endothelial cells (HDMEC). In a similar in vitro
model, capillary endothelial cells were irradiated with a single
dose of 10 Gy and displayed significantly increased apoptosis,
as well as an increase in active MMP-1 and -2 (Vorotnikova
et al. 2004). MMP-2 expression was also increased at 24 h, as
was MMP-2 enzyme activity at 24 and 48 h, following a single
dose of 4 Gy irradiation in endothelial cells cultured from nor-
mal human breast tissue (Oh et al. 2014). In contrast, MMP-9
expression decreased in these cells at 24 and 48 h following
irradiation (Oh et al. 2014). Whilst these studies suggest MMP,
particularly the gelatinase MMP-2, are directly involved in the
endothelial response to radiation, further in vivo studies are
warranted.

























































MMP signalling regulates endothelial mediators of
RIGT
MMP and Vascular Endothelial Growth Factor (VEGF)
VEGF plays a variety of roles in the regulation of microvascu-
lature. It is capable of increasing vascular permeability, caus-
ing transient vasodilation, and promoting endothelial
proliferation, migration, and differentiation, all of which stimu-
late angiogenesis (Ferrara et al. 2003, Chidlow et al. 2007).
The primary ability of the MMP family, particularly MMP-2
and -9, to increase VEGF, lies in their ability to cleave collagen
IV to release sequestered VEGF (Bergers et al. 2000, Kalluri
2003). Once VEGF has been released it is able to bind to
VEGF receptors on endothelial cells and induce angiogenesis
via a tyrosine kinase pathway (Lee et al. 2015). MMP-2, and 9
have also been suggested to change the structure of VEGF,
cleaving larger VEGF isoforms and increasing bioavailability;
however, Hawinkels found MMP-9 to have no effect in cleav-
ing VEGF165 to the smaller, soluble isoform VEGF121 in HT29
colon carcinoma and fibroblast spheroids (Belotti et al. 2003,
Kalluri 2003, Hawinkels et al. 2008). Hawinkels and colleagues
(2008) showed a decrease in extracellular localization of hep-
aran sulphate proteoglycans (HSPG), suggesting a release of
VEGF from the ECM via cleavage of HSPG by MMP-9. Bergers
et al. (2000) cultured normal, non-transgenic pancreatic islets
from C57/B16 mice with MMP-9. Cells were then washed and
embedded in collagen gels containing endothelial cells.
Whilst control islets, with no added MMP-9, failed to elicit an
angiogenic response from the endothelial cells, islets treated
with MMP-9 promoted the endothelial cells to form sprouts
towards the islet. VEGF levels were 2-fold higher in the
medium of MMP-9-treated islets, and MMP-9-treated islets
showed no angiogenic response of endothelial cells when an
anti-VEGF antibody was added. This suggests that the MMP-9
mediated endothelial response is regulated by VEGF (Bergers
et al. 2000). A study by Bhoopathi and colleagues (2010)
found VEGF expression following secreted protein acidic and
rich in cysteine (SPARC) overexpression to be MMP-9-depend-
ent in human medulloblastoma cell lines. These studies high-
light a complex involvement of MMP, particularly MMP-9,
with VEGF and it is likely that differences in the pathway
occur based on tissue types and the tissue environment
(pathological vs. normal tissue).
MMP and Transforming Growth Factor-b
The effect of TGF-b on the microvasculature is complex, with
TGF-b having several different effects on the endothelium,
depending on the signalling pathway (Goumans et al. 2003).
Ionizing radiation has been shown to alter the signalling
pathways of TGF-b in endothelium, reducing the activation of
the activin receptor-like kinase 1 (ALK1) pathway and enhanc-
ing the ALK5 pathway activation (Kruse et al. 2009,
Scharpfenecker et al. 2009). This change in signalling path-
ways is thought to alter the way in which endothelial cells
respond to TGF-b, with ALK5 inhibiting and ALK1 stimulating
endothelial cell proliferation and migration (Goumans et al.
2003). The degradation of the small collagen-associated
proteoglycan, decorin, by several MMP members has been
shown in several studies to sequester latent TGF-b, converting
it to its active state (Imai et al. 1997). TGF-b1 and MMP-9
mRNA levels have been shown to be significantly increased
at 3 and 7 days, as was TGF-b2 from day 1, following 10 Gy
abdominal X-irradiation (Strup-Perrot et al. 2005). Despite this
link between MMP-9 and TGF-b, associated changes to the
microvasculature are yet to be explored.
MMP and anti-angiogenic mediators
Several MMP subtypes have been associated with the anti-
angiogenic mediators, endostatin, tumstatin, and angiostatin
(Kalluri 2003, Tolstanova et al. 2011). Endostatin and tumstatin
are both anti-angiogenic mediators formed from the c-ter-
minal portions of collagens XVIII and IV, respectively
(Sudhakar et al. 2003). Both collagen IV and XVII, found in
vascular basement membranes, can be broken down by
active forms of MMP-2, cleaving endostatin from collagen
XVII, and increasing thrombospondin-1, which has been
shown to be upregulated early and late in an animal model
of CIGT (Bowen et al. 2007). MMP-2, -7, -9, and -12 are also
capable of cleaving plasminogen to form angiostatin
(Sternlicht and Werb 2001). MMP-9, endostatin, VEGF, and
platelet-derived growth factor receptor (PDGFR) were
increased at different time-points in an animal model of
ulcerative colitis, with increased endostatin and VEGF being
correlated with increased size of colonic lesions (Tolstanova
et al. 2011). However, the effects of endostatin and angiosta-
tin on endothelial cells are yet to be clarified, with transfec-
tion of the MMP-9 gene in vivo inducing endostatin release
and significantly reducing tumour growth rate and microves-
sel area in mammary adenocarcinomas in mice (Bendrik et al.
2008). This could be due to biphasic effects of endostatin,
and differential effects depending on cell type (Guan et al.
2003, Folkman 2006). Despite this, COL-3 (Metastat;
Collagenex Pharmaceuticals, Newtown, PA, USA), a specific
inhibitor of MMP-2 and MMP-9, did not increase tumour
growth rate of advanced solid malignancies in clinical trials
and three patients with disease progression prior to treat-
ment had prolonged stable disease (>6 months) (Syed et al.
2004). Further studies are now warranted to characterize
MMP-9 and associated downstream angiogenic mediators
in RIGT.
MMP and endothelial permeability
MMP-2, -7, and -9 have also been shown to play extensive
roles in endothelial permeability due to their ability to shed
VE-cadherin and cleave occludin; two tight junction proteins
with essential roles in maintaining tissue permeability. MMP-7
sheds epithelial-cadherin from adherens tight junctions to
remodel cell-cell contacts and facilitate cell migration
(McGuire et al. 2003). VEGF-A, a possible downstream medi-
ator of several MMP subtypes, is also capable of increasing
junction adhesion molecule -C expression, stimulating occlu-
din and VE-cadherin phosphorylation and decreasing occludin
and VE-cadherin at endothelial tight junctions (Antonetti et al.

























































1998). This link between matrix metalloproteinases, which
have been shown to be upregulated in RIGT, and the phos-
phorylation of endothelial tight junctions, highlights a poten-
tial new involvement for the MMP family in intestinal
endothelial dysfunction and increased permeability in RIGT.
Take home messages
RIGT is one of the most prevalent dose-limiting toxicities mani-
festing following radiotherapy (Sonis and Keefe 2013, Lalla
et al. 2014). It involves debilitating pain and increases the risk
of infection in patients receiving radiotherapy. Due to many of
the severe side-effects of RIGT, it is often necessary to reduce
the dosage, or halt anti-neoplastic therapies, leading to
decreased remission and increased mortality (Lalla et al. 2014).
Despite the prevalence and burden of this pathology, there
are currently no effective treatments for RIGT and its pathobi-
ology remains to be clearly understood. Various MMP mem-
bers have been shown to be altered in the intestine following
irradiation, in the settings of both acute and delayed RIGT
(Strup-Perrot et al. 2004, 2006, Angenete et al. 2009). The
gastrointestinal microvasculature has also been implicated in
RIGT development, with endothelial apoptosis occurring early
in the pathology, and pathological angiogenesis being
observed in several models of RIGT (Paris et al. 2001, Kruse
et al. 2004, Yeoh et al. 2005). Several MMP subtypes are cap-
able of regulating many angiogenic and anti-angiogenic endo-
thelial mediators, such as VEGF, TGF-b, endostatin, and
angiostatin, highlighting a strong link for their role in RIGT-
associated microvascular changes. Thus the present review
proposes a vascular mediator pathway, regulated by altered
MMP expression or activation following irradiation, as being
involved in intestinal microvascular changes seen in both
acute and delayed RIGT. Although further study is necessary,
the MMP family presents a unique target in the development
of novel therapies for RIGT. Due to the complex nature of
members of the MMP family, and differential effects based on
the type of MMP, tissue type, and pathology, extensive studies
are required. As RIGT is a prevalent and debilitating adverse
effect of anti-neoplastic therapies, any future studies focusing
on the biological basis of this pathology will aid in the devel-
opment of anti-mucotoxic therapies of much clinical value.
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Abstract
Purpose Radiotherapy-induced gut toxicity (RIGT) is associ-
ated with diarrhoea, pain and rectal bleeding and can occur as
an acute or chronic toxicity. The microvasculature has been
shown to be altered in the development of RIGT; however, the
features are not yet characterized. We hypothesized that apo-
ptosis of microvascular cells would occur early in the gastro-
intestinal tract following fractionated irradiation, followed by
late microvascular changes, including sclerosis and
telangiectasis.
Methods Female Dark Agouti rats were treated with a 6-week
fractionated radiation schedule of 3 × 2.5 Gy doses per week
localized to the abdomen. At 3, 6 and 15 weeks, the intestines
were assessed for markers of acute and chronic injury includ-
ing morphological changes, collagen deposition, apoptosis
and proliferation.
Results Apoptosis of microvascular cells significantly in-
creased at 6 and 15 weeks in the jejunum (p = 0.0026 and
p = 0.0062, respectively) and at 6 and 15 weeks in the colon
(p < 0.0001 and p = 0.0005, respectively) in rats receiving
fractionated radiation to the abdomen. Histopathological
changes of the colon microvasculature were also seen from
week 3, including thickening of the lamina propria and dilat-
ed, thickened, telangiectatic vessels.
Conclusions Findings of this study provide evidence of re-
gional and timing-specific changes in the intestinal microvas-
culature in response to fractionated radiotherapy which may
play a role in development of both acute and chronic RIGT.
Keywords Mucositis . Radiotherapy .Microvasculature .
Gastrointestinal . Apoptosis
Introduction
Radiotherapy-induced gut toxicity (RIGT) is an adverse effect
of radiotherapy for cancer, which may occur as an acute tox-
icity (also referred to as gastrointestinal mucositis or acute
radiation enteropathy) or chronic toxicity (also chronic radia-
tion enteropathy) [1, 2]. In patients receiving radiotherapy for
abdominal or pelvic tumours, approximately 60–80% develop
symptoms of acute gut toxicity, including, but not limited to,
nausea, diarrhoea, pain and fatigue [1]. Chronic gut toxicity
may also occur following radiotherapy and includes symp-
toms such as altered intestinal transit, gut dysmotility and less
commonly intestinal obstruction or fistulae formation [1].
Despite these symptoms, there remain few treatment options
for RIGT, largely hindered by a lack of understanding of the
underlying pathobiology [1, 3]. This is particularly true for the
endothelium. Late rectal bleeding is one of the most common
symptoms of RIGT following high-dose radiotherapy for
prostate cancer, occurring in up to 70% patients [4, 5]. This
points to a likely impact of radiation on the normal intestinal
microvasculature. Whilst intestinal epithelial cell apoptosis [6,
7], activation of transcription factors such as NF-κB [8] and a
cascade of inflammatory mediators including pro-
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inflammatory cytokines and matrix metalloproteinases [9, 10]
are well known to be involved in RIGT, these pathways are yet
to be characterized in the endothelium.
Paris and colleagues (2001) assessed changes to endothe-
lial apoptosis in the jejunum of C57BL/6 mice who received
8–15 Gy whole body irradiation. Whilst this study showed
that endothelial apoptosis occurred early (4 h) following irra-
diation, the model was largely based on GI syndrome, in
which doses are not clinically translatable in the context of
radiotherapy for cancer [11]. Additionally, later preclinical
studies showed conflicting results, in which endothelial apo-
ptosis did not to occur early during GI syndrome and did not
contribute to the severity of toxicity [12, 13]. Abderrahmani
and colleagues (2012) found a significant increase in endothe-
lial apoptotic cells in the villus lamina propria 4 and 5 h fol-
lowing 19 Gy intestinal irradiation in mice [14]. This was
significantly lower in plasminogen activator inhibitor-1
(PAI-1) knockout mice, which had significantly reduced acute
and ate radiation-induced intestinal injury when compared to
wild-type mice [14]. Whilst this again suggests a link between
early endothelial apoptosis and intestinal injury, epithelial ap-
optosis was also significantly lower in PAI-1 knockout mice at
the 5-h time point, making it difficult to suggest which may be
contributing to the reduced toxicity [14].
Despite the lack of consensus of the literature on endothe-
lial apoptosis in RIGT, changes to intestinal microvasculature
have been identified, both clinically and pre-clinically [4, 8].
Yeoh and colleagues (2005) assessed histological changes of
archived colorectal tissue samples from 28 patients with colo-
rectal carcinoma who had received either preoperative short-
term pelvic irradiation or long-term neoadjuvant chemoradio-
therapy. Short-term radiation involved a total dose of 25 Gy
using the 4 field box technique, over 5 fractions in 1 week.
Long-term neoadjuvant chemoradiotherapy involved concur-
rent 5-FU (300 mg/m2/day) and pelvic irradiation with 45 Gy
in 25 fractions over 5 weeks. Yeoh et al. (2005) demonstrated
telangiectatic, fibrosed and sclerosed blood vessels in the lam-
ina propria, submucosa and fat layer of the gastrointestinal
tract following abdominal radiation. The study did not assess
these changes in direct relation to the occurrence of RIGT in
the patients; however, 16 out of 28 of recruited patients did
experience symptoms of gastrointestinal toxicity during treat-
ment [8]. In pre-clinical studies, tortuous telangiectatic vessels
have been seen in the rectum of mice irradiated with a single
dose of 20 Gy. These did not resolve at the completion of the
study (30 weeks following irradiation); however, these chang-
es were not investigated in relation to clinical parameters of
gastrointestinal toxicity in these mice [4].
Despite the observation of pathological blood vessels in
RIGT, few studies have investigated specific vascular changes
in an in vivo model of fractionated irradiation. Several studies,
however, have assessed thrombogenic changes to the micro-
vasculature in an attempt to characterize mediator pathways
underpinning vascular-related symptoms such as rectal bleed-
ing, including changes to levels of vascular mediators such as
thrombomodulin, protease-activated receptor-1 (PAR-1) and
von Willebrand factor (vWF) [15–17]. Wang and colleagues
(2002) found a statistically significant decrease in the number
of thrombomodulin-positive blood vessels in the intestines of
Sprague-Dawley rats who had received fractionated radiation
(33.6 Gy in 8 daily fractions or 67.2 Gy in 16 daily fractions)
to a surgically induced scrotal hernia. Irradiated rats also
displayed mucosal ulceration and inflammation during early
RIGT (1 day and 2 weeks following cessation of radiation),
vascular sclerosis and reactive fibrosis of the subserosa and
submucosa in delayed RIGT (6 and 26 weeks following radi-
ation). Decreases in thrombomodulin are known to increase
PAR-1 and decrease protein C activation, leading to upregu-
lation of inflammatory mediators and endothelial dysfunction
[15, 17]. These changes in vascular mediator upregulation
following radiotherapy suggest a change in pathophysiologi-
cal state of the intestinal microvasculature; however, further
studies are needed to determine how this is affecting micro-
vascular cell kinetics.
Thus, the present study aimed to determine changes to
microvascular apoptosis and proliferation following fraction-
ated abdominal radiation in an animal model of RIGT. The
study also aimed to assess clinical and histopathological pa-
rameters of RIGT including changes to body weight and epi-
thelial apoptosis to assess the timeline of these changes in the
context of microvascular damage. In the present study, we
demonstrate for the first time significantly increased intestinal
microvascular apoptosis and significantly reduced microvas-
cular proliferation following fractionated radiation in rats.
Materials and methods
Ethics
This study was conducted in accordance with ethics approved
by the Animal Ethics Committees at both The University of
Adelaide (M-041-2006) and the Institute of Medical and
Veterinary Science (IMVS) (78/05) and complied with the
National Health and Medical Research Council (Australia)
Code of Practice for Animal Care in Research and Teaching
(2007).
Animals and experimental design
Seventy female Dark Agouti (DA) rats, weighing 155 to 170 g
on arrival, were housed under controlled conditions with 12 h
dark and 12 h light cycles. Rats had ad libitum access to water
and standard rat chow. The experimental design was based on
our previously published pilot study [18]. Briefly, rats (n = 5
per time point) were randomly assigned into three groups
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receiving radiation and three groups receiving sham irradia-
tion. Prior to irradiation, rats in both treatment and control
groups were anaesthetized with 4% isofluorane and placed
into a custom-built container [18]. Rats in the treatment
groups were irradiated, limited to the abdomen by lead
shielding, at a dose of 2.5 Grey (Gy)/fraction three times a
week to a total of 45 Gy/18 fractions/6 weeks prescribed to
depth of 3.3 cm using a Varian Clinac Linear Accelerator
(Varian Medical Systems) with focus-skin distance of
130 cm. Control rats received sham irradiation in the same
course as treated rats. Groups of rats were killed at the ends
of weeks 1 to 6, representing acute toxicities from short- and
long-course radiation, and at 15 weeks, representing a de-
layed, or chronic, toxicity. Animals were closely monitored
in the immediate recovery period (30 min from radiation) and
were then monitored daily for weight change, diarrhoea, dull/
ruffled coat, change in temperament, reluctancy to move and
skin reaction to radiation, throughout the experimental time
course.
Gastrointestinal tissue collection
Gastrointestinal tissue was collected as previously described
by Yeoh and colleagues (2007). Following flushing of the
small and large intestine with cold isotonic saline, sections
of jejunum (at 25% length of small intestine from the pylorus)
and colon (at 50% length of large intestine) were resected into
2-cm sections, fixed in 10% neutral formalin and embedded in
paraffin for further analysis. In preparation for staining, sec-
tions were cut using a rotary microtome (Leica) to 4 μm and
were mounted on uncoated slides for haemotoxylin & eosin
(H&E) and Picro sirius red staining or FLEX immunohisto-
chemistry (IHC) microscope slides (Dako) for IHC.
Histology
H&E staining was conducted to determine morphological
changes to the jejunum and colon following irradiation as
described previously [18], including villous blunting or fu-
sion, crypt loss, inflammation, vessel dilation and oedema.
Picro Sirius red staining was used to determine total tissue
collagen levels as described previously [19]. Briefly, sections
were dewaxed in xylene and hydrated in a series of graded
ethanol. Picro Sirius red solution (0.5 g Sirius red F3B in 500-
ml saturated aqueous picric acid solution) was applied to sec-
tions and left at room temperature for 1 h. Sections were then
washed using acid water (0.5% acetic acid in H2O),
dehydrated, cleared and coverslipped.
Images of H&E and Picro Sirius red-stained tissue
were taken using NanoZoomer scanning equipment
(Hamamatsu,Japan), and images were analysed using
NanoZoomer Digital Pathology software (NDP.view2,
Hamamatsu). H&E-stained tissue was assessed using a
previously validated damage scoring method in which sec-
tions were given a score of either 0 or 1 for the presence of
the following factors: disruption of the brush border, crypt
loss/architectural disruption, disruption of crypt cells, infiltra-
tion of polymorphonuclear cells and lymphocytes, dilation of
lymphatics and capillaries, oedema and villous fusion and
atrophy in the jejunum. Picro Sirius red-stained tissue was
assessed qualitatively. All assessments were conducted in a
blinded fashion by one assessor (RLS).
Immunohistochemistry
Activated caspase 3 and Ki67 proteins were visualized by IHC
staining in intestinal tissue from rats killed at the end of weeks
3, 6 and 15 to determine levels of apoptosis, proliferation and
microvascular cell dysfunction, respectively. Caspase 3 and
Ki67 primary antibodies were utilized as previously published
[19, 20]. A Dako-automated staining system (Autostainer link
48 and PT Link, Dako) was used to conduct IHC for caspase 3
(Abcam #ab44976, 0.200 mg/ml), Ki67 (Abcam #ab16667,
concentration not provided) at dilutions of 1:1000 and 1:1200,
respectively. IHC was conducted according to manufacturer’s
instructions using the EnVision™ FLEX kit for Dako
autostainer link systems (Dako) and as previously described
[21]. Briefly, 4-μm sections of jejunum and colon mounted on
IHC microscope slides (Dako) were dewaxed in histolene and
rehydrated through a series of graded ethanols. Antigen re-
trieval was conducted using a Tris/EDTA antigen retrieval
buffer (0.37 g/l EDTA, 1.21 g/l Tris; pH 9.0) in the PT link
antigen retrieval system (Dako) in which the buffer was
preheated to 65 °C following which slides were added then
heated to 97 °C for 20 min. Slides were placed in the
autostainer, and sections were blocked for 5 min using the
FLEX 0.3% hydrogen peroxide block (Dako). A protein block
(0.25% casein in PBS, containing stabilizing protein and
0.015 mol/l sodium azide, Dako) was then applied for
30 min to reduce non-specific background staining of tissue,
followed by application of the primary antibody for 60 min.
Rabbit HRP-labelled polymer conjugated to goat anti-rabbit
or goat anti-mouse (Dako), depending on the specifications of
the antibody, was then applied for 30 min as a labelling and
secondary antibody system. Sections were visualized using
DAB (EnVision™ FLEX kit, Dako) and counterstained with
Harris’ haematoxylin for 20 s, dehydrated in 100% ethanol,
cleared with histolene and coverslipped. Images were taken
using NanoZoomer scanning equipment (Hamamatsu) and
DAB staining of villi (jejunum only), crypts, and microvascu-
lature was analysed on NanoZoomer Digital Pathology soft-
ware (NDP.view2, Hamamatsu). Cell counts per crypt (aver-
age of 15 crypts per section) were taken for caspase 3 and
Ki67 staining in the jejunum and colon mucosa as well as in
the villi of the jejunum. Cell counts of caspase 3 and Ki67-
immunostained cells were also performed on the
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microvasculature in the lamina propria and submucosa in
which stained cells were counted in 15 microvessels per sec-
tion and were then averaged to give stained cells per vessel.
All sections were assessed in a blinded fashion by one asses-
sor (RLS).
Statistical analysis
Group means for histological damage scoring and apoptotic
and proliferative cell counts were compared between sham-
irradiated and irradiated rats per time point. All statistical anal-
ysis was conducted using the program Graphpad Prism (ver-
sion 6). Differences between study group means were
analysed using a two-way ANOVA with Sidak’s multiple
comparison. Asterisks denote significance compared to con-
trol at the time point, where *<0.05, **<0.01, ***<0.001 and
****<0.0001. Bars on graphs represent standard error of the
mean
Results
Response of animals to fractionated radiation
Animals receiving fractionated irradiation to the abdomen
three times a week displayed significantly lower weight
gain (represented as a % from baseline) at weeks 3
(p = 0.0055) and from 6 weeks onwards (p < 0.05) when
compared to animals receiving sham irradiation (Fig. 1).
Whilst some rats were observed to have a dull/ruffled coat
raised around the neck following irradiation, no significant
differences were observed in any other clinical parameters
including diarrhoea, change in temperament, reluctancy to
move or skin reaction to radiation (data not shown). Small
intestinal weight was significantly higher in irradiated rats
at 15 weeks (p < 0.0001) (Table 1). There were no signif-
icant differences in large intestinal weight between irradi-
ated and control rats (Table 1).
Fractionated radiation-induced microvascular changes
to the jejunum and colon
Jejunum
Damage scoring was not significantly altered in the jejunum at
any time point (Suppl. 1). Despite this, thickening of the lam-
ina propria and dilated, thickened, telangiectatic vessels were
seen at week 6 in H&E-stained sections (Fig. 2). This thick-
ening of the intestinal microvasculature was confirmed using
Picro Sirius red in which fibrotic thickening of the microvas-
culature was also seen, extending from weeks 3 to 15 (Fig. 2).
No significant difference was seen in the villus height or crypt
depth (data not shown).
Colon
Damage scoring of the colon was significantly increased
compared to controls at week 3 (p = 0.043) (Suppl. 1).
Histopathological changes of the colon microvasculature
were seen in rats receiving irradiation from week 3.
Thickening of the lamina propria and dilated, thickened,
telangiectatic vessels were seen from 3 weeks after the first
radiation dose and had resolved by week 6 (Fig. 2). This
thickening of the intestinal microvasculature was con-
firmed using Picro Sirius red staining and vasodilation,
and fibrosis of the microvasculature was observed 6 weeks
from the first radiation dose (Fig. 2). Crypt depth was sig-
nificantly higher in the colon of rats receiving radiation
when compared to control rats at 5 weeks (p = 0.022).
No significant differences were noted at any other time
point (data not shown).
Small intestinal weight was significantly higher in irradiat-
ed rats at week 15 (p < 0.0001) when compared to time
matched controls. Large intestinal weight did not significantly
differ between groups at any time point. Data presented as
mean ± standard deviation. * denotes significance compared
to time matched control where ****p < 0.0001
Fractionated radiation-induced microvascular cell
apoptosis and reduced microvascular proliferation
in the jejunum and colon
Jejunum
Apoptosis of microvascular cells significantly increased
at 6 and 15 weeks in the jejunum (p = 0.0026 and
Fig. 1 Percentage body weight change from baseline (day 0) of DA rats
following fractionated abdominal irradiation. Percentage body weight
gain was significantly lower in irradiated rats when compared to
controls at week 3 (p < 0.0001) and every week from week 6 until
study completion in week 15 (6–9 weeks, p < 0.05; 10–15 weeks,
p < 0.01). Shaded area of graph represents course of fractionated or
sham irradiation. Asterisk denotes significances compared to control
where *p < 0.05, **p < 0.01
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p = 0.0062, respectively) in rats receiving fractionated
radiation to the abdomen (Fig. 3). Cell proliferation,
measured by Ki67 immunostaining, was not significantly
altered at any time point in the jejunal microvasculature
(Fig. 4).
Colon
Colonic microvascular cell apoptosis was significantly in-
creased at 6 weeks (p < 0.0001) and 15 weeks (p = 0.0005)
in rats receiving fractionated radiation when compared to con-
trol (Fig. 3). No significant changes in microvascular apopto-
sis were seen between groups at 3 weeks. Microvascular cell
proliferation was significantly decreased 3 weeks from first
dose in the colon (p = 0.0072) and was not significantly al-
tered at week 6 (Fig. 4). In contrast, proliferation significantly
increased at 15 weeks in the colon microvasculature
(p = 0.0041).
Fractionated radiation-induced apoptosis in the epithelial
cells of the crypts of the jejunum and colon
Jejunum
Apoptosis, as determined by caspase 3 immunostaining,
was significantly higher in the epithelial cells of the je-
junum crypts of irradiated rats at 3 and 6 weeks
(p = 0022 and p < 0.0001, respectively) (Fig. 5).
Jejunal crypt apoptosis was not significantly altered at
the 15-week time point. There were also no significant
changes in apoptosis in the villi of the jejunum at any
time point assessed.
Colon
Apoptosis was also significantly increased in the epithelial
cells lining the colonic crypts at 6 weeks when compared to
control (p = 0.014) (Fig. 5). Again, no significant changes
were seen at any other time point.
Fractionated radiation-induced proliferation
in the epithelial cells of the jejunum and colon
Jejunum
There were no significant changes seen to proliferation indices
in the jejunal crypts or villi at any time point after irradiation
(data not shown).
Colon
Proliferative cells in the colon crypts, as determined by Ki67
immunostaining, were significantly higher in the radiation
group at 6 weeks when compared to control (p = 0.026)
(Supp. 2). No further significant changes were seen in the
proliferative indices at any other time point.
Discussion
RIGT is a debilitating adverse effect of radiotherapy for can-
cer; however, RIGT pathobiology is not entirely understood,
hindering the development of novel treatments. Key findings
from this study demonstrate an increase in apoptotic cells of
the microvasculature following fractionated abdominal radia-
tion in rats. Of particular interest, apoptosis of the colon mi-
crovasculature was shown to occur 15 weeks following initial
irradiation in the colon, 9 weeks following the last dose of
radiation. Although previous studies have assessed changes
in vascular mediator expression and histopathological features
of endothelial dysfunction in RIGT [15, 22], this is the first
study showing microvascular apoptosis to be occurring in the
delayed, or chronic, phase of RIGT, as displayed in the 15-
week time point of the current study. This late microvascular
apoptosis in the colon may be linked to mediators previously
known to contribute to intestinal endothelial dysfunction fol-
lowing irradiation such as transforming growth factor beta
(TGFβ), PAR-1 and von willebrand factor [15, 16].
RIGTwas shown to occur in the present study, with irradi-
ated rats gaining significantly less weight compared to sham-
irradiated controls and increased apoptosis in crypts of both
the jejunum and colon. This is in support of previous studies
Table 1 Small intestinal weight
and large intestinal weight of DA
rats following fractionated
irradiation to the abdomen




















assessing RIGT following fractionated radiation in vivo [19].
Yeoh and colleagues (2007) described significantly increased
apoptosis in crypts of both the jejunum and colon from weeks
1–6 in DA rats administered a 6-week course of fractionated
radiation to the abdomen (3 × 2.5 Gy/week). The studies did,
however, differ with regard to proliferation of cells in the
crypts. The present study showed an increase in proliferation
at 6 weeks in the colonic crypts, as opposed to a significant
decrease in proliferating cells throughout the course of radia-
tion in the aforementioned study [19]. This could be explained
in part by the differences between assessments of proliferating
cells, with the present study using immunostaining of Ki67, a
protein expressed in all active phases of the cell cycle, as
opposed to mitotic cell count. Apoptosis was also shown to
Fig. 2 Morphological changes to jejunum and colon microvasculature
following fractionated irradiation. a H&E-stained jejunal
microvasculature with dilated, telangiectatic vessels indicated by
arrows. b Picro Sirius red-stained jejunal microvasculature in which
fibrotic thickening of vessels can be seen from week 3 following
irradiation (indicated by arrowheads). c H&E-stained colonic
microvasculature displaying formation of telangiectatic vessels (indicated
by arrows) following fractionated irradiation. d Picro Sirius red-stained
colonic microvasculature with a thickened vessel indicated by
arrowhead. ×40 magnification. Scale bar = 30 μm
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be highest at 6 weeks in both the jejunum and colon, indicat-
ing an accumulative effect of fractionated radiation on damage
to the gastrointestinal mucosa. This is consistent with what has
previously been seen in models of fractionated irradiation, in
which it is proposed that the epithelial cells are able to regen-
erate due to breaks in the course of radiation [19]. This is
reflected in the relatively unchanged levels of proliferation
in the jejunum and colon throughout the time course of the
study.
The significant increase in wet weight of the small intestine
is most likely explained by changes associated with chronic,
or delayed, RIGT. In this late phase, reactive fibrosis often
occurs, leading to fibrotic thickening of the muscle layer, sub-
mucosa and vascular walls [15]. Several studies have assessed
this in in vivo models of delayed radiation-induced enteropa-
thy, and increases in collagen deposition and upregulation of
fibrotic mediators including TGFβ have been shown [15, 16].
These changes, coupled with oedema and inflammatory infil-
trate, could be leading to this increased wet weight of the small
intestine, although parameters of histopathological damage,
including oedema and presence of neutrophils, were not sig-
nificantly increased in the jejunum at any time point in the
current study.
This study is the first to show changes to microvascular
apoptosis and proliferation in an in vivo fractionated radiation
model. Of particular interest is the sustained microvascular
cell apoptosis occurring 9 weeks following the cessation of
irradiation in the colon (week 15 of the study). Despite this,
Fig. 3 Caspase 3 immunostaining of the jejunum and colon
microvasculature. a Caspase 3 significantly increased in the microvessel
of the jejunum at 6 and 15 weeks. b Caspase 3 staining increased in the
colon microvasculature at 6 and 15 weeks. c Caspase 3 staining of the
jejunal microvasculature. Arrow indicates apoptotic microvascular cells,
with arrowhead indicating unstained red blood cells. dCaspase 3 staining
of the colonic microvasculature with arrows indicating apoptotic
microvascular cells at 6 and 15 weeks. Scale bar = 30 μm, ×40
magnification. * Significance compared to control where **p < 0.01,
***p < 0.001, ****p < 0.0001
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numbers of apoptotic cells in the crypts of the colon were not
significantly higher than controls at the 15-week time point.
Whilst this long-term microvascular apoptosis has not previ-
ously been shown, changes to the intestinal microvasculature
have been observed many months following chemotherapy,
and the biology of these cells has shown to be altered [15, 22].
Wang and colleagues (2002) have shown an increase in
thrombomodulin, an endothelial transmembrane glycoprotein
and a decrease in protein C, an anticoagulant and anti-
inflammatory protein, in a rat model of chronic radiation en-
teropathy. This increase in thrombomodulin leads to endothe-
lial dysfunction, involving decreased thromboresistance and
the activation of protease-activated receptor 1 (PAR-1) [15,
17]. These mediator changes, particularly thrombomodulin
and activated protein C, could play a role in the microvascular
cell apoptosis seen in this delayed toxicity phase in the present
study. Both thrombomodulin and protein C have been shown
to be protective in models of endothelial apoptosis, thought to
be due to the ability of protein C to decrease the expression
and activation of transcription factor NF-kB and downregulate
pro-apoptotic proteins p53 and Bax [23–25]; however, this
link has not yet been explored in the context of RIGT.
The current study provides a link between the development
of RIGT, particularly late RIGT, and intestinal microvascular
changes, including microvascular cell apoptosis, early senes-
cence and late proliferation. Whilst mucosal damage was
significantly increased in the colon 3 and 6 weeks into the
fractionated radiation schedule, as shown by various indices
including damage scoring, apoptosis and decreased prolifera-
tion, apoptosis and proliferation were observed in the micro-
vascular cells in the delayed RIGT time point of 15 weeks,
9 weeks following the last dose of fractionated irradiation.
Despite this, weight gain of irradiated rats was significantly
lower than control rats from 6 weeks onwards. These results
indicate that changes to the intestinal microvasculaturemay be
driving toxicity observed in the later time points, indicative of
chronic, or delayed, RIGT. In order to determine whether
these factors are causally related, the effects of endothelial
damage on the intestinal response to RIGT need to be ex-
plored in more depth. Preliminary, in vitro studies have indi-
cated that the endothelial cell response to radiationmay induce
epithelial dysfunction, independent of the BAX-mediated ap-
optosis of epithelial cells following direct irradiation [26]. If
this pathway could be attenuated, it may lessen gastrointesti-
nal toxicity, thus reducing the severity of RIGT. However, this
distinct mechanism needs to be further explored to determine
possible mediators of this response, thus providing targets for
the development of novel treatments.
Apoptosis of endothelial cells following radiation has also
been shown to occur in endothelial cells of other tissues, in-
cluding lung, brain, spinal cord and kidney [18, 27, 28].
Whilst few studies have assessed changes to intestinal
Fig. 4 Ki67 immunostaining of the jejunum and colonmicrovasculature.
a Ki67-stained microvascular cells significantly decreased in the colon at
week 3 and significantly increased at week 15. b Ki67 staining of the
colon microvasculature. Scale bar = 30 μm, ×40 magnification. *
Significance compared to control where **p < 0.01
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endothelium following irradiation, endothelial apoptosis of
the intestinal microvasculature has been shown to occur short-
ly following single-dose irradiation in vivo [14, 29].
Endothelial apoptosis in vascular endothelial cells in the lam-
ina propria of intestinal crypts was observed 4 h following
14 Gy whole-body irradiation of C57BL/6 J mice [29]. In a
similar study by Abderrahmani and colleagues (2012),
C57BL/6 J mice received a single dose of 19 Gy gamma
irradiation to a segment of exposed intestine. Endothelial ap-
optosis in the lamina propria of the villi was shown to be
significantly increased at 4 and 5 h following irradiation when
compared to control [14]. Whilst microvascular apoptosis was
not observed in the earliest time point of the present study
(3 weeks), this may be due to the differences between
fractionated and single-dose radiation. These studies,
together with common clinical symptoms including rectal
Fig. 5 Apoptosis of jejunal and colonic crypts following fractionated
irradiation. a Caspase 3-immunostained cells significantly increased at
3 (p = 0.0029) and 6 weeks (p < 0.0001) when compared to control. b
Caspase 3-immunostained cells were significantly increased in the colon
crypts at 6 weeks in the irradiated group (p = 0.0145). c Caspase 3
immunostaining in the jejunal crypts with apoptotic cells indicated by
arrows. d Caspase 3 immunostaining in the colonic crypts with apoptotic
cells visible at week 6. Scale bars = 40 μm. Asterisk denotes significance
compared to controls where *p < 0.05, ****p < 0.0001
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bleeding and late reactive fibrosis, and results of the present
study, highlight a role of the intestinal microvasculature in the
pathophysiology of RIGT.
Conclusion
Changes in cell kinetics, specifically apoptosis and prolifera-
tion, were observed in the intestinal microvasculature
throughout the entire time course of fractionated irradiation
in vivo. Findings of this study highlight a role for intestinal
microvasculature in both acute and chronic RIGT and impli-
cate intestinal endothelium as being a potential target for the
development of novel treatments.
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Abstract
Purpose Radiotherapy-induced gut toxicity (RIGT) is associated with significant diarrhoea, pain and rectal bleeding. Matrix
metalloproteinases (MMPs) have been reported to be involved in chemotherapy-induced gut toxicity and RIGT following single-
dose irradiation in vivo. We therefore proposed MMPs would be involved in the pathobiology of RIGT following fractionated
irradiation.
Methods Dark Agouti rats were treated with fractionated radiation (3 × 2.5 Gy/week for 6 weeks). Rats were killed at 3, 6 and
15 weeks to represent acute and chronic toxicities. Sections of jejunum and colon were immunostained for MMP-1, MMP-2,
MMP-9 andMMP-14. Relative mRNA expression in jejunum and colon was quantified by RT-PCR forMMP-1,MMP-2,MMP-
9 andMMP-14. Western blotting was also conducted on jejunum and colon tissue collected at week 6 to determine protein levels
of pro- and active MMP-2.
Results MMP-2 total protein levels, determined by western blotting, significantly increased in both the jejunum (p = 0.0359) and
the colon (p = 0.0134) 6 weeks into the fractionated radiation schedule. MMP-1, MMP-2, and MMP-14 mRNA expression
significantly increased in the jejunum. MMP-2 mRNA expression was also significantly increased in the colon. Immunostaining
of MMP-2 was observed to be increased in both crypt enterocytes and the lamina propria.
Conclusions MMP-2 plays a role in the pathobiology of gastrointestinal toxicities following fractionated irradiation. Whilst
MMP-1 and MMP-14 mRNA expression was increased, this occurred only in the jejunum, suggesting MMPs are differentially
involved in RIGT depending on the intestinal region. Further studies are needed to elucidate the role these mediators play in the
development and potentiation of RIGT.
Keywords Mucositis . Radiotherapy . Endothelium . Gastrointestinal .Matrixmetalloproteinase
Introduction
Radiotherapy-induced gut toxicity (RIGT) is a debilitating
side effect of radiotherapy for cancer, estimated to affect over
80% of patients depending on target area and radiation sched-
ule [18, 27]. Symptoms differ depending on time from last
dose and can be generally divided into acute and chronic tox-
icities, with acute toxicities involving diarrhoea, pain, rectal
bleeding and histopathological changes to the gut, including
villous blunting, crypt disruption and telangiectasia [21, 33].
Chronic symptoms include incontinence, rectal bleeding and
ulceration, often due to reactive fibrotic thickening of the mus-
cle layer and microvascular walls in the small and large intes-
tines [27]. Both acute and chronic RIGT lead to significant
decreases in quality of life and can lead to radiotherapy dose
reductions or cessation of treatment [20]. Despite this, limited
treatment options remain, and most target individual symp-
toms alone [10].
Matrix metalloproteinases (MMPs), a 24-member family
of zinc-dependent endopeptidases, have recently been
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identified in the development of RIGT [3, 25, 26].
Expression of MMPs can be increased at the transcriptional
level by mediators known to contribute to the pathogenesis
of RIGT, including pro-inflammatory cytokines and the
activation of p53 by NF-κB [14, 26, 32, 34]. MMPs are
synthesised as pro-zymogens and can either be secreted or,
in the case of membrane type-MMPs (MT-MMPs),
expressed on the cell surface [23, 31]. Pro-MMPs require
proteolytic activation to allow for degradation of the extra-
cellular matrix. Activation of pro-MMPs can be induced
via the plasminogen-plasmin cascade or, in the case of
MMP-2 specifically, by MT1-MMP (also known as
MMP-14) [24]. MMP activation is also regulated by tissue
inhibitors of matrix metalloproteinases (TIMPs), which are
capable of inhibiting active MMPs [1, 24].
Following activation, MMPs are capable of altering cell
growth, inflammation, cell death or angiogenesis via the up-
regulation of downstream mediators such as pro-
inflammatory cytokines, growth factors and chemokines [6,
12, 21]. MMP-2, MMP-3 and MMP-9, for example, are ca-
pable of activating the pro-inflammatory cytokine interleukin-
1β [17]. Many of these mediators are known to be involved in
the development of RIGT, with pro-inflammatory cytokines
such as tumour necrosis factor alpha (TNF-α), and
interleukin-1beta (IL-1β) being involved in the propagation
of inflammation and eventually ulceration, implicatingMMPs
in this pathobiology [11, 26].
Due to these widespread effects and possible link to RIGT,
Strup-Perrot and colleagues (2006) assessed levels ofMMP-2,
MMP-3, MMP-9 and MMP-14 in the colon of rats irradiated
with a single abdominal dose of 10 Gy. mRNA expression of
all assessed MMPs was significantly increased in the colon,
and protein levels of both pro- and active MMP-2 were also
significantly increased 1, 3 and 7 days following irradiation
[26]. Few studies have assessed changes in MMP expression
in RIGT clinically; however, protein expression of MMP-2,
but notMMP-1 orMMP-9, has been shown to be significantly
increased in the irradiated normal rectal tissue of patients who
had received short-term preoperative fractionated radiothera-
py for rectal cancer [3]. These studies clearly highlight possi-
ble differences in MMP expression dependent on intestinal
region, time since last dose and single-dose vs fractionated
radiation schedules. Thus, further research investigating
MMPs in different intestinal regions is required in order to
better clarify our understanding of the role of the MMP path-
way in RIGT.
Whilst studies have linked increases in MMPs to RIGT, no
study to date has assessedMMPs inmultiple regions of the gut
following fractionated irradiation in a clinically relevant mod-
el of RIGT. As it is clear from the aforementioned studies that
MMP expression is dependent on many factors, including
intestinal region and radiation schedule, the present study
aimed to assess expression and localisation of MMP-1,
MMP-2,MMP-9 andMMP-14, in both the jejunum and colon
in a rat model of fractionated RIGT. The Dark Agouti rat
model of RIGT has been utilised in this study due to prior
characterisation of the histopathological response to RIGT in
this model, the fractionated radiation schedule reflecting clin-




This study was conducted in accordance with ethics approved
by the Animal Ethics Committees at the University of
Adelaide (M-041-2006) and the Institute of Medical and
Veterinary Science (78/05) and complied with the National
Health and Medical Research Council (Australia) Code of
Practice for Animal Care in Research and Teaching at the time
of the study.
Animals and experimental design
Experimental design was as previously described [22, 33].
Briefly, 30 female Dark Agouti (DA) rats were randomly
assigned into groups receiving radiation and groups receiving
sham irradiation). Prior to irradiation, rats in treatment and
control groups were anaesthetised and placed into a custom-
built container, limiting radiation to the abdomen [22, 33].
Rats in the radiation group were irradiated at a dose of
2.5 Gy/fraction three times a week for 6 weeks prescribed to
a depth of 3.3 cm using a Varian Clinac Linear Accelerator
(Varian Medical Systems, USA) with focus-skin distance of
130 cm. Rats in both sham irradiated and irradiated groups
were killed at the ends of weeks 3, 6 and 15 (n = 5 per treat-
ment group at each time point). These time points
corresponded to total accumulated doses of 0 Gy (sham irra-
diated controls), 22.5 Gy (3-week time point), or 45 Gy (6-
and 15-week time points). These time points and doses were
calculated to represent acute toxicity (< 12 weeks from start of
abdominal irradiation) and delayed toxicity (≥ 12 weeks from
start of abdominal irradiation). Gastrointestinal tissue was col-
lected following flushing, with two 2-cm sections of jejunum
(at 25% length of small intestine from the pylorus) and colon
(at 50% length of large intestine) resected. One section of
tissue was formalin-fixed and paraffin-embedded, and the oth-
er was snap frozen in liquid nitrogen and stored at − 80 °C.
RNA isolation and reverse transcription
RNA isolation was performed using the Nucleospin® RNA II
kit (Macherey-Nagel, Duren, Germany) as previously de-
scribed [22]. Briefly, ~ 15 mg of tissue was homogenised in
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cell lysis buffer and beta-mercaptoethanol using the
TissueLyser LT (Qiagen) with stainless steel beads (Qiagen).
The lysate was filtered through silica membrane filter col-
umns, 70% ethanol was added, the silica membrane was
desalted and DNA was digested using the DNAse reaction
mixture. Following washing and drying of the silica mem-
brane, RNA was eluted in 60 μl of RNase-free water. RNA
concentration and purity were determined using the TAKE3
plate and Synergy My Reader (BioTek). RNAwas converted
to cDNA using the iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA, USA) according to manufacturer’s protocol.
Total cDNA concentration and purity were quantified using
the TAKE3 plate and Synergy My Reader. Stock cDNAwas
diluted to 100 ng/μl with nuclease-free water.
Real-time polymerase chain reaction
Quantitative RT-PCR was performed using the Rotor Gene
3000 (Corbett Research, Sydney, Australia). Reaction mix-
tures contained 1 μl of cDNA, 5 μl of SYBR green PCR
Master Mix (Applied Biosystems), 5 μl of nuclease-free water
and 0.5 μl each of 50 pmol/μl forward and reverse primers
(Table 1). Thermal cycling conditions were optimised for each
target gene and melt curve analysis was performed to deter-
mine the presence of any dimers. Conditions included a dena-
turation step at 95 °C for 10 min and 40 cycles at 95 °C (15 s),
annealing at 55 °C (MMP-1 and MMP-9), 56 °C (MMP-14)
or 60 °C (MMP-2) (15 s) and acquiring at 72 °C (20 s). The
housekeeping gene used was 18S, which was determined to
be stable throughout treatment groups. Primer efficiency was
between 90 and 110% for each target gene against 18S, and
thus the 2―ΔΔCT method was used to determine fold change in
gene expression relative to 18S and untreated controls from
each time point.
Immunohistochemistry
MMP proteins were visualised using immunohistochemical
(IHC) staining in jejunal and colonic tissue from rats killed
at the end of weeks 3, 6 and 15 to determine protein
localisation. An automated staining system (Autostainer link
48 and PT Link, Dako) was used to conduct IHC for MMP-1
(no. PAB12708, Abnova), MMP-2 (no. ab37150, Abcam),
MMP-9 (no. ab58803, Abcam) and MMP-14 (no. ab53712,
Abcam), at concentrations of 2 μg/ml (MMP-1), 1.25 μg/ml
(MMP-2 and MMP-9) and 2.5 μg/ml (MMP-14). The
EnVision™ FLEX kit for Dako autostainer link systems
(Dako) was used as previously described [30]. Slides were
scanned using the Nanozoomer (Hamamatsu Photonics) and




Protein was extracted from 30-mg sections of snap frozen
jejunum and colon. Sections were homogenised in cooled
Eppendorf tubes with homogenising beads at 50 GHz for
5 min with 250 μl of 1:10 protease inhibitor cocktail (10 μg/
ml in sterile PBS, EDTA free; no. P8340, Sigma) in RIPA
buffer (no. R0278, Sigma) using the TissueLyser LT
(Qiagen) with stainless steel beads (Qiagen). Beads were re-
moved and tubes were centrifuged at 10,000×g for 15 min at
4 °C. Supernatant was collected and protein was quantified
using the BCA protein quantification assay (no. 23227,
Thermo Scientific) according tomanufacturer’s protocol; after
which, it was stored at − 80 °C.
Western blotting
Western blotting was performed to quantify levels of pro- and
active forms of MMP-2 protein in the jejunum and colon
following fractionated irradiation. The iBlot™ 2 dry blotting
system (Invitrogen) was used to perform the western blot ac-
cording to manufacturer’s protocol. Samples were prepared
with 30 μg of total protein, 10 μl Bolt LDS Sample Buffer
(no. B0008, ThermoFisher), 4 μl of Bolt Reducing Agent (no.
B0009, ThermoFisher) and dH2O to yield a total sample
Table 1 Primer sequences for housekeeping and target genes
Gene Primer sequence (5′-3′) Nucleotide position Amplicon length (bp) Tm (°C) Ref
18S F: CAT TCG AAC GTC TGC CCTAT




MMP-1 F: CCT TCC TTT GCT GTT GCT TC




MMP-2 F: CTG ATA ACC TGG ATG CAG TGCT




MMP-9 F: AAG CCT TGG TGT GGC ACG AC




MMP-14 F: GTG GAT GGA CAC CGA GAA CT





volume of 40 μl. Samples were vortexed, heated at 70 °C for
10 min and pipetted into lanes of a 4–12% Bis-Tris plus 12-
well gel (no. NW04122, ThermoFisher) in the iBlot™ mini
gel tank with 1× SDS Running buffer (20× Bolt MES
Running Buffer in dH2O, no. B0002, ThermoFisher). Five-
microliter Bio-Rad Precision Plus Protein™ dual colour stan-
dard (no. 1610374, Bio-Rad) was used as a standard ladder.
Electrophoresis was run at a constant 150 V for 45 min. The
iBlot transfer system was used with copper transfer stacks to
transfer from gel to a PVDF membrane (no. IB24002,
ThermoFisher). The membrane was washed with TBST,
reactivated with methanol, rinsed with dH20 and immersed
in 1× iBind fluorescent detection (FD) solution (iBindTM
FD Solution Kit, no. SLF1019, ThermoFisher). Primary anti-
bodies for MMP-2 (no. ab37150, Abcam) and beta-actin (no.
ab8224, Abcam) were diluted in iBind FD solution at 5 and
0.167 μg/ml, respectively. The secondary antibody (IRDye
800CWgoat anti-Rabbit, no. 925–32,211, Li-Cor) was diluted
in iBind FD solution at a concentration of 0.33 μg/ml. The
iBind system (no. SLF1010, ThermoFisher) was used, with
iBind FD solution applied to the card, to add the primary and
secondary antibodies to the membrane. The membrane was
left overnight and scanned using the LI-COR Odyssey CLx
imager at 800 nMwith an intensity of 3.0.MMP-2 bands were
quantified against the beta-actin housekeeping band using
Image Studio™ software (Li-Cor).
Statistical analysis
Means for each treatment group (sham irradiated and irradiat-
ed) were compared at each time point. Following normality
testing, differences between treatment group means were
analysed using either a two-way ANOVAwith Sidak’s multi-
ple comparison or a Kruskal-Wallis test with multiple com-
parison. Asterisks denote significance compared to control at
the time point, where *< 0.05, **< 0.01, ***< 0.001 and
****< 0.0001.
Results
Fractionated irradiation induced intestinal
upregulation of MMP-1, MMP-2 and MMP-14
at the transcriptional level
Jejunum
RT-qPCR was performed to determine mRNA expression of
MMP-1, MMP-2, MMP-9 and MMP-14 following fractionat-
ed irradiation. MMP-1 mRNA expression was significantly
increased in the jejunum 3 weeks into the fractionated radia-
tion schedule (p = 0.0086) but not at the 6- or 15-week time
points (Fig. 1a). MMP-2 mRNA expression increased 172-
fold at week 3 in the jejunum (p < 0.0001) but was not signif-
icantly different at other timepoints (Fig. 1b). MMP-9 mRNA
expression was not significantly altered at any time point un-
der investigation (Fig. 1c). MMP-14 mRNA expression was
significantly increased in the jejunum at week 3, by 26-fold,
and at week 6, by 24-fold (p = 0.0002 and p = 0.0065, respec-
tively). There was no significant difference seen at 15 weeks
following radiation (Fig. 1e).
Colon
There were no significant changes to MMP-1 mRNA expres-
sion in the colon (Fig. 2a) at any time point under investiga-
tion. MMP-2 mRNA expression significantly increased by
14- and 24-fold at 3 and 6 weeks in the colon (p = 0.0313
and p = 0.0001, respectively) (Fig. 2b). However, no signifi-
cant change was seen at 15 weeks after radiation. MMP-9
mRNA expression was not significantly altered at any of the
time points investigated (Fig. 2c). In contrast to what was
observed in the jejunum, MMP-14 was not significantly al-
tered at any time point in the colon (Fig. 2e).
Protein expression and localisation of MMP-2 was
altered in the colon following fractionated irradiation
As changes in mRNA expression of MMP-1, MMP-2 and
MMP-14 were observed, immunohistochemistry was qualita-
tively assessed to initially determine any changes in protein
localisation or staining intensity prior to conducting western
blotting. MMP-2 immunostaining appeared to increase fol-
lowing irradiation, represented by an increase in cytoplasmic
staining in crypt enterocytes observed at weeks 3 and 6
(Fig. 3). There was also a slight increase in localisation of
MMP-2 to the lamina propria, particularly of the microvascu-
lature, at weeks 3 and 6 (Supplementary Fig. 1). Staining
intensity of the other MMPs assessed, MMP-1, MMP-9 and
MMP-14, did not appear to be altered in the jejunum or colon
at any time point under investigation.
Pro- and active forms of MMP-2 protein were
significantly increased in the jejunum following
fractionated irradiation
As increases in immunostaining of MMP-2 were seen at
6 weeks, but unable to be quantified, western blotting was
undertaken for MMP-2 in both the jejunum and colon at the
6-week time point. The 6-week time point was chosen due to a
maximum radiation dose at this time point (45 Gy), as well as
significant histopathological damage, including apoptosis of
both the jejunal and colonic crypts and microvascular cells as
previously reported [17]. Levels of both pro- and active
MMP-2 were able to be quantified via western blotting, as
these forms have different molecular weights and thus present
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as separate bands. Pro-MMP-2 was significantly increased in
both the jejunum (p < 0.0001) and colon (p < 0.0001) when
compared against housekeeping band intensity (β-actin) and
average intensity of controls (Fig. 4). Active MMP-2 was
significantly increased following irradiation in the jejunum
(p = 0.0011) but not in the colon (Fig. 4).
Discussion
The current study assessed mRNA and protein expression of
several MMPs thought to be involved in the development of
RIGT in a model of fractionated irradiation. A key finding of
this study suggests MMP-2 mRNA expression is upregulated
Fig. 1 Expression of MMP-1, MMP-2, MMP-9 and MMP-14 in the
jejunum following abdominal irradiation. a mRNA expression of
MMP-1 was significantly increased by 3.5-fold at week 3 (p = 0.0086).
b MMP-2 was significantly increased by 172-fold 3 weeks into the frac-
tionated radiation course (p < 0.0001). c MMP-9 mRNA expression was
not significantly altered at any time point in the jejunum. d MMP-14
expression was significantly increased by 26-fold and 24-fold at the 3-
and 6-week time points, respectively (p = 0.0002; p = 0.0065). Dotted line
represents baseline fold change. Data shown is mean + standard error of
the mean (SEM). Asterisks denote significance compared to controls at
each time point, where **< 0.01, ***< 0.001 and ****< 0.0001, n = 5
Fig. 2 Expression of MMP-1,
MMP-2, MMP-9 andMMP-14 in
the colon following abdominal
irradiation. a Colonic MMP-1
mRNA expression was not sig-
nificantly altered at any time point
(p > 0.05). b Colonic MMP-2
mRNA expression was signifi-
cantly increased at week 3, with a
14-fold increase (p = 0.0313).
MMP-2 expression was also sig-
nificantly increased at week 6 by
24-fold (p = 0.0001). Colonic
mRNA expression of MMP-9 (c)
and MMP-14 (d) were not signif-
icantly altered at any time point.
Dotted line indicates baseline fold
change. Data shown is mean +
SEM. Asterisks denote signifi-
cance compared to controls at
each time point, where *< 0.05
and ***< 0.001, n = 5
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in both the small and large intestine in response to abdominal
fractionated irradiation. MMP-1 andMMP-14 mRNA expres-
sion was also significantly increased in the jejunum only. The
increases in these MMPs occurred alongside loss of body
weight, increases in histopathological damage and microvas-
cular changes previously shown in the same model [22].
The key finding of a significant increase inMMP-2 mRNA
expression in both the jejunum and colon early in the fraction-
ated radiation schedule accords with the consistent upregula-
tion ofMMP-2 reported in both clinical and preclinical studies
of RIGT [2, 26].MMP-2 expression was increased 172-fold at
the 3-week time point in the jejunum, but not significantly
altered at 6 weeks, despite an increase in cumulative dose. It
is possible that the fractionated schedule of radiation is a con-
tributor to this, with repeated healing occurring between doses
over the 6-week radiation schedule, possibly leading to a de-
crease in MMP-2 expression. As MMP-2 immunohistochem-
ical staining was also increased in the colonic crypts at the 3-
and 6-week time points, protein levels were further quantified
using western blotting to ascertain differences in pro and ac-
tive forms. Whilst MMPs are expressed in their latent forms,
activation is essential to many of the downstream effects
(Hofmann 2000). Both pro- and active MMP-2 were signifi-
cantly increased in the jejunum following irradiation; howev-
er, only pro-MMP-2 was significantly increased in the colon.
Rats receiving fractionated irradiation had significantly lower
weight gain, significantly increased histopathological damage
scoring in the colon, telangiectatic vessel formation and apo-
ptosis in the crypts of the jejunum and colon occurring at the
Fig. 3 MMP-1, MMP-2 and
MMP-9 immunostaining in the
colonic crypts following fraction-
ated irradiation. a MMP-1 stain-
ing intensity in the colonic crypts
was not altered at any time point
following fractionated irradiation.
b MMP-2 immunostaining was
increased in the colonic crypts
following 22.5 and 45 Gy frac-
tionated irradiation (weeks 3 and
6, respectively). c MMP-9 immu-
nostaining was not altered in the
colonic crypts. ×10 magnifica-
tion, scale bar = 30 μm (applies to
all images in same row), n = 5
Support Care Cancer
same time points as significant increases in MMP-2 mRNA
and protein expression [22].
Strup-Perrot and colleagues (2006) showed protein levels
of pro- and active MMP-2 to be increased 1, 3 and 7 days in
the colon following 10-Gy abdominal irradiation in rats.
However, the jejunum was not assessed in the aforementioned
study. MMP-2 protein expression has been correlated with
decreased mean bursting pressure and breaking strength dur-
ing anastomic healing 3 and 7 days following 40-Gy fraction-
ated irradiation in Wistar rats [4]. Clinically, active MMP-2
levels have correlated to poor outcomes in RIGTand radiation
enteritis [2]. Angenete and colleagues (2007) found increased
levels of MMP-2 in both tumour tissue and tumour-adjacent
normal rectal tissue within the radiation field to correlate with
fistula formation in patients who had received preoperative
fractionated irradiation (5 × 5 Gy) for rectal cancer. This in-
crease of MMP-2 following radiation, in both preclinical and
clinical studies, supports the findings of the present study.
Correlation of this increase with poor outcomes such as im-
paired anastomic healing, and fistula formation, suggests
MMP-2 may be a clinical target for the treatment of RIGT.
Fig. 4 MMP-2 protein expression
was significantly increased in the
jejunum and colon 6 weeks into
the fractionated radiation
schedule. a Jejunal levels of
relative pro-MMP-2 were signifi-
cantly increased at 6 weeks (p <
0.0001). b Jejunal levels of active
MMP-2 were significantly in-
creased at 6 weeks (p = 0.0011). c
Colonic levels of pro-MMP-2
were significantly increased at
week 6 (p < 0.0001). d Colonic
levels of active MMP-2 were not
significantly altered at 6 weeks
(p > 0.05). e Representative
MMP-2 bands at 72 kDA (pro-
MMP-2) and 64 kDA (Active
MMP-2) and B-actin housekeep-
ing band at 42 kDa in both the
jejunum and colon. MMP-2
bands were quantified against the
beta-actin housekeeping band
using Image Studio™ software.
Data shown is mean + SEM.
Asterisks denote significance
compared to controls at each time
point, where **< 0.01, ***<
0.001 and ****< 0.0001, n = 5
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Following transcriptional upregulation and activation of
secreted pro-MMP-2, MMP-2 is capable of degrading several
ECM components, such as collagen IV and VXII, plasmino-
gen and decorin, to active downstream products such as vas-
cular endothelial growth factor (VEGF), transforming growth
factor beta (TGFβ) and form angiostatin, endostatin and
tumstatin [21]. ActiveMMP-2 is also able to shed and activate
pro-inflammatory cytokines such as TNF-α and IL-1β [7].
Active MMP-2 is thus able to indirectly alter cell signalling,
altering cell growth, migration and angiogenesis and in the
present study is upregulated at the same time point as apopto-
sis in both the jejunum and colon [22, 31]. Previous studies
have confirmed significantly increased expression of pro-
inflammatory mediators, such as TNF-α and IL-1β, in animal
models of RIGT [9, 15]. This supports a possible pathway in
which MMP-2 may be contributing to the exacerbation of
acute RIGT through the activation of these pro-inflammatory
mediators. Future studies assessing specific inhibition of
MMPs, particularly MMP-2, as a possible treatment for
RIGT should investigate the potential involvement of pro-
inflammatory cytokines in this pathway. From the results of
the present study, when considered in the context of previous
literature, it is likely that the upregulation and activation of
intestinal MMP-2 following irradiation play an important role
in the pathogenesis of RIGT [3, 7, 26].
MMP-14 was also significantly upregulated in the jejunum
following irradiation in the present study. As previously men-
tioned, MMP-14 is intricately involved with the activation of
pro-MMP-2 [7]. Active MMP-14 expressed on the cell surface
binds to TIMP-2 via the N-terminal domain. This complex then
acts as a receptor for pro-MMP-2 after which a free MMP-14
molecule is able to cleave and activate pro-MMP-2 [7]. This
mechanism of MMP-2 activation by MMP-14 may be reflected
in the present study, in which levels of both pro- and active
MMP-2 were concurrently increased with MMP-14 expression
in the jejunum. However, pro- but not active MMP-2 was in-
creased in the colon, in which MMP-14 mRNA expression was
not significantly altered. Differences between the response of the
jejunum and colon to radiation have been characterised in previ-
ous studies [5, 22]. Loss of epithelial cell lining and villi has been
noted 6–24 h following single-dose irradiation in rats [5]. In
contrast, damage to the structure of the colonic crypts occurs
from 24 h following irradiation [5]. The upregulation of MMP-
14 at acute time points in the jejunum corresponds to significant-
ly lower weight gain and apoptosis in both epithelial and endo-
thelial apoptosis in the samemodel [22]. Apoptosis has also been
shown to occur earlier in the jejunum than in the colon in the
model of fractionated irradiation used in the present study [22].
Whilst the timing of these events is likely altered in a fractionated
radiation schedule, this reflects a differing profile of RIGT in the
different intestinal regions. Additionally, the increase inMMP-14
expression in the present study does not appear to correspond to
increased cumulative doses, with relative expression similar at
both 3- and 6-week time points. However, the direction of the
relationship between the increase in MMP expression and the
histopathological damage in the gut remains unclear. The pattern
of MMP-2 and MMP-14 expression following radiation poten-
tially supports the role of MMP-14 in the activation of MMP-2,
which should be considered when exploring MMP inhibition as
a treatment for RIGT.
In the present study, MMP-1 mRNA expression was found
to be significantly increased in the jejunum following 22.5-Gy
fractionated abdominal irradiation. This was not reflected in
protein localisation, with no changes inMMP-1 immunostain-
ing in the jejunum or colon. MMP-1 is classified as a collage-
nase due to its ability to degrade collagen and gelatin; howev-
er, it is also capable of activating pro-MMP-9 [13].
Transcription of MMP-1 can be increased in response to
pro-inflammatory cytokines, epidermal growth factor as well
as following activation of p38 mitogen-activated protein ki-
nases (MAPK), which has previously been shown to be in-
creased in RIGT [13, 16, 19]. Al-Dasooqi and colleagues
(2010) found MMP-1 protein expression to be downregulated
early and upregulated late during chemotherapy-induced gut
toxicity (CIGT), suggesting a role for MMP-1 in healing.
MMP-1 could be playing a similar role in the present study
as i t i s known to r egu l a t e ce l l m ig r a t i on and
reepithelialisation; however, MMP-1 was not altered in the
chronic RIGT time point of the present study, 6 weeks follow-
ing the cessation of radiation [21]. It is possible that any in-
crease in MMP-1 could have returned to baseline at this point.
In contrast with the Strup-Perrot and colleagues (2006)
study, assessing MMP levels following irradiation in rats we
found no significant difference in MMP-9 mRNA expression.
MMP-1 andMMP-14 mRNA expressions, likeMMP-2, were
significantly increased in the jejunum. Despite the significant-
ly increased mRNA expression of these MMPs, no changes in
immunostaining intensity or localisation were observed. This
lack of post-translational modification of the remaining
MMPs may be due to the time points of the present study in
which all tissue was collected 24 h following irradiation, de-
spite different cumulative radiation doses at the 3- and 6-week
time points. MMP-9 has been shown to be increased 3–7 days
following irradiation in rats; however, this has been assessed
in models of single-dose irradiation [3, 26]. Changes in
mRNA expression do not always correlate strongly with pro-
tein expression so it is also possible that these changes had no
molecular manifestation [8]. Additional studies are required to
further assess the role of these MMPs in RIGT in different
regions, models and with different treatment schedules.
Conclusion
Whilst this study is consistent with previous studies assessing
MMP expression following radiation, this is the first study to
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assess the MMP expression in multiple regions of the gut in a
fractionated radiation model of RIGT. Key findings of this
study suggest MMP-2 to be involved in the development of
RIGT in both the small and large intestine following abdom-
inal fractionated radiation. MMP-2 is widely understood to be
overexpressed in many human cancer and levels of active
MMP-2 have been shown to increase risk of metastasis of
head and neck cancer [7]. This study presents a unique possi-
bility for specific MMP inhibitors to improve radiotherapy-
induced gastrointestinal toxicities whilst not reducing efficacy
of cancer treatment. Further studies are now warranted to as-
sess these inhibitors for their therapeutic potential in RIGT.
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Abstract 
 
Purpose: Radiotherapy-induced gut toxicity (RIGT) is a debilitating effect of radiotherapy for cancer, 
often resulting in significant diarrhoea and pain. Previous studies have highlighted roles of the intestinal 
microvasculature and matrix metalloproteinases (MMPs) in the development of RIGT. We hypothesized 
vascular mediators would be significantly altered in a dark agouti (DA) rat model of RIGT. Additionally, 
we aimed to assess the effect of MMP-2 and -9 inhibition on the response of tumour-associated 
microvascular endothelial cells (TAMECs) to radiation.  
Methods: Dark Agouti (DA) rats were administered 2.5 Gy abdominal irradiation (3 times/week over 6 
weeks). Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), von 
Willebrand factor (VWF), angiostatin, and endostatin expression was assessed at 3, 6 and 15 weeks. 
Additionally, DA rat mammary adenocarcinoma tumour-associated microvascular endothelial cells 
(TAMECs) were used to assess the effects of radiation (12 Gy) and the MMP inhibitor SB-3CT on 
MMP, VEGF, and TGFβ expression, and cell viability.  
Results: VEGF mRNA expression was significantly increased in the colon at week 15 (p = 0.0012), and 
TGFβ mRNA expression was significantly increased in both the jejunum and colon at week 3 (p = 
0.0280, and p = 0.0310, respectively). Endostatin immunostaining was significantly increased at week 3 
(p = 0.0046), and angiostatin at 3 and 6 weeks (p = 0.0022, and p = 0.0135, respectively). MMP-2 and -
9 mRNA and total protein levels were significantly increased following irradiation of TAMECs. Although 
this increase was significantly attenuated by SB-3CT, it did not significantly alter endothelial cell viability 











Conclusions: Findings of this study support the involvement of VEGF, TGFβ, angiostatin, endostatin, 
and MMP-2 in the pathobiology of RIGT. However, the relationship between these mediators is 
complex and needs further investigation to improve understanding of their therapeutic potential in 












Radiotherapy-induced gut toxicity (RIGT), estimated to affect 60-80% of patients receiving radiotherapy 
for abdominal or pelvic tumours, induces debilitating symptoms including, but not limited to, diarrhoea, 
pain, rectal bleeding, and incontinence (Theis et al. 2010; Shadad et al. 2013; Hauer-Jensen et al. 
2014). RIGT is often divided into acute and chronic toxicity, with acute changes involving 
histopathological damage to villi and crypts, and chronic involving reactive fibrotic thickening (Yeoh et 
al. 2007; Theis et al. 2010). Previous research has suggested the involvement of the intestinal 
microvasculature in the development of RIGT, and several mediators have been investigated (Kruse et 
al. 2004; Yeoh et al. 2007; Stansborough et al. 2017). NFκB, proinflammatory cytokines, and matrix 
metalloproteinases (MMPs) are all upregulated in the intestine following radiation, and have 
downstream effects on vascular mediators such as vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGFβ), von Willebrand factor (VWF), and the antiangiogenic mediators 
endostatin and angiostatin (Stansborough et al. 2016). Whilst a link has been proposed in RIGT 
(Stansborough et al. 2016) there is limited research which has investigated changes in these mediators 
in the intestinal microvasculature during a fractionated radiation schedule.  
Our previous studies have shown the intestinal microvasculature to be involved in RIGT, with 
apoptosis, cytostasis, telangiectasis, and fibrotic thickening occurring early and late following 
fractionated irradiation in dark agouti (DA) rats (Yeoh et al. 2005; Stansborough et al. 2017). In 
addition, several regulators of angiogenesis and vascular physiology including, but not limited to, TGFβ, 
VEGF, and VWF, are known to be altered in the intestine following irradiation (Wang et al. 2001; Wang 
et al. 2002; Milliat et al. 2006; Lenting et al. 2012; Boerma et al. 2013). VEGF, bound to heparin in the 
extracellular matrix, is able to be released by matrix metalloproteinases (MMPs) such as MMP-2, and 
MMP-9 (Carmeliet 2005). The anti-angiogenic mediators angiostatin and endostatin have also been 
shown to increase in response to irradiation of cancer endothelial cells derived from human breast 











formation of these cells, suggesting angiostatin is involved in endothelial regulation following irradiation 
(Oh et al. 2014). Although it appears angiostatin and endostatin are involved in endothelial response to 
irradiation this connection is yet to be explored in RIGT. With the increasing investigation of the 
possible use of anti-angiogenic agents as adjuvant cancer therapies alongside chemotherapy or 
radiotherapy, targeting mediators such as vascular endothelial growth factor (VEGF) and endostatin, 
the role of these mediators in RIGT needs to be further explored. 
Previous research has clearly shown MMPs are involved in RIGT, with MMP-2 in particular shown to be 
significantly increased during RIGT (Strup-Perrot et al. 2006). It has also been hypothesised MMPs are 
involved in microvascular changes and alteration to vascular mediators such as VEGF, TGFβ, and 
VWF in RIGT (Stansborough et al. 2016). MMPs are able to regulate the expression of several of these 
mediators via the degradation of the extracellular matrix (ECM) leading to the release of latent VEGF 
and TGFβ, as well as forming angiostatin and endostatin by cleaving plasminogen and collagen XVIII 
respectively (Sternlicht and Werb 2001; Kalluri 2003; Carmeliet 2005). In degrading the ECM, MMPs 
also promote endothelial migration, proliferation and tube formation (Kalluri 2003). Despite previous 
literature, a direct link has not been established between MMPs and vascular mediator expression 
following radiation, and the effect of these changes on endothelial cells. Thus the present study aimed 
to first confirm the alteration of vascular mediators VEGF, TGFβ, VWF, angiostatin, and endostatin in 
the jejunum and colon following fractionated irradiation in DA rats. We then aimed to determine whether 
inhibition of MMP-2 and -9 with SB-3CT altered endothelial viability and expression of these vascular 
mediators in primary tumour-associated microvascular endothelial cells (TAMECs) derived from DA rat 
mammary adenocarcinomas. TAMECs have been successfully cultured for previous, similar 
experiments, have been phenotyped, and their cultivation in DA rats allows for consistency between 
both components of the study (Bateman et al. 2013). In utilising this primary in vitro model we aimed to 
assess the effects of SB-3CT on tumour endothelial response to irradiation as an initial investigation 











component of the study does not directly translate to RIGT, further studies are required to assess the 
effects of SB-3CT on intestinal endothelium following irradiation. However, results of the present study 
form a foundation for further investigation into the possible use of SB-3CT following irradiation. 
Materials and Methods 
Ethics 
Both studies were conducted in accordance with ethics approved by the Animal Ethics Committees at 
the University of Adelaide (M-041-2006; M-2015-117) and complied with the National Health and 
Medical Research Council (Australia) Code of Practice for Animal Care in Research and Teaching 
(2013). 
Animals and Experimental Design  
Archival tissue from a prior study was utilised in the in vivo component of the present study, and 
experimental design has been previously described (Yeoh et al. 2007; Stansborough et al. 2017). 
Briefly, 30 female Dark Agouti (DA) rats were randomly assigned into two groups, one group receiving 
sham irradiation, and one group receiving a schedule of fractionated irradiation. Both groups of rats 
were anaesthetised using 3% halothane in 100% oxygen and placed into a custom-built container, with 
rats in the treatment group receiving fractionated abdominal irradiation using a Varian Clinac Linear 
Accelerator (Varian Medical Systems, USA) at a dose of 2.5 Gray (Gy) (depth = 3.3 cm, focus-skin 
distance = 130 cm) 3x per week for a total dose of 22.5 Gy in 9 fractions and 45 Gy in 18 fractions over 
3 and 6 weeks, respectively (Yeoh et al. 2007). Rats were killed at 3, 6, or 15 weeks from first 
irradiation dose (n = 5 per time point). Animals were monitored daily and clinical record sheets kept. 
Sections of jejunum (30% of small intestinal length when measured from the pylorus) and colon 
(midlength of the large intestine) were collected as previously described and either formalin-fixed and 











RNA isolation and reverse transcription 
RNA isolation was performed using the Nucleospin® RNA II kit (Macherey-Nagel, Germany) according 
to manufacturers’ protocol. Briefly, 15-20 mg of jejunal and colonic tissue was homogenized using the 
TissueLyser LT (Qiagen) and Nucleospin® RNA II kit reagents (Macherey-Nagel, Germany). The lysate 
was filtered through silica membrane filter columns, desalted, DNA was digested using the DNAse 
reaction mixture, and the silica membrane was washed and dried. RNA was eluted in 60 µl RNase-free 
water. The TAKE3 plate and Synergy MyReader (BioTek) was used to determine RNA concentration 
and purity. RNA (1 µg) was converted to cDNA using the iScript cDNA synthesis (Bio-Rad, USA) 
according to manufacturer’s protocol. The TAKE3 plate and Synergy MyReader was again used to 
determine total cDNA concentration and purity and stock cDNA was diluted to 100 ng/µl with nuclease-
free water.  
Real-time polymerase chain reaction (RT-PCR) 
RT-PCR was performed using the Rotor Gene 3000 (Corbett Research, Sydney, Australia) according to 
manufacturer’s protocol. Reaction mixtures contained 1 µl of cDNA, 5 µl of SYBR green (Applied 
Biosystems, Foster City, CA), 5 µl of nuclease-free water, and 0.5 µl each of 50 pmol/µl forward and 
reverse primers (Table 1). Thermal cycling conditions were as described; denaturation step at 95°C for 
10 minutes, and included 40 cycles at 95°C for 10 s, annealing at 60ºC (VWF, TGFβ, and MMP-2), or 
55ºC (VEGF and MMP-9), for 15 s, and extension and acquiring at 72°C for 20 seconds. 18S was used 
as the housekeeping gene. Primer efficiency was calculated to be between 90-110% for each target 
gene against 18S, and thus the 2-∆∆CT method was used to determine fold change in gene expression 
relative to the housekeeping gene and sham irradiated controls from each time point. 
Immunohistochemistry (IHC) 
Angiostatin and endostatin proteins were visualised by IHC staining in the colon at 3, 6, and 15 week 











used with the EnVision™ FLEX kit for Dako autostainer link systems (Dako, Denmark) as previously 
described (Stansborough et al. 2017). The anti-angiostatin primary antibody (#ab2904, Abcam), and 
anti-endostatin primary antibody (#GTX37706, GeneTex), were used at 6.66 µl/ml and 20 µl/ml, 
respectively. Slides were scanned using the Nanozoomer (Hamamatsu Photonics, Japan) at 40x 
magnification. ImageScope imaging software (Leica Biosystems, Germany) was used to analyse 
angiostatin and endostatin in which percentage of positively stained cells was calculated in the lamina 
propria of each section (averaged from ten randomly selected 40x sections per slide). 
Isolation of tumour-associated microvascular endothelial cells (TAMECs) 
Tumour-associated microvascular endothelial cells were isolated and cultured as previously described 
(Bateman et al. 2013). Briefly, Dark Agouti (DA) rats were injected subcutaneously with DA mammary 
adenocarcinoma cells, and 8 days following, tumours were removed and processed under sterile 
conditions. Surrounding connective tissue was removed and tissue was mechanically disrupted into 1 
mm fragments. The tissue was enzymatically digested in collagenase/dispase (Sigma), and incubated 
with 0.25% trypsin/EDTA (Bateman et al. 2013). Following this, the tissue was centrifuged and 
resuspended in complete growth medium, consisting of supplemented Dulbecco’s Modified Eagle 
Media (DMEM) (28% HEPES buffer, 10% foetal bovine serum (FBS), and 1% L-glutamine, penicillin, 
streptomycin) and filtered through a 100 µm nylon cell strainer (Corning). The resultant suspension was 
added to gelatinised culture flasks and incubated at 37ºC. Tumour-conditioned medium (TCM) was 
added to the TAMECs every 24-48 hours to maintain the endothelial cell culture. Endothelial culture 
was confirmed using immunostaining for endothelial cell markers, as previously described (Bateman et 










Table 1. 18S, VEGF, TGFβ, VWF, MMP-2, and MMP-9 primer sequences 
 
Treatment of TAMECs 
TAMECs at passages 1-2 were detached with trypsin, pelleted, counted, diluted to 1 x 109 cells/mL, and 
split evenly across 4 x 50 ml falcon tubes to represent the four treatment groups (vehicle control, SB-
3CT alone, irradiation alone, and irradiation and SB-3CT combined). Cells were then treated for 24 
hours with either 0.01% DMSO in H20 (vehicle control), or 1 µm SB-3CT. SB-3CT concentration was 
determined by dose response assays (data not shown) and was determined to be within the Ki range of 
inhibiting MMP-2 and MMP-9 (Ki = 14 nM and Ki = 600 nM, respectively), without inhibiting MMP-1, -3, 
or -7 (Ki = 206 µM, Ki = 15 µM, Ki = 96 µM, respectively) (Brown et al. 2000). Following this, falcon 
tubes containing the cells were either sham irradiated, or received 12 Gy gamma irradiation using a 
Cs137 source (IBL-437 Blood Irradiator). Cells were immediately plated according to individual 
experimental conditions. An XTT assay was used to conduct a radiation dose response assay and was 
based on an initial dose range of 0-12 Gy. 12 Gy resulted in a significant decrease in cell viability 
without causing excessive cell death (data not shown). Dosimetry was calculated prior to radiation and 
based on dose rate calculations, calibrated monthly based on degradation constant. 
Protein and RNA extraction from TAMECs 
Following irradiation and/or SB-3CT pre-treatment, TAMECs were seeded into 6-well plates at a cell 
density of 1 x 105 cells/well, and incubated for 24 hours. Following incubation, the media was collected 
and immediately placed on ice. Cells were pelleted and supernatant was collected and stored at -80ºC. 
Lysis buffer (Macherey-Nagel RNA kit) was added to each well. Wells were scraped and cells and 
buffer were collected and disrupted using a 26-gauge needle. β-mercaptoethanol (3.5 µl) was added to 
each tube, vortexed, and further RNA extraction and cDNA conversion was performed according to kit 











MMP 2 and 9 activity assays 
MMP-2 and -9 activity was assessed in supernatant collected from treatment TAMECs, using MMP-2 
and -9 activity assay kits (QuickZyme). Experiments were conducted according to kit protocol. Briefly, 
duplicate diluted samples (1:2 dilution with assay buffer), serially diluted standards, and assay buffer 
controls, were pipetted into the assay plate. The plate was covered and incubated at 4ºC overnight. The 
wells were aspirated and washed with assay buffer, and 50 µl of P-Aminophenyl mercuric acetate 
(APMA) solution (0.5 mM APMA in 0.05% DMSO/assay buffer) was added to wells containing 
standards, and to one of the two duplicate sample wells. Assay buffer was added to the remaining 
sample wells, and detection reagent was added to all wells. The plate was shaken for 20 seconds and 
read at 405 nm to obtain the baseline value, repeated at 6 and 22 hours. Data was analysed by 
subtracting the average blank value from each sample value, creating a standard curve based on the 6 
hour data and plotting the standard concentration against the blank subtracted standard values, 
applying a best-fit curve, and calculating the sample concentrations graphically.    
XTT Assay 
In preparation for XTT assay, 1x105 treated TAMECs were passaged intro 96-well flasks and were left 
to adhere for 24 hours. Following adhering, XTT was performed according to kit protocol (Cell 
Proliferation Kit II (XTT, Sigma), with labelling and electron coupling reagents being prepared 
immediately before removing media from wells, replacing with 100 µl fresh media, and adding 50 µl per 
well of the prepared XTT reagent. The plates were incubated for 6 hours and the plate was read at 490 
nm using the TAKE3 plate and Synergy MyReader.  
Immunocytochemistry (ICC) 
Prior to experimentation of TAMECs, expression of VEGF, VWF, TGFβ, MMP-2, and MMP-9 under 
normal conditions was confirmed using immunocytochemistry (Supplementary Figure 1). Briefly, treated 
TAMECs were passaged into 8-well chamber slides at 2x105 cells/well and left to adhere for 24 hours. 











PBS, incubated with 3% H2O2 in PBS for 5 minutes to reduce non-specific staining, washed, and 
incubated with Triton-X block (100 µl TX-100 and 0.1 g sodium citrate in 100 mL H20) for 8 minutes to 
permeate the cell membrane. The cells were washed and blocked using the normal serum blocking 
reagent (Level 2 USA™ Ultra Streptavidin Detection System kit, Signet Laboratories). Primary 
antibodies (MMP-2; #ab37150, Abcam, MMP-9; #ab58803, Abcam, VEGF; #ab46154, Abcam, VWF; 
#ab6994, Abcam, TGFβ; #ab92486, Abcam) were prepared at previously optimised concentrations of 2 
µl/ml (VWF & MMP-2), 4 µl/ml (VEGF & MMP-9), and 10 µl/ml (TGFβ), and added to each well for 60 
minutes. Cells were washed and a linking reagent (Level 2 USA™ Ultra Streptavidin Detection System 
kit, Signet Laboratories) was applied for 20 minutes. A peroxidase-labelled ultra-streptavidin labelling 
reagent (Signet Laboratories) was applied for 20 minutes, followed by a 1 minute incubation with 
diaminobenzidine (DAB) chromogen in 0.03% hydrogen peroxidase (Signet Laboratories) for 
visualization. Cells were washed, chambers were removed, and slides were counterstained with Lillie 
Meyers haematoxylin (1:10), washed, dehydrated, and coverslipped. 
Statistical Analysis 
Graphpad Prism (version 6) software was used to perform statistical analysis. Normality was 
determined and differences between study group means were analysed using either a one-way or two-
way ANOVA with Sidak’s multiple comparison, or a Kruskal-Wallis test with multiple comparison. 
Asterisks denote significance compared to control at the time point, where * <0.05, ** <0.01, *** <0.001, 












Fractionated irradiation induced changes in weight gain and histopathological damage 
Clinical and histological response to fractionated irradiation for this study has been previously published 
(Stansborough et al. 2017). Briefly, rats receiving fractionated irradiation had significantly lower weight 
gain at week 3 (p = 0.0055), and from week 6 until the completion of the study (p < 0.05), when 
compared to sham irradiated controls (Stansborough et al. 2017). Histopathological damage scoring 
was significantly increased in the colon, but not in the jejunum, at week 3 (p = 0.043). However, 
thickening of the lamina propria, telangiectatic vessel formation, and apoptosis were observed in both 
the jejunum and colon following irradiation (Stansborough et al. 2017). 
VEGF and TGFβ were significantly increased in the colon following irradiation in DA rats 
Despite no significance effect in the jejunum, VEGF mRNA expression was significantly increased in 
the colon at the 15-week time point (p = 0.0012) (Figure 1A + B). TGFβ mRNA expression significantly 
increased in both the jejunum and colon 3 weeks into the radiation schedule (p = 0.0280 and p = 
0.0310, respectively), however was not significantly increased at 6- or 15-weeks in either region (Figure 
1C + D). VWF mRNA expression was not significantly altered at any time point following fractionated 
irradiation in jejunum or colon (Figure 1E + 1F). 
 
Figure 1. VEGF, TGFβ, and VWF expression in the jejunum and colon following fractionated radiation. 
A VEGF mRNA expression in the jejunum following fractionated irradiation B VEGF mRNA expression 
in the colon following fractionated irradiation C TGFβ mRNA expression in the jejunum fractionated 
irradiation. D TGFβ expression in the colon following fractionated irradiation. E Relative mRNA 











colon. Dotted line represents baseline fold change. * = significance compared to control. * <0.05, ** 
<0.01, n=5. Data = mean + standard error of the mean (SEM). 
 
Angiostatin and endostatin immunostaining was significantly increased in the colon following 
fractionated irradiation 
Endostatin was immunostaining significantly increased in the lamina propria of the colon at the 3-week 
time point only (p = 0.0046) (Figure 2A + 2C). Angiostatin immunostaining was significantly increased at 
3- and 6-weeks in the colon lamina propria (p = 0.0022, and p = 0.0135, respectively) (Figure 2B + 2C). 
There were no significant alterations at week 6 or 15.  
 
Figure 2. Endostatin (A) and angiostatin (B) immunostaining in the lamina propria of the colon following 
fractionated irradiation. Cell positivity was calculated using ImageScope software and is determined as 
number of positively stained cells/number of total cells. * denotes significance compared to controls at 
the same time-points, ** <0.01, *** <0.001. Data = mean + SEM, n=5. Scale bars = 20 µm, 40x original 
magnification. 
SB-3CT significantly attenuated the expression of MMP-9 following irradiation of TAMECs 
Relative mRNA expression of MMP-2 was not significantly altered following irradiation of TAMECs 
when compared to controls (p = ns; Figure 3A). However, TAMEC MMP-2 expression following 
irradiation was significantly reduced when pre-treated with SB-3CT, as compared to the radiation only 
group (p = 0.0034) (Figure 3A). MMP-9 mRNA expression was significantly increased following 
irradiation of TAMECs (0.0022). This was significantly attenuated by SB-3CT (p < 0.0001). Despite this 
attenuation of MMP-2 and -9, SB-3CT did not significantly alter cell viability following irradiation, 













Figure 3. MMP-2 (A) and -9 (B) mRNA expression following irradiation of TAMECs, with/without SB-
3CT. Dotted line represents baseline fold change. * = significance compared to control. * <0.05, ** 




SB-3CT significantly attenuated MMP-2 and -9 protein expression following irradiation 
Total protein levels of both MMP-2 and MMP-9 were significantly increased in TAMEC supernatant 
following 12 Gy irradiation (p = 0.046, and p = 0.0401, respectively) (Figure 4A and 4C). This increase 
in total MMP-2 and -9 protein levels was significantly attenuated by the administration of SB-3CT (p = 
0.0119, and p = 0.0209, respectively). The ratio of active: total MMP-2 and -9 were not significantly 
altered following irradiation of TAMECs. However the ratio of active: total MMP-2 was significantly 
increased in the radiation + SB-3CT group, compared to control (p = 0.0379). The ratio of active: total 
MMP-9 was not significantly altered in the radiation + SB-3CT group when compared to all other groups 












Figure 4. Total and active: total ratio of secreted MMP-2 and -9 protein concentration following 
irradiation and MMP inhibition in TAMECs. A Total MMP-2 protein concentration B Ratio of active: total 
MMP-2 protein levels C Total MMP-9 protein concentration D Ratio of active: total MMP-9 protein 
levels. * = significance compared to control. * <0.05. Data = mean + SEM. n = 12 
 
 
SB-3CT did not alter tumour-associated microvascular endothelial cell viability following irradiation 
SB-3CT alone did not significantly alter cell viability; as measured via XTT assay; both irradiation (12 
Gy), and irradiation + SB-3CT significantly reduced cell viability of TAMECs (p = 0.0236, and p = 
0.0003, respectively) (Figure 5). There was no significant difference between the radiation alone, and 
radiation + SB-3CT groups (p = ns; Figure 5).  
 
Figure 5. Cell viability of TAMECs following irradiation and MMP inhibition. * = significance compared 
to control. * <0.05, *** <0.001. Data = mean + SEM. n = 8 
 
VEGF and TGFβ mRNA expression were not significantly altered following irradiation of TAMECs 
RT-PCR was used to assess relative mRNA expression of VEGF and TGFβ following irradiation and 
MMP inhibition in TAMECs. VEGF and TGFβ mRNA expression were unaltered by both irradiation and 












Figure 6. VEGF and TGFβ mRNA expression following irradiation of TAMECs with or without SB-3CT. 
VEGF (A) and TGFβ (B) mRNA expression were not significantly altered following irradiation of 
TAMECs, with or without the presence of SB-3CT. Dotted line represents baseline fold change. Data = 




Although the pathobiology of RIGT is complex, MMPs, the intestinal microvasculature, and associated 
vascular mediators have been shown to be involved (Stansborough et al. 2016). Key findings from this 
study show mRNA expression of VEGF and TGFβ mRNA expression to be significantly increased in 
the intestines following RIGT, and is the first study to show an increase in angiostatin and endostatin 
during RIGT. However, the pattern of upregulation of these mediators was different, occurring at 
different time points and in different intestinal regions. Further, this study assessed the effect of the 
MMP-2 and -9 inhibitor, SB-3CT, on tumour-associated microvascular endothelial cells (TAMECs) 
following irradiation. Both mRNA and protein expression of MMP-2 and -9 were significantly 
upregulated in TAMECs following irradiation, however irradiation did not significantly alter VEGF or 
TGFβ expression in these cells. SB-3CTsignificantly attenuated MMP-2 and -9 mRNA and protein 
expression, however, it did not alter cell viability of TAMECs following irradiation.  
VEGF mRNA expression was significantly increased in the colon at the 15 week time point of the DA rat 
RIGT model. VEGF may have a protective role in gastrointestinal injury, with higher levels of VEGF 
expression correlating with less severe gastric ulcers in murine models of stress-induced gastric 
ulceration (Malara et al. 2005). VEGF has also been shown to regulate normal vasculature in the small 
intestinal villi, with excessive inhibition resulting in regression of normal microvasculature, and reduced 
vascular density (Howdieshell et al. 2001; Saif et al. 2007; Pollom et al. 2015). Clinically, the inhibition 











intestinal villi, and induce epithelial ulceration, supporting a role for VEGF in healing (Mangoni et al. 
2012; Pollom et al. 2015). This regulatory role could be consistent with the timing of VEGF upregulation 
seen in the present study, occurring at the 15 week time-point in the colon only. At this time point, 9 
weeks following the last radiation dose, we have clearly documented and reported on a transition from 
acute to chronic RIGT phenotype which is able to be seen histologically (Stansborough et al. 2017). 
This effect is likely due to alteration of the wound healing process, as well as vascular changes 
resulting in impaired delivery of healing agents to the damaged tissue (Mangoni et al. 2012). This study, 
in combination with findings of previous literature, suggests a role for VEGF in the progression to 
chronic RIGT, possibly playing a part in wound healing following acute RIGT. This potential role of 
VEGF in RIGT needs to be further explored, particularly with the increased study of anti-VEGF as 
adjuvant cancer therapies (Barney et al. 2013; Pollom et al. 2015). When VEGF inhibitors (VEGFIs) are 
combined with radiotherapy, gastrointestinal toxicity has been shown to significantly increase (Barney 
et al. 2013; Pollom et al. 2015). This potential for increased intestinal toxicity needs to be considered 
when determining the clinical potential of these agents. 
Whilst TGFβ expression was significantly increased 3 weeks into the fractionated radiation schedule in 
our rat model of RIGT, consistent with previous literature, it was not significantly upregulated at 6 and 
15 weeks, nor was it altered following irradiation of TAMECs (Richter et al. 1998; Wang et al. 2001). 
The lack of increase in TGFβ at the chronic RIGT time point was somewhat unexpected and in contrast 
with previous literature (Kleifeld et al. 2001). This may be explained by the different models used in the 
study by Wang and colleagues (2001, in which a scrotal hernia is surgically induced and the 
fractionated schedule uses higher doses over a shorter period of time (Wang et al. 2001). Our previous 
studies have shown fibrotic changes to the lamina propria and microvasculature at both the 6 and 15 
week time points (Stansborough et al. 2017). With the complex interactions of TGFβ it is possible that 
the early upregulation of TGFβ, or alterations in the receptors of TGFβ are involved in these fibrotic 











TGFβ being capable of opposing angiogenic effects, highly dependent on conditions and tightly 
regulated in the endothelium by the receptors ALK1 and ALK5 (Goumans et al. 2003). Whilst TGFβ 
binding with ALK5 has an anti-angiogenic effect, inhibiting endothelial cell migration and proliferation, 
ALK1 binding has the opposite effect (Goumans et al. 2003). Thus the ratio of ALK5 to ALK1 seems to 
be key to the functional role of TGFβ in pathological conditions. Further studies, both in vitro and in 
vivo, are needed to investigate the ALK5 to ALK1 ratio and determine where this balance lies in 
endothelial response to irradiation, and during RIGT, in order to determine the role of TGFβ in its 
pathobiology.  
Angiostatin and endostatin immunostaining was shown to be significantly elevated in the lamina propria 
of both the jejunum and colon. This occurred only during the acute time points, with angiostatin 
increasing at 3 and 6 weeks, and endostatin at 3 weeks. The anti-angiogenic mediators angiostatin and 
endostatin, fragments of plasmin and type XVIII collagen, respectively, are responsible for inhibiting 
endothelial cell proliferation and migration, as well as inducing apoptosis in the case of endostatin 
(Ribatti 2009). Endostatin is also known to directly inhibit MMP-2 (Abdollahi et al. 2004). Although this 
current study is the first to assess angiostatin and endostatin in an animal model of RIGT, response of 
angiostatin to radiation has previously been assessed in vitro (14). Oh and colleagues (2014) finding 
angiostatin protein levels to be significantly increased in human breast tissue derived cancer 
endothelial cells following 4 Gy irradiation (Oh et al. 2014). Whilst endostatin has not yet been 
investigated in RIGT, Endostar, a recombinant human endostatin, has been shown to significantly 
decrease MMP-2, -9, -14, and VEGF immunostaining in nasopharyngeal carcinoma xenografts in mice 
following 6 Gy irradiation (Peng et al. 2012). Although the roles of angiostatin and endostatin likely 
differ in normal vs tumour tissue response to radiation, these studies, in combination with the present 












MMP-2 and -9 mRNA and protein expression was significantly increased following irradiation of 
TAMECs. The significant increase in MMP-2 expression is consistent with previous studies finding an 
increase in MMP-2 24 hours following 4 Gy irradiation of human normal endothelial cells and TAMECS 
(NECs and CECs, respectively) derived from breast tissue (Oh et al. 2014). However, the same study 
found MMP-9 not to be altered by irradiation of TAMECs in contrast to the findings of our current study 
(Oh et al. 2014). This is not entirely unexpected, due to species and tissue differences between the two 
studies, with MMP-9 regulation known to depend on cell type (Vincenti and Brinckerhoff 2007). Despite 
these conflicting results, the similarities between the studies highlight a role for MMP-2, in particular, in 
endothelial regulation following irradiation.  
The increase in MMP-2 and -9 expression was also significantly attenuated, both at the mRNA and 
protein level, by the pre-treatment of TAMECs with SB-3CT. SB-3CT is the first mechanism-based 
MMP inhibitor, potently and selectively inhibiting MMP-2 and -9. The effect of SB-3CT is unique in its 
selectivity, as it forms a reactive species within the active sites of MMP-2 and -9 (Kruger et al. 2005) 
and was developed in response to a lack of efficacy of broad-spectrum, synthetic MMP inhibitors when 
used as anti-cancer therapies in clinical trials.  
An unexpected finding in the present study was the significant decrease in mRNA expression of MMP-2 
and MMP-9 following pre-treatment with SB-3CT in TAMECs following irradiation, as the mechanism of 
action of SB-3CT is in inhibiting activation. Additionally, SB-3CT significantly increased MMP-2 activity 
in TAMECs when combined with irradiation, having no effect on activity of MMP-9. The significant 
decrease in proMMP expression by SB-3CT is not unprecedented, with SB-3CT significantly 
decreasing proMMP-9 levels in a mouse model of transient focal cerebral ischemia (37). The study 
hypothesized this decrease was likely due to a positive feedback mechanism between MMP activity 











To our knowledge, this is the first study to assess mRNA expression of MMP-2 and -9 following SB-3CT 
administration. There are endogenous mediators that can be regulated by active MMP-2 and -9, such 
as TGFβ, and pharmacological reagents, such as doxycycline, that have been shown to regulate the 
mRNA expression of MMP-2 and -9 by altering mRNA stability (Yan and Boyd 2007). Whether SB-3CT 
is regulating transcription via a similar process, by affecting the promotor regions of these MMPs, or 
through disruption of a positive feedback mechanism, is unclear. The regulation of mRNA expression of 
both MMP-2 and MMP-9 by SB-3CT should be investigated further and current studies are underway in 
our laboratory. 
The use of a single cell type in this study is a limitation as normal and tumour endothelial cells are 
phenotypically different and subsequently respond differently to irradiation; therefore it is likely that the 
response of normal gut endothelial to SB-3CT would differ to the findings of the present study (Oh et al. 
2014). Thus, in order to further assess the possible effects of MMP inhibition in RIGT, future studies 
assessing SB-3CT in an in vivo model of RIGT are warranted. However, the findings of this study 
highlight a relationship between radiation, MMP expression and tumour endothelium. Due to the 
potential use of specific MMP inhibitors as cancer therapies, and with the involvement of both MMP’s 
and the endothelium in the development and progression of RIGT, the findings of this study highlight 
the need for further research and consideration as to possible dual effects of MMP inhibitors in this 
setting (Strup-Perrot et al. 2006; Angenete et al. 2009; Stansborough et al. 2017). 
Conclusion 
The findings of this study support a role for the vascular mediators VEGF, TGFβ, angiostatin, and 
endostatin in RIGT following fractionated irradiation. Additionally, MMP-2 and -9 were shown to be 
involved in endothelial response to radiation in vitro, however inhibition by SB-3CT did not alter cell 
viability. The findings of the in vitro component of the present study elucidate the effects of SB-3CT on 











MMP expression, and confirm the role of MMP-2 in particular in the endothelial response to irradiation.  
These results highlight the need for further pre-clinical studies to assess the effect of MMP inhibitors 
and anti-angiogenic drugs in RIGT, particularly as these drugs are currently being investigated as 
adjuvant cancer therapies.  
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Supplementary Figure 1. Conformational staining of MMP-2, MMP-9, VWF, and VEGF in tumour-


















































Table 1. 18S, VEGF, TGFβ, VWF, MMP-2, and MMP-9 primer sequences 
 








18S F CATTCGAACGTCTGCCCTAT 
R GTTTCTCAGGCTCCCTCTCC 




VEGF F AGGCGAGGCAGCTTGAGTTA 
R CTGTCGACGGTGACGATGGT 
1601-1766 166 62 
64 
(Zhang et al. 
2014) 
TGFβ F ATGACATGAACCGACCCTTC 
R ACTTCCAACCCAGGTCCTTC 
897-1073 177 60 
60 
(Close et al. 
2005) 
VWF F GCCTCTACCAGTGAGGTTTTGAAG 
R ATCTCATCTCTTCTCTGCTCCAGC 




MMP-2 F CTG ATA ACC TGG ATG CAG TGCT 
R CCA GCC AGT CCG ATT TGA 
2138-2272 135 55  
50 
(Al-Dasooqi 
et al. 2010) 
MMP-9 F AAG CCT TGG TGT GGC ACG AC 
R TGG AAA TAC GCA GGG TTT GC 
760-876 117 56  
52 
(Vikman et 
al. 2007) 
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